Drug, bio-affecting and body treating compositions inventions 12/08

20080317666 - Colonic delivery of active agents: Drug delivery devices that are orally administered, and that release active ingredients in the colon, are disclosed. In one embodiment, the active ingredients are those that inactivate antibiotics, such as macrolides, quinolones and beta-lactam containing antibiotics. One example of a suitable active agent is an enzyme such as beta-lactamases. In... Agent: David S. Bradin Womble Carlyle Sandridge & Rice

20080317667 - Compositions and methods for inhibiting growth of smad4-deficient cancers: The present invention is in the fields of cell biology, immunology and oncology. The invention relates to the discovery that there is a relationship between the expression levels of the tumor suppressor gene smad4 (also known as dpc4) and integrin αvβ6, and the responsiveness of patient populations to αvβ6-active compounds... Agent: Howrey LLP - Dc

20080317668 - Integrin targeted synthetic ligands for diagnostic and therapeutic applications: The present invention relates to a novel class of diagnostically or therapeutically effective compounds comprising novel aza-bicycloalkane based cyclic peptides, acting as a targeting moiety towards integrin receptors.... Agent: Nixon & Vanderhye, PC

20080317669 - Cloning of honey bee allergen c: The present invention relates to a nucleic acid encoding a polypeptide capable of binding to IgE from subjects allergic to venom of an insect from the order Hymenoptera having a homology of more than 70% to the amino acid sequence of SEQ ID NO: 2, which is the honey bee... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20080317670 - Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have... Agent: Attn: John W. Wallen, Iii Ambrx, Inc.

20080317671 - Non-imidazole heterocyclic compounds: Certain non-imidazole heterocyclic compounds are histamine H3 modulators useful in the treatment of histamine H3 receptor mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20080317672 - Detection of anomalies in measurement of level of hypnosis: The invention relates to detection of anomalies related to a measurement of the hypnotic level of a subject. In order to detect when a measure indicative of the hypnotic level of a subject is anomalous either due to a medical reason or due to an interference, the measure is monitored... Agent: Andrus, Sceales, Starke & Sawall, LLP

20080317675 - Low osmolar x-ray contrast media formulations: The present invention generally relates to nonionic x-ray contrast media formulations, radiological compositions containing such agents and methods for x-ray visualization utilizing such compositions. The invention especially relates to injectable radiological compositions for x-ray visualization comprising a pharmaceutically acceptable vehicle and a mixture of a monomer, being a triiodo-substituted benzene... Agent: Kenneth D Goetz Mallinckrodt Inc

20080317673 - Method for diagnosing and treating bronchial asthma: A method for diagnosing and treating a bronchial asthma by classifying a patient's asthma as Type I, Type II or Type III based on the patient's symptoms is disclosed. The symptoms for the three types of asthma are disclosed together with recommended treatment guidelines for each type to optimize treatment... Agent: Lowe Hauptman Ham & Berner, LLP

20080317676 - Biocompatible fluorescent imaging agents: This invention relates to new fluorescent chemical entities that are designed to attach to biocompatible molecules to form in vivo optical imaging agents.... Agent: Goodwin Procter LLP Patent Administrator

20080317674 - Method and reagent for measuring nitroreductase enzyme activity: R1 and R2 are selected from C1-C4 alkyl, —(CH2)n—P, —{(CH2)2—O}p—R6 and group W; where P is selected from COOR7, SO3− and OH, W is mono- or di-substituted nitrobenzyl, R6 is methyl or ethyl, R7 is selected from H, C1-C4 alkyl and CH2OC(O)R8, where R8 is methyl, or t-butyl, n is... Agent: Ge Healthcare Bio-sciences Corp. Patent Department

20080317677 - Laser marked dosage forms: The present invention relates to a coated dosage form having openings to expose the core material or an intermediate coating layer. The invention also relates to methods for manufacturing such coated dosage forms.... Agent: Philip S. Johnson Johnson & Johnson

20080317678 - Laser marked dosage forms: The present invention relates to a coated dosage form having openings to expose the core material or an intermediate coating layer. The invention also relates to methods for manufacturing such coated dosage forms.... Agent: Philip S. Johnson Johnson & Johnson

20080317679 - Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses: e

20080317680 - Sunless tanning composition and method of sunless tanning: A sunless tanning composition having dihydroacetone and an amphoglycinate (amphoacetate) in an amount effective for sunless tanning is provided. Also provided is a method of sunless tanning having the step of topically applying to the skin an effective amount of a sunless tanning composition having dihydroacetone and an amphoglycinate.... Agent: Charles N.j. Ruggiero Ohlandt, Greeley, Ruggiero & Perle, L.L.P.

20080317681 - Compositions containing a stain removing complex, and methods of making and using the same: A composition in the form of a chewing gum composition, a confectionery composition or consumable film composition containing a stain removing complex including a stain removing agent having therapeutic properties and a cyclodextrin compound and methods of preparing and using the same to remove stains from dental material including teeth.... Agent: Watov & Kipnes, P.C.

20080317682 - Tooth bleaching agent: A bleaching agent for brightening teeth that is comprised of a solvent, a pharmaceutically acceptable oxidation agent, and a varnish former. A kit that includes a bleaching agent and lip and cheek retractor.... Agent: Bond, Schoeneck & King, PLLC

20080317683 - Carrageenan and carrageenan-containing products: The present invention discloses a carrageenan composition comprising: sodium in the range of about 5.410 to about 8.230%, preferably about 6.300 to about 8.230%, and more preferably about 7.380 to about 8.230%; potassium in the range of about 0.023% to about 0.248%, preferably about 0.023 to about 0.238%, and more... Agent: J M Huber Corporation

20080317688 - Body wash with sunscreen: There is provided a body wash composition that includes sun screen materials. The body wash composition is formulated so that it may be applied during normal hygiene activities, such as washing. However, the composition applies an effective of sun screen material to the body such that the sun screen continues... Agent: Gallagher & Kennedy, P. A.

20080317687 - Cosmetic and pharmaceutical oil-in-water emulsions containing an ester quat: The present invention relates to an ester quat of a defined structure useful for the preparation of cosmetic and pharmaceutical oil-in-water emulsions, and to oil-in-water emulsions which comprise said ester quat.... Agent: Scully Scott Murphy & Presser, PC

20080317686 - Cosmetic composition for skin care: The invention relates to the use of siloxanes for emulsifiers for cosmetic compositions for skin care as well as cosmetic emulsions comprising such emulsifiers. The composition comprises an aminofunctional organopolysiloxane for W/O emulsions, O/W emulsions and multiple emulsions. The emulsions are formed easily, are very stable and needs not to... Agent: Millen, White, Zelano & Branigan, P.C.

20080317685 - Photoprotective cosmetic compositions comprising photostabilized dibenzoylmethane compounds and siloxane-containing arylalkyl benzoate amide compounds: Photostable, topically applicable cosmetic/dermatological compositions contain at least one dibenzoylmethane sunscreen compound and at least one photostabilizing siloxane-containing arylalkyl amide compound of formula (I) below:... Agent: Buchanan, Ingersoll & Rooney PC

20080317684 - Topical compositions: Topical compositions are disclosed that are useful for delivering a therapeutic level of an NSAID to a target within a subject having a local inflammatory disorder. A composition of the present invention comprises a Drug and a solvent system, wherein the solvent system comprises at least two solvent alcohols and... Agent: Frost Brown Todd, LLC

20080317690 - Film-forming resins as a carrier for topical application of pharmacologically active agents: The invention provides a biological dressing for treatment of a dermatological disease comprised of one or more resins or other film-forming agents, a topically acceptable volatile solvent, and a pharmacologically active agent. The combined one or more resins are present in a suitable amount such that the composition, when the... Agent: Dla Piper LLP (us)

20080317689 - Transdermal preparation for external use containing antiinflammatory/analgesic agent: A transdermal preparation for external use which contains a photosensitive NSAID and a UV blocker having a high ability to migrate into the skin. Thus, it becomes possible to ensure, in a transdermal preparation for external use containing a NSAID, the inhibition of the onset of light-induced non-immunological or immunological... Agent: Edwards Angell Palmer & Dodge LLP

20080317691 - Peptide-based conditioners and colorants for hair, skin, and nails: Peptides have been identified that bind with high affinity to hair, skin, and nails. Peptide-based hair conditioners, hair colorants, skin conditioners, skin colorants, and nail colorants based are described. The peptide-based hair conditioners and hair colorants consist of a hair-binding peptide coupled to a hair conditioning agent or a coloring... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20080317692 - Suicide substrates of tyrosinase and use thereof: The present invention provides a novel compound and a method of using the compound to inactivate tyrosinase activity in a subject comprising administering the patient with an effective amount of this novel compound.... Agent: Wpat, PC Intellectual Property Attorneys

20080317693 - Composition containing a polyester and a branched hydrocarbon compound: The present patent application relates to a composition containing a certain type of polyester and a branched hydrocarbon compound. Also described is a cosmetic treatment method employing the composition and the use of this composition for caring for or making up the skin or lips. Novel polyesters are also described.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080317694 - Deodorizing preparations: wherein R1 is a linear alkyl and/or alkenyl group containing from about 6 to 22 carbon atoms, a 2-ethylhexyl, an isotridecyl, an isostearyl group or a group derived from a polyol containing 2 to 15 carbon atoms and at least two hydroxyl groups; R2 has the same meaning as R1... Agent: Fox Rothschild LLP

20080317695 - Hair care compositions: The invention provides a hair care composition comprising a water-soluble, nonionic polymer of ethylene oxide and a water-soluble, nonionic cellulose ether.... Agent: Unilever Patent Group

20080317696 - Hair care compositions based on a dendritic macromolecule built up from anhydride units: A cosmetic and personal care composition comprising a dendritic macromolecule built up from anhydride units.... Agent: Unilever Patent Group

20080317697 - Shaving kit and method of shaving comprising a personal care composition and an in shower body lotion: The present invention relates to a shaving kit that comprises a first personal care article, a second personal care article and a shaving razor. The first personal care article comprises a personal care composition contained within a package. The personal care composition comprises a surfactant, water and at least 15%... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080317699 - Chemically modified dendrimers: Dendrimers comprising N-acyl urea terminal moieties are described herein. The dendrimers can be used, for example, in the treatment of arthritis.... Agent: Fish & Richardson PC

20080317698 - Personal care compositions containing at least two cationic polymers and an anionic surfactant: n

20080317700 - Synthesis and biological activity of photopolymerizable derivatives of glyphosate: The present invention holds forth improvements in the field of herbicide synthesis, their application, and methods of plant and weed control and antifouling. The present invention includes the synthesis of new acrylate and methacrylate derivatives of a glyphosate. Two isomers resulting from a hindered rotation around the amide CN bond... Agent: Roger A. Gilcrest

20080317701 - Phosphate ion adsorbent: bound thereto directly or through a spacer. The phosphate ion adsorbent of the present invention is advantageous not only in that the adsorbent specifically adsorbs phosphate ions in a living body, but also in that the adsorbent has high adsorbability to phosphate ions, thus useful in removing the phosphate ions... Agent: Frishauf, Holtz, Goodman & Chick, PC

20080317702 - Method for treating microorganisms and/or infectious agents: This invention relates to a method comprising contacting a microorganism and/or an infectious agent with an effective amount of a polymer composition to reduce or eliminate the reproductivity, metabolism, growth and/or pathogenicity of the microorganism and/or infectious agent, the polymer composition comprising water, a water-soluble film forming polymer, a chelating... Agent: Renner Otto Boisselle & Sklar, LLP

20080317703 - Novel composition for xerostomia: An oral care composition is described for use in the treatment or alleviation of the symptoms of dry mouth comprising polyvinyl pyrrolidone (PVP) or a derivative thereof, an anionic mucoadhesive polymer and an orally acceptable carrier or excipient.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080317704 - Control of ice-crystal growth by non-proteinaceous substance: The present invention makes it possible to attain various applications using antifreeze activity without an antifreeze protein. The agent for the inhibition of ice-crystal growth includes a non-proteinaceous substance, wherein an aqueous solution of the non-proteinaceous substance in a concentration of 10 mg/ml causes the deposition of non-flat disk-shaped ice... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080317705 - Promoting wound healing by administering a prostaglandin e and granulocyte-macrophage colony stimulating factor: A method of promoting healing of a wound in a patient, the method comprising administering to the patient (i) a prostaglandin E (PGE) or an agonist thereof and/or an agent that increases the local concentration or effect of PGE and (ii) granulocyte-macrophage colony stimulating factor (GMCSF) or a derivative thereof.... Agent: Nixon Peabody LLP - Patent Group

20080317709 - Methods for treating head or neck cancer using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or... Agent: Jones Day

20080317708 - Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3dione: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or... Agent: Jones Day

20080317707 - Pegylated interleukin-10: Interleukin-10 (IL-10) conjugated via a linker to one or more polyethylene glycol (PEG) molecules at a single amino acid residue of the IL-10, and a method for preparing the same, are provided. The method produces a stable mono-pegylated IL-10, which retains IL-10 activity, where pegylation is selective for the N-terminus... Agent: Dnax Research Inc. Legal Department

20080317706 - Targeted conjugates and radiation: The invention relates to a method for enhancing an endogenous immune response-mediated elimination of a population of cancer cells in a host. The method comprises the steps of administering to the host a composition comprising an immunogen conjugated to a vitamin receptor-binding ligand selected from the group consisting of a... Agent: Barnes & Thornburg LLP

20080317710 - Methods for treating autoimmune or demyelinating diseases: The present invention relates to novel therapeutic or prophylactic treatment in human subjects. The present invention results in part from the discovery that antagonists of IL-18Rα are effective in vivo for treating diseases. Accordingly, the invention provides a method of treating, preventing or ameliorating the symptoms of an autoimmune or... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080317712 - Arylpiperidinyl and arylpyrrolidinyl tripeptide hepatitis c serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20080317711 - Treatment of optic neuritis: The present invention provides a method for treating a patient having demyelinating optic neuritis (DON) comprising the sequential or simultaneous administration of a steroid compound and an interferon-beta protein. It is found that early, aggressive treatment of IFN-b is beneficial in such a treatment regimen, for example where the interferon-beta... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080317713 - Derivatives of growth hormone and related proteins: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in... Agent: Sheridan Ross PC

20080317714 - Method of treating hepatitis b viral infection: The present invention provides the use of PEG-IFN-α conjugates in association with ribavirin for the treatment of chronic hepatitis B infections. The present invention also provides a method for treating chronic hepatitis B infections in patients in need of such treating comprising administering an amount of PEG-IFN-α conjugate in association... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080317715 - Anti-bacterial agents: A method of killing bacteria before disease is caused in a mammal by applying a panel of bacteriophages on the mammal, wherein the panel comprises a first vir mutant bacteriophage mutated from a temperate prophage isolated from a first strain of bacteria, wherein the first vir mutant bacteriophage is infectious... Agent: Kenneth I. Kohn Kohn & Associates

20080317717 - Anti-hepatitis b virus ribozymal nucleic acid: This invention relates to ribozymes which cleave Hepatitis B Virus (HBV) at CUC sites. Suitable ribozymes may, for example, cleave at GGCUCUCUCGUCCC, CCUCAGCUCUGUAUCG or GAGGACUCUUGGA recognition sequences in HBV RNA. Ribozymal DNA, vector systems and pharmaceutical compositions are provided which may be useful, for example, in the treatment of HBV... Agent: Banner & Witcoff, Ltd.

20080317716 - Fusion proteins of mycobacterium tuberculosis: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and nucleic acids encoding such compositions and fusion proteins. The compositions of the invention increase serological sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and... Agent: Townsend And Townsend And Crew, LLP

20080317723 - Lymphatic endothelial cells materials and methods: The present invention is directed to methods and compositions for isolating lymphatic endothelial cells from a mixed population of cells. More particularly, the inventors have found that certain antibodies that recognize the extracellular domain of VEGFR-3 can be used to specifically isolated lymphatic endothelial cells substantially free of other contaminating... Agent: Marshall, Gerstein & Borun LLP

20080317721 - Method for the treatment of retinopathy of prematurity and related retinopathic diseases: The present invention provides a method for treating retinopathy of prematurity (ROP) and related retinopathic diseases. The method comprises administering to the retina of a mammal suffering from, or at risk of developing, retinopathy of prematurity or a related retinopathic disease an amount of cells from a vasculotrophic lineage negative... Agent: Olson & Cepuritis, Ltd.

20080317722 - Methods and compositions involving developmental decision promoter regions: The present invention concerns s-SHIP promoter and developmental decision promoter compositions and methods of using the promoter. It includes polynucleotides, vectors, host cells, and transgenic animal including a developmental decision promoter, for example, an s-SHIP promoter, controlling the expression of a heterologous nucleic acid. Methods of the invention concern methods... Agent: Fulbright & Jaworski L.L.P.

20080317718 - Cell differentiation of adipose-derived precursors cells: The present invention provides a simple method for controlled differentiation of adipose-derived precursor cells. A method is provided for preparing a differentiated cell. The method comprises A) obtaining a mixture by mixing a) an adipose-derived precursor cell and b) a differentiated cell corresponding to a desired site; and B) culturing... Agent: Seed Intellectual Property Law Group PLLC

20080317720 - Fat-derived progenitor cell and use thereof: An objective of the present invention is to provide methods for producing progenitor cells which show a high proliferation ability ex vivo and promote neovascularization or myocardium regeneration, by culturing pluripotent cells in a medium containing adrenomedullin (AM) and/or vascular endothelial growth factor (VEGF). Moreover, another objective of the present... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080317719 - Regulating stem cells: A method is provided, including in vitro stimulating an initiating cell population (ICP) of at least 5 million cells that have a density of less than 1.072 g/ml, and at least 1% of which are CD34+CD45−/dim, to differentiate into a progenitor/precursor cell population (PCP). A method is provided, including in... Agent: Cooper & Dunham, LLP

20080317724 - Micropatterned t cell stimulation: The invention relates to methods of expanding, stimulating or activating T cells by modulating the spatial organization of signal molecules presented to the T cells.... Agent: Schwegman, Lundberg & Woessner, P.A.

20080317725 - Compositions and methods of treating chronic kidney disease: The invention relates to nutritional compositions and methods of using these compositions for the treatment of renal disease. More particularly, the invention discloses compositions of vitamins, minerals, amino acids, and/or proteins in amounts that can be used to supplement the nutritional deficiencies observed in patients afflicted with renal disease, renal... Agent: Morriss Obryant Compagni, P.C.

20080317726 - Proteases for pharmaceutical use: The pharmaceutical use of proteases related to amino acids 1-274 of SEQ ID NO: 2, the serine protease derived from Bacillus licheniformis, which is also designated subtilisin Carlsberg, optionally in combination with a lipase and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI),... Agent: Novozymes North America, Inc.

20080317729 - Ammonium salts and ammonium salt/mineral salt clathrate compounds for use as vehicle and effective form for pharmaco-medical applications and for use as phase transfer agents for chemical applications: R1, R2, R3 and R4=alkyl and substituted alkyl straight-chain or branched, optionally having an alcohol, ether, silyether, ester, amino or amide function, H or aryl-alkyl, with aryl being an aromatic or heteroaromatic ring having optionally additional substituents, such as alkyl having 1 to 4 C atoms, OH, NR*2 with R*2=O,... Agent: Jordan And Hamburg LLP

20080317728 - Lowering uric acid to prevent or accelerate recovery of acute renal failure: Disclosed herein are methods of preventing acute renal failure, ARF, as well as treating and accelerating the recovery of patients experiencing ARF. The inventors believe that an elevated serum uric acid, either occurring at baseline in the patient, or being brought about post-operatively is a major factor leading to ARF.... Agent: Beusse Wolter Sanks Mora & Maire

20080317727 - Method of skin treatment for rosacea using epidermal growth factor: Compositions and methods for the prevention and treatment of skin and ocular rosacea using epidermal growth factor and an acceptable carrier are disclosed.... Agent: Hannah N. Sivak

20080317730 - Compositions useful for recovering original trophism and pigmentation, and for stimulating growth of the integumentary apparatus, uses and products thereof: The present invention relates to compositions and products comprising at least one proteolytic enzyme adapted to promoting the restoration of original trophism of the integumentary apparatus, the original pigmentation and stimulating the growth thereof and, particularly, improving the viability of the pilifer follicles, even in scar tissue areas.... Agent: Steinfl & Bruno

20080317731 - Phospholipases, nucleic acids encoding them and methods for making and using them: The invention provides novel polypeptides having phospholipase activity, including, e.g., phospholipase A, B, C and D activity, patatin activity, phosphatidic acid phosphatases (PAP)) and/or lipid acyl hydrolase (LAH) activity, nucleic acids encoding them and antibodies that bind to them. Industrial methods, e.g., oil degumming, and products comprising use of these... Agent: Verenium C/o Mofo S.d.

20080317732 - Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally: Methods for treatment and/or prevention of Alzheimer's disease comprising inactivating peripheral AP in serum to a reduce A(3 in the brain. Methods comprise expression of amyloid peptide inactivating enzyme on bone marrow cells; and coupling of amyloid peptide inactivating enzyme to hematopoietic cells.... Agent: Mcdermott Will & Emery LLP

20080317733 - Cosmeceutical compositions and methods with biologically active ingredients: Cosmeceutical formulations are personalized to address an individual's nutrient deficiencies and genetic predispositions for premature aging of the skin. Growth factors and high doses of inefficiently absorbed nutrients are nanoencapsulated and delivered topically to improve the function, health, and appearance of skin and hair.... Agent: Azimi Nazli

20080317734 - Nutraceutical compositions and methods with biologically active ingredients: Nutraceutical formulations are personalized to address an individual's nutrient deficiencies. Growth factors and high doses of inefficiently absorbed nutrients are nanoencapsulated and delivered orally to improve the function, health, and appearance of the individual.... Agent: Nazli Azimi

20080317735 - Pharmaceutical preparation with rna as hemostasis cofactor: Pharmaceutical preparations which comprise RNA or one or more coagulation-promoting fragments of RNA in amounts sufficient to promote coagulation and to promote fibrinolysis are described. They are in particular advantageously employed together with an activator for hemostatic processes such as factor VII-activating protease (FSAP)... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080317736 - Methods for enlarging the diameter of a biological conduit in a human subject: The invention provides methods for treating an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s) have... Agent: Fried, Frank, Harris, Shriver & Jacobson LLP

20080317737 - Drug combination for the treatment of skin disorders: A topical treatment for skin disorders and diseases comprising a combination of at least one antifungal agent and at least one hydroxy acid agent formulated into shampoos, creams, lotions, gels, sprays, foams, pads, films, patches, and solutions for treatment of skin disorders and diseases in both humans and animals.... Agent: Robert L. Knechtel, M.d., J.d.

20080317741 - Biomarkers for anti-nogo-a antibody treatment in spinal cord injury: This disclosure of this invention confirms, at the level of gene expression, the injured spinal cord and motor cortex as the primary sites of action of the anti-Nogo-A antibody treatment applied intrathecally. The disclosure further provides methods for predicting the response of a subject to a medicament comprising an anti-Nogo-A... Agent: Novartis Corporate Intellectual Property

20080317742 - Biomarkers of francisella infection: The instant invention concerns Francisella bacteria mediated degradation of alkaline phosphatase (AP). Detection of AP degradation may be used to determine the presence of Francisella bacteria in a sample. Furthermore, methods for identifying and treating Francisella infections by detecting AP degradation are described. Methods of the invention also concerns methods... Agent: Fulbright & Jaworski L.L.P.

20080317739 - Method for treating skeletal disorders resulting from fgfr malfunction: The invention provides materials, reagents, systems, and methods for identifying agents useful for treating diseases resulting from abnormal (e.g., excessive) FGF receptor signaling. The invention also provides (therapeutic) agents thus identified, and methods of using such agents in treating such diseases. In certain embodiments, the invention relates to the treatment... Agent: Wolf Greenfield & Sacks, P.C.

20080317738 - Mylks as modifiers of branching morphogenesis and methods of use: Human MYLK genes are identified as modulators of branching morphogenesis, and thus are therapeutic targets for disorders associated with defective branching morphogenesis function. Methods for identifying modulators of branching morphogenesis, comprising screening for agents that modulate the activity of MYLK are provided.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20080317740 - Use of nk cell inhibition to facilitate persistence of engrafted mhc-i-negative cells: The present invention relates to the use of a means for inhibiting NK cell function to increase persistence and/or engraftment of MHC-I negative cells, such as MAPCs.... Agent: Thompson Hine L.L.P. Intellectual Property Group

20080317743 - Human artificial chromosome containing human antibody lambda light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission: The present invention relates to a human artificial chromosome which is genetically transmissible to the next generation with high efficiency and the method for using the same. More specifically, the present invention relates to: a human artificial chromosome in which an about 3.5 Mb to about 1 Mb region containing... Agent: Baker Botts L.L.P.

20080317746 - Anti-il2 antibodies: The invention relates to a humanized monoclonal antibody or fragment thereof which specifically binds to human interleukin-2 (IL2), wherein said humanized monoclonal antibody neutralizes the activity of human IL2 by binding to said human IL2 prior to, during, and/or subsequent to the binding of said human IL2 to the human... Agent: Fulbright & Jaworski L.L.P.

20080317744 - Indole and benzimidazole derivatives: The present invention relates to new indole and benzimidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula:... Agent: Novartis Vaccines And Diagnostics Inc.

20080317748 - Mammalian receptor proteins; related reagents and methods: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.... Agent: Dnax Research Inc. Legal Department

20080317745 - Methods of diagnosing, treating, or preventing plasma cell disorders: The present invention relates to methods and compositions for the diagnosis, treatment, management, or prevention of plasma cell disorders, including systemic light-chain amyloidosis (AL) and multiple myeloma (MM). In particular, the invention encompasses the use of anti-CD32B antibodies, analogs, derivatives or fragments thereof, or compounds or agents that bind to... Agent: The Nath Law Group

20080317747 - Recombinant anti-cd30 antibodies and uses thereof: The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's disease cells in the... Agent: Seattle Genetics, Inc.

20080317749 - Use of cytokine expression to predict skin inflammation; methods of treatment: Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19, and/or IL-23.... Agent: Dnax Research Inc. Legal Department

20080317750 - Antibody antagonists of ve-cadherin without adverse effects on vascular permeability: The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine cells indicated that E4B9 indeed cross-reacts with human VE-cadherin (FIG. 6). This finding facilitates... Agent: Imclon Lerner, David, Littenberg, Krumholz & Mentlik, LLP

20080317751 - Idiotype vaccination with bispecific and multispecific immunoglobulin molecules: The present application relates to immunoglobulin polypeptides comprising at least two immunoglobulin complementarity determining regions, one that binds to an immune receptor and the other which comprises an idiotype to which an immune response is desired.... Agent: Klarquist Sparkman, LLP

20080317752 - Inhibition of tumorigenesis by inhibition of a6b4 integrin: Inhibitors of a6b4 integrin that target beta 4 are used as therapeutic agents to inhibit tumorigensis in individuals, including humans, of tumors that express a6b4 integrin. The therapeutic agent may be an antibody or a small molecule, for example a laminin-5 analog, which binds to a6b4 integrin and inhibits its... Agent: Marina Larson & Associates LLC Re: Msk

20080317753 - Selecting patients for therapy with a her inhibitor: A method for selecting patients for therapy with a HER inhibitor, such as pertuzumab, based on gene expression analysis is described. A method for assessing HER phosphorylation or activation in a biological sample via gene expression analysis is also described.... Agent: Genentech, Inc.

20080317756 - Antibodies to chemokine alpha-5: The present invention relates to a novel CKα-5 protein which is a member of the alpha chemokine family. In particular, isolated nucleic acid molecules are provided encoding the human CKα-5 protein. CKα-5 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Antibodies and... Agent: Foley And Lardner LLP Suite 500

20080317755 - Compositions and methods for the therapy and diagnosis of colon cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group PLLC

20080317754 - Human osteoclast derived cathepsin: Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20080317757 - Human monoclonal antibody binding to hgm-csf and its antigen binding portion: [Means for Solving Problems] An anti-hGM-CSF monoclonal antibody which is a human monoclonal antibody capable of binding to hGM-CSF and neutralizing bioactivity of the hGM-CSF, wherein the anti-hGM-CSF monoclonal antibody has a light chain (L chain) represented by an amino acid sequence of sequence number 1, and has a heavy... Agent: Pearl Cohen Zedek Latzer, LLP

20080317758 - Polypeptide variants with altered effector function: The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.... Agent: Genentech, Inc.

20080317760 - Compositions and methods for diagnosing and treating cancer: Monoclonal antibodies that specifically bind to an extracellular domain of human Jagged 1 and inhibit growth of a tumor comprising cancer stem cells are described. Also described is a method of treating cancer that comprises administering a therapeutically effective amount of a monoclonal anti-Jagged 1 antibody.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080317759 - Therapeutic uses of factors which inhibit or neutralize mif activity: The present invention relates to methods of treating disorders related to cellular overproliferation comprising neutralizing the production or activity of macrophage migration inhibitory factor (MIF). The invention also relates to therapeutic compositions comprising factors which inhibit or neutralize MIF activity, such as, MIF antisense RNA molecules and MIF monoclonal antibodies... Agent: Law Office Of John K. Pike, PLLC

20080317761 - Peptide-mediated protein transduction into cells of the hematopoietic lineage: A pharmaceutical composition comprises a therapeutic peptide or protein, a transport moiety capable of transporting said first peptide or protein into a hematopoietic cell differentiated from a common myeloid progenitor, and a linker between said first protein and said transport moiety, said linker susceptible to cleavage by an intracellular enzyme... Agent: Howson And Howson

20080317762 - Bacterial contact inhibition and methods therefor: Contemplated compositions and methods relate to bacterial contact inhibition that is conferred by two gene products, CdiA and CdiB, which are encoded by the genes cdiA and cdiB, respectively. A further gene product CdiI, encoded by the gene cdiI confers immunity to contact inhibition caused by CdiAB.... Agent: Fish & Associates, PC Robert D. Fish

20080317763 - Regulation of metalloprotease cleavage of cell surface proteins: Elucidation of the crystal structure of an ADAM10 substrate-recognition and proteinase-positioning module comprising the protein cysteine-rich and disintegrin domains, and detailed functional analysis revealed that an acidic pocket within the cysteine-rich domain forms a substrate-recognition site. The binding of this pocket to receptor/ligand complexes facilitates effective ligand cleavage, which is... Agent: Leydig Voit & Mayer, Ltd

20080317764 - Antibodies against 25-hydroxyvitamin d: The present invention concerns processes for producing antibodies against 25-hydroxyvitamin D, the antibodies produced according to the invention as well as methods for the detection of 25-hydroxyvitamin D using these antibodies.... Agent: Roche Diagnostics Operations Inc.

20080317766 - Costimulatory molecules and uses thereof: The invention relates to a novel costimulatory pathway mediated by a member of the semaphorin protein family, Sema4A, which is selectively expressed on the surface of dendritic cells. In addition, the invention relates to the use of Sema4A protein and protein derivatives in a method for the identification of immunomodulatory... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080317765 - Method for removal of toxins from mucosal membranes: The present invention provides novel mucoadhesive compounds useful in the prevention of diseases and disorders of or which arc associated with the mucosal membrane.... Agent: The Nath Law Group

20080317768 - Bioconjugated nanoparticles: The present disclosure relates to compositions and methods for the treatment of a disease, e.g., cancer or pathogenic infection, using a bioconjugated nanoparticle comprising a biocompatible quantum dot conjugated to a targeting moiety. The targeting moiety allows for the nanopaticle to bind to a cancer cell or pathogenic organism. The... Agent: Moore And Van Allen PLLC For Boeing

20080317767 - Tripartitle raftophilic strutures and their use: The present invention relates to a compound comprising a tripartite structure in the format C-B-A or C′-B′-A′ wherein moiety A and moiety A′ is a raftophile, moiety B and moiety B′ is a linker, moiety C and moiety C′ is a pharmacophore; and wherein moiety B and B′ is a... Agent: Fulbright & Jaworski L.L.P.

20080317770 - Induction of immunological tolerance: A method of creating tolerance to transplanted cells, tissue, or organs without the need for continuous immunosuppression. A tolerizing dose of a cell or tissue within a membrane structure is implanted into a patient. Once the patient becomes tolerant to the cell or tissue, a tissue or organ is implanted... Agent: Knobbe Martens Olson & Bear LLP

20080317769 - Vaccine composition comprising alpha-galactosylceramide as an adjuvant for intranasal administration: The present invention related to a vaccine composition comprising alpha-galactosylceramide (αGalCer) as an adjuvant for the intranasal administration. The present inventors administered αGalCer together with a tumor cell antigen or a virus antigen to the nasal cavity of a mouse and then confirmed that the αGalCer effectively induced not only... Agent: Klarquist Sparkman, LLP

20080317771 - Anti-clusterin oligoclonal antibodies for diagnosis and prediction of the aggressiveness of tumours, diagnostic method and related kits: The invention concerns anti-clusterin oligoclonal antibodies able to recognize and bind in a selective and specific way antigenic epitopes of clusterin isoforms to be used in tumours diagnosis and in the prediction of their malignancy grade, diagnostic method and related kits.... Agent: Arent Fox LLP

20080317772 - Compounds and methods for treatment and diagnosis of chlamydial infection: Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with... Agent: Seed Intellectual Property Law Group PLLC

20080317773 - Conjugates that contain the homeodomain of antennapedia: The subject invention pertains to a conjugate comprising: (a) a first region comprising the homeodomain of antennapedia or a variant thereof, and (b) a second region not naturally associated with the first region. In one embodiment, the second region of the conjugate comprises a protein of at least 100 amino... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080317774 - Composition for inhibiting thrombosis: The present invention provides a composition for inhibiting thrombus formation, comprising a given plant component derived from amla, tea, hibiscus, cocklebur, gymnema, Hizikia fusiforme or carrageenan, which can be used for foodstuff, quasi-drugs, medicaments and feeds.... Agent: Birch Stewart Kolasch & Birch

20080317775 - Bacterial antigens and uses thereof: Novel enzymes, processes and antigenic structures useful in producing vaccines and compounds useful in combating gram-negative bacteria are described. Enzymes were isolated from the slime mould Dictyostelium discoideum and used to specifically degrade lipopolysaccharide (LPS). Enzymatic degradation permits residues of the LPS molecule, including immunogenic epitopes of the core oligosaccharide... Agent: Ade & Company Inc.

20080317776 - Vaccines containing viruses involved in avian malabsorption syndrome and methods of administration therefor: The causative agent(s) of Avian Malabsorption Syndrome (MAS) are isolated and used to prepare vaccines for use in the prevention of diseases resultant therefrom. The vaccines contain at least two avian viruses—the reovirus and adenovirus—and optionally include another virus which inflicts poultry. The viruses may be live, attenuated live, or... Agent: Wyeth Patent Law Group

20080317777 - Cdna construct of salmonidae alphavirus: The invention concerns recombinant DNA's comprising cDNA of genomic RNA of a Salmonidae alphavirus preceded by a spacer sequence, under the control of a suitable promoter. Said recombinant DNA's are useful for obtaining expression vectors, producing recombinant Salmonidae alphavirus, and for obtaining vaccines.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080317778 - Modified vaccinia ankara virus variant and cultivation method: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a... Agent: Law Office Of Salvatore Arrigo

20080317779 - Hiv tat-cd4 hybrid molecules and methods of use thereof: Hybrid molecules comprising CD4 minimal modules or mimetics that bind to HIV Env polypeptides in combination with one or more HIV Tat polypeptides are described. Also described are complexes of these hybrid molecules with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides.... Agent: Novartis Vaccines And Diagnostics Inc.

20080317780 - Viral vaccine and method for preparation thereof: The invention relates to a viral vaccine, especially a retroviral vaccine, and methods of forming such a vaccine. The vaccine is formed from a whole-killed virus suspension in a cell lysate or culture medium, wherein the virus is killed by exposure to a chloramine compound at a level adequate to... Agent: Borden Ladner Gervais LLP Anne Kinsman

20080317781 - Vaccines for diseases of fish: Fish are immunized by a mass vaccination method, such as by immersion in water containing an attenuated strain of a pathogenic bacterium that does not effectively cause disease in fish when the non-attenuated pathogenic bacterium is exposed to the fish by immersion. An illustrative example of the method is for... Agent: Howard Eisenberg, Esq.

20080317782 - Clostridial toxin derivatives and methods for treating pain: Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting... Agent: Dean G. Stathakis (t2-7h) Allergan, Inc.

20080317783 - Clostridial toxin derivatives and methods for treating pain: Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting... Agent: Dean G. Stathakis (t2-7h) Allergan, Inc.

20080317784 - Immunogenic compositions containing anthrax antigen, biodegradable polymer microparticles, and polynucleotide-containing immunological adjuvant: Immunogenic compositions and kits, as well as methods of stimulating immune responses and methods of immunization using the same. The compositions and kits comprise: (a) an antigen derived from Bacillus anthracis; (b) polymer microparticles comprising a biodegradable polymer; and (c) a polynucleotide-containing immunological adjuvant.... Agent: Mayer & Williams

20080317785 - Vaccine: The invention provides a vaccine comprising secreted protein derived from Mycobacterium avium subsp paratuberculosis (M. ptb) substantially free of whole organisms of that species either dead or alive. The secreted protein may be obtained from a culture of M. ptb with the microorganisms being removed by centrifugation and subsequent filtration.... Agent: Jacobson Holman PLLC

20080317786 - Genetically modified babesia parasites expressing protective tick antigens and uses thereof: The present invention relates to methods for stable transfection of Babesia parasites, and for vaccines conferring immunity against parasitic arthropods.... Agent: Usda-ars-office Of Technology Transfer Patent Advisors Office

20080317787 - Anti-malaria vaccine: There is provided, inter alia, a method for the prophylaxis of productive malaria infection in travelers to endemic regions comprising the administration of suitable amounts of a formulation comprising a Plasmodium antigen or an immunogenic fragment or derivative thereof and an adjuvant, comprising a lipid A derivative and a saponin... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080317788 - Additive for domestic washing processes: Additive for processes of domestic washing or others, and like cosmetics additive for shampoo and other compounds and of hygiene personal, susceptible to be incorporated to the process after the washing and to be clarified of the process that is constituted by a product micro-encapsulation chosen of between a cosmetic,... Agent: Patent, Copyright & Trademark Law Group

20080317794 - Agglomerate particles, method for producing nanocomposites, and the use thereof: The invention relates to agglomerate particles which are constructed from agglomerated nanoscale primary particles and also to a method for incorporation of these particles in a polymer matrix and to the use of these agglomerate particles.... Agent: Leydig Voit & Mayer, Ltd

20080317789 - Carrageenan process: The present invention discloses a process for treating precipitated carrageenan, comprising the steps of (a) treating the precipitated carrageenan with an aqueous treatment solution containing an alkali or a salt, (b) washing the treated precipitated carrageenan in water, and (c) drying the washed precipitated carrageenan.... Agent: J M Huber Corporation

20080317792 - Composition based on mineral concentrates derived from precious stones: e

20080317796 - Hair care cosmetic composition: This hair care cosmetic composition contains (A) colloidal silica core/silicone shell particles consisting of (1) 90 wt % to 10 wt % cores of colloidal silica and (2) 10 wt % to 90 wt % shells of polyorganosiloxane represented by the mean formula R1aSiO(4-a)/2 (wherein R1's are the same or... Agent: Foley And Lardner LLP Suite 500

20080317795 - Highly charged microcapsules: The invention encompasses compositions containing sol-gel microcapsules that are highly positively charged. The sol-gel capsules generally contain additives. The invention also encompasses methods for producing highly charged microcapsules using cationic additives which can include cationic polymers. The methods allow for the encapsulation of polar or non-polar active ingredients.... Agent: Wilson Sonsini Goodrich & Rosati

20080317791 - Kappa carrageenan: Disclosed is a carrageenan composition comprising sodium, potassium, calcium and magnesium.... Agent: J M Huber Corporation

20080317793 - Method for make-up or care of the nails: The present invention relates to a method for make-up and/or care of the nails comprising gluing onto the nail, by means of an adhesive, a flexible sheet comprising at least one layer of at least one organic and/or inorganic material, the organic or inorganic material and/or the adhesive containing at... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080317790 - Process for treatment of kappa carrageenan: The present invention relates to a process for treating precipitated carrageenan, comprising the steps of (a) treating the precipitated carrageenan with an aqueous treatment solution containing an alkali or a salt, (b) washing the treated precipitated carrageenan in water, and (c) drying the washed precipitated carrageenan.... Agent: J M Huber Corporation

20080317797 - Tooth whitening products and methods of making the same: A dissolving strip for tooth whitening the strip having at least a first tooth contacting layer and a second outer layer. The first tooth contacting layer has a solid tooth whitening active in an amount which reacts within a predetermined time when placed on a tooth. The second outer layer... Agent: Vidas, Arrett & Steinkraus, P.A.

20080317798 - Disposable nonwoven cleansing mitt: A disposable nonwoven cleansing mitt adapted to be retained on a user's hand during use is provided. The disposable nonwoven cleansing mitt is releasably carrying a personal care composition.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080317800 - Biocidal composition: The present invention relates to a biocidal composition, a method for its production and the use of the biocidal composition.... Agent: Fulbright & Jaworski, LLP

20080317799 - Nanoemulsion therapeutic compositions and methods of using the same: The present invention relates to methods and compositions for treating pulmonary infection. In particular, the present invention provides nanoemulsion compositions and methods of using the same to treat bacteria associated with biofilms (e.g., found in pulmonary infections). Compositions and methods of the present invention find use in, among other things,... Agent: Casimir Jones, S.c.

20080317801 - Control of rodents: Control of Rodents A particulate mixture for use in the control of rodents which comprises a mixture of a plurality of bait particles and a plurality of non-bait particles, wherein each bait particle comprises matter edible by a rodent and a rodenticide and wherein each non-bait particle comprises matter edible... Agent: Bozicevic, Field & Francis LLP

20080317802 - Air filter having antimicrobial property: The present invention relates to an antimicrobial composition having antibacterial and antifungal properties and to an air filter manufactured using the composition. The filter of the present invention, comprising a filtration media treated with the antimicrobial composition having antibacterial and antifungal properties, has excellent antibacterial and antifungal properties, and thus... Agent: 3m Innovative Properties Company

20080317803 - Aqueous rodenticide formulations: The present invention comprises novel aqueous rodenticide formulations, cereal grains treated with these formulations, and methods of controlling rodents based on these formulations.... Agent: Brinks, Hofer, Gilson & Lione

20080317804 - Neem oil lotion preparation and wipe: Provided in embodiments of the present invention is a neem oil lotion preparation impregnated in a fabric wipe to enable individualized application of an organic pesticide on human skin or a plant. In one embodiment, a wipe includes a fabric sheet impregnated with neem oil, an emulsifier, an emollient, a... Agent: Marger Johnson & Mccollom, P.C.

20080317806 - Antiparasitic compounds: A compound of Formula (A), wherein R1 is C1-C5 alkyl, C3-C6 branched alkyl, C4-C7 cycloalkyl, C8-C12 fused or bridged polycycloalkyl, or heterocyclic ring, where any of the preceding alkyl, cycloalkyl or heterocyclic ring groups may be singly or multiply substituted with X; R2 is H or R1; and X is... Agent: Howrey LLP - Dc

20080317805 - Locally administrated low doses of corticosteroids: This invention provides for using a locally delivered low dose of a corticosteroid to treat pain caused by any inflammatory disease including sciatica, herniated disc, stenosis, mylopathy, low back pain, facet pain, osteoarthritis, rheumatoid arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low... Agent: Medtronic Spinal And Biologics Attn: Noreen Johnson -IPLegal Department

20080317807 - Strontium fortified calcium nano-and microparticle compositions and methods of making and using thereof: Compositions containing strontium fortified calcium nanoparticles and/or microparticles, and methods of making and using thereof are described herein. The strontium fortified calcium compounds contain calcium ions, calcium atoms, strontium ions, strontium atoms, and combinations thereof and one or more anions. Exemplary anions include, but are not limited to, citrate, phosphate,... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080317808 - Hyarulonic acid derivative based three dimensional matrix: Use of a biological material containing: e) a three-dimensional matrix based on a hyaluronic acid derivative and optionally f) chondrocytes and/or mesenchymal cells partially or completely differentiated towards chondrocytes for the preparation of a graft to be surgically implanted into a joint cartilage damaged by or to be protected against... Agent: Jay S Cinamon Abelmanfrayne & Schwab

20080317815 - Induction of a physiological dispersion response in bacterial cells in a biofilm: where is a single or double carbon-carbon bond, m is 1 or 2, n is 2 to 15, and R is a carboxylic acid, a salt, an ester, or an amide, where the ester or amide is an isostere or biostere of the carboxylic acid. The composition additionally contains... Agent: Nixon Peabody LLP - Patent Group

20080317810 - Methods and compositions for reducing oxalate concentrations: The present invention provides methods and compositions for oxalate degradation. The present invention comprises devices comprising oxalate-reducing enzymes. The enzymes may be directly attached or incorporated in coatings on the devices. Such devices are useful in treatments where oxalate or oxalic acid deposits interfere. Methods for making and using such... Agent: Troutman Sanders LLP

20080317813 - Nanobead releasing medical devices: Medical devices comprising nanobeads encapsulating one or more bioactive agents and methods of use thereof are provided.... Agent: Squire, Sanders & Dempsey LLP

20080317812 - Spacer with a coating thereon for use with an implant device: The present invention relates to a spacer, such as a polymeric spacer, for use with an implant device, e.g., a bone plate, for splinting a fracture of a bone. The spacer includes a body defining a bone healing surface, wherein at least a portion of the bone healing surface has... Agent: Wood, Herron & Evans, LLP (zimmer)

20080317811 - Treatment of cancer using tlr3 agonists: The present invention relates generally to the fields of genetics and medicine. More specifically, the present invention relates to improved methods of treating cancers using a TLR3 agonist, by assessing the expression of TLR3 receptor by cancer cells.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080317814 - Tube for connecting marteriovenous and interposition for medical operation: Disclosed herein are a tube for arteriovenous anastomosis useful in hemodialysis patients and an insert for use in medicinal operation in the body. The tube or the insert are repetitively treated with a medicament on the surface thereof, which provides stable communication between an artery and a vein of a... Agent: JeffersonIPLaw, LLP

20080317809 - Use of k -252a and kinase inhibitors for the prevention or treatment of hmgb1-associated pathologies: The present invention relates to the use of K-252a, a physiologically active substance produced by microorganisms, and of its salts or synthetic and/or chemically modified derivatives for the prevention or treatment of HMGB1 associated pathologies. More particularly, the present invention relates to the use of K-252a for the prevention or... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080317817 - Methods of manufacturing a delivery system for promoting bone growth: A method for manufacturing a delivery system that includes a bone growth promoting material encapsulated within a water-absorbing, water-gelatinizable covering used to promote bone growth in order to repair a bone defect and/or strengthen a weakened bone region. The delivery system may be shaped and sized in order to fit... Agent: Workman Nydegger 1000 Eagle Gate Tower

20080317816 - Porous objects having immobilized encapsulated biomolecules: A porous object includes a porous material having internal pore surfaces and external pore surfaces. Releasing material encapsulated biomolecules are immobilized on at least one of the internal pore surfaces, at least one of the external pore surfaces, or combinations thereof.... Agent: Julia Church Dierker Dierker & Associates, P.C.

20080317818 - Interpenetrating networks, and related methods and compositions: The present invention provides interpenetrating polymeric networks (IPNs), and related methods and compositions. The hydrogel material of this invention comprises an interpenetrating network of two or more polymer networks, wherein at least one of the polymer networks is based on a biopolymer. Also provided is a method of producing the... Agent: Dla Piper LLP (us)

20080317819 - Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas: A contact lens for delivery of a multiplicity of drugs includes a lens body with a first drug incorporated in a first zonal area of the lens body and a second drug incorporated in a second zonal area of the lens body. The first and second drugs are dissimilar and... Agent: Walter A. Hackler, Ph.d. Patent Law Office

20080317820 - delivery system: A control release device for the delivery of active components, the device including; a rigid housing containing at least one discrete aperture therein, and a driving substance containing the active component(s) placed within the housing, characterized in that the driving substance swells in the presence of fluid, driving the substance... Agent: Kremblas, Foster, Phillips & Pollick

20080317824 - Chocolate coated spherical filled capsules: Described is a spherical coated capsule comprising a coating-free capsule having (i) a liquid or viscous core (1) and (ii) a solid shell (2) surrounding this core, and a solid chocolate coating (4) surrounding said coating-free capsule, wherein the diameter of the spherical chocolate coated capsule is in the range... Agent: Connolly Bove Lodge & Hutz LLP

20080317823 - High pressure processing of bioactive compositions: The present invention relates to a method of pressure treating a bioactive composition comprising at least one bioactive component to prevent the growth of at least one unwanted microorganism while retaining a desired level activity of the at least one bioactive component. The bioactive component is selected from one or... Agent: Knobbe Martens Olson & Bear LLP

20080317821 - Lipase inhibitors: e

20080317822 - Methods for delivery of nanosome encapsulated agents: Vitamins, minerals, antioxidants, and growth factors are encapsulated in nanosomes and the nanosomes suspended in beverages. The nanosomes effectively cross the through the stomach and into the blood stream to be delivered to cells while protecting the contents encapsulated in the cell from degradation prior to delivery to the final... Agent: Greenberg Traurig LLP (la)

20080317825 - Pharmaceutical preparation that can be administered orally for treating fish, production method for said preparation and use of the latter: The present invention is directed to a pharmaceutical preparation for oral application for treatment of fish, in particular for vaccination of fish of the salmon family and other fish having a comparable digestive system against bacterial and/or viral infections, in particular against VHS and IHN. The invention is also directed... Agent: Norris, Mclaughlin & Marcus, P.A.

20080317828 - Fentanyl compound-containing edible patch to be applied to oral mucosa: There is provided a film-type edible oral mucosal patch comprising a main ingredient, a fentanyl compound, contained in a base comprising (A) a semi-synthetic water-insoluble polymer compound, (B) a semi-synthetic water-soluble polymer compound, (C) a synthetic water-soluble polymer compound, (D) a water-soluble polyhydric alcohol and (E) a pH-adjusting agent. The... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080317827 - Methods and devices for delivering therapeutic agents to target vessels: Methods of preparing devices for delivering at least one therapeutic agent to a target vessel in a mammal, the devices prepared by such methods, and uses of such devices for delivering a therapeutic agent, such as an antiproliferative agent, to a target vessel.... Agent: Woodcock Washburn LLP

20080317826 - Porous keratin constructs, wound healing assemblies and methods using the same: A porous keratin construct for use in wound healing is disclosed. The porous keratin construct may be used standing alone or in combination with a synthetic foam backing layer. Either the porous keratin construct or the porous keratin construct and synthetic foam combination may be used in a wound therapy... Agent: Holland & Hart, LLP

20080317829 - Method for the production of a wound pad: The invention relates to a method for producing a wound pad, by means of which the permeability of the wound pad can be adjusted. The inventive method makes it possible to produce wound pads for a wide range of therapeutic applications.... Agent: Akerman Senterfitt

20080317830 - Compositions and methods for the treatment of wounds and scar tissue: Compositions for the treatment of wounds and/or scars are described herein. The compositions contain between 1 and up to 30% by weight, more preferably between 1 and 20%, most preferably between about 5 and 10% by weight particles, such as titanium dioxide or a similar material in a pharmaceutically acceptable... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080317831 - Hemostatic sponge and method of making the same: A device for promoting the clotting of blood includes a web of non-woven fibers of a polymer having a hemostatic agent disposed on the fibers. The fibers are randomly arranged to form the web. When the device is applied to a bleeding wound, at least a portion of the hemostatic... Agent: Michaud-duffy Group LLP

20080317833 - Novel anti-inflammatory androstane derivatives: d

20080317832 - Transdermal delivery system comprising glycopyrrolate to treat sialorrhea: In one aspect, the invention includes a method for treating sialorrhea, comprising the steps of identifying a patient afflicted with sialorrhea and administering a therapeutically effective amount of glycopyrrolate to the patient using a transdermal route of administration. In another aspect, the invention is a transdermal drug delivery system for... Agent: Leydig Voit & Mayer, Ltd

20080317839 - Amino acid lipids and uses thereof: This disclosure provides a range of amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs,... Agent: Nastech Pharmaceutical Company Inc Mdrna, Inc.

20080317840 - Compositions and methods for polymer-caged liposomes: The present invention provides liposomal compositions and methods of using such compositions in vitro and in vivo. In particular, the present invention provides stable, polymer-caged liposomes comprising a pH responsive delivery mechanism for delivery of nucleic acids, peptides, small molecules, drugs, etc. in vitro and in vivo.... Agent: Casimir Jones, S.c.

20080317834 - Compounds and methods for modulating cerebral amyloid angiopathy: The invention provides methods of inhibiting cerebral amyloid angiopathy. The invention further provides methods of treating a disease state characterized by cerebral amyloid angiopathy in a subject.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080317838 - Liposomal vaccine compositions comprising a polysaccharide antigen and a protein adjuvant: A liposomal composition, preferably a vaccine, comprising liposomes formed of liposome forming compounds, containing coentrapped polysaccharide antigen and T-cell dependent protein carrier, such as tetanus toxoid or diphtheria toxin modified to render it non-toxic. The invention is of use in the production of vaccines against Haemophilus influenzae, Streptococcus pneumoniae or... Agent: Morrison & Foerster LLP

20080317837 - Peptide epitopes of apolipoprotein b: The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.... Agent: Gauthier & Connors, LLP

20080317835 - Personalized nutrient deficiency assay methods: Assays are preformed to determine nutrient deficiency levels in an individual to address the deficiencies and improve health and longevity. Nutraceutical and cosmeceutical products containing nanoencapsulated active ingredients are provided, in addition to dietary, exercise, sleep, and other lifestyle recommendations.... Agent: Nazli Azimi

20080317836 - Topical compositions for anti-aging skin treatment: This invention discloses anti-aging skin treatment compositions and methods that utilize plant-based copper and zinc antioxidant complexes.... Agent: Theodore Jay Apt 600

20080317842 - Fast wet-massing method for the preparation of calcium-containing compositions: The present invention relates to a novel process for the preparation of a granulate comprising a calcium-containing compound as an active substance. The method comprises a method for the preparation of a granulate comprising a calcium-containing compound as an active substance, the method comprising, i) feeding a granulation chamber with... Agent: Edwards Angell Palmer & Dodge LLP

20080317841 - Pharmaceutical composition containing coated, floating particles: A dosage form exhibiting delayed transit time through the GI tract. The dosage form comprises a plurality of buoyant particles, each comprising an inner drug-containing core, an intermediate layer surrounding said core and a release rate-controlling outer coating.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080317843 - Nanoparticulate formulations of modafinil: The present invention is directed to compositions comprising a nanoparticulate modafinil compositions, or a salt(s), or an enantiomer(s), or a prodrug(s), or a polymorph(s) or derivative thereof, having improved bioavailability. The nanoparticulate modafinil composition formulation particles of the composition have an effective average particle size of less than about 2000... Agent: Fox Rothschild, LLP Elan Pharma International Limited

20080317844 - Pharmaceutical delivery systems for hydrophobic drugs and compositions compositions comprising same: A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also... Agent: Foley And Lardner LLP Suite 500

20080317845 - Duloxetine formulation: A duloxetine pellet formulation comprises: (i) a core including a desired amount of duloxetine; (ii) an enteric coating comprising hydroxypropylmethylcellulose phthalate (HPMCP) as an enteric polymer; and, optionally, (iii) a separating layer located between the core and the enteric coating, the separating layer including polyvinyl alcohol and a low molecular... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080317846 - Pulsatile release histamine h2 antagonist dosage form: A unit dosage form, such as a capsule or the like, for delivering drugs into the body in a circadian release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. Each bead population exhibits a pre-designed rapid or sustained release profile with or without... Agent: Arent Fox LLP

20080317847 - Hydrostatic delivery system for controlled delivery of agent: The present invention provides a hydrostatic delivery system including a hydrostatic couple and an agent of interest. The hydrostatic couple includes at least one hydrodynamic fluid-imbibing polymer, and at least one hydrostatic pressure modulating agent. This delivery system has the ability to control the release of one or more agents... Agent: Arent Fox LLP

20080317850 - Buccal delivery system: A buccal delivery system capable of being blended in a normal dry powder process and compressed using a standard tabletting machine, said buccal delivery system comprising a matrix of: (a) an effective amount of one or more active ingredients; (b) an amount of one or more polyethylene glycols or derivatives... Agent: Reed Smith LLP

20080317849 - Method for improving the medical treatment of pain: Methods for improving pain management in a mammal, the methods comprising administering a combination of a strontium-containing compound and a second therapeutically and/or prophylactically active substance selected from the group consisting of analgesic agents, anti-inflammatory agents and palliative agents to the mammal. Pharmaceutical compositions for use in such methods, comprising... Agent: Jones Day

20080317848 - Oral dosage forms for propiverine or pharmaceutically acceptable salts thereof having prolonged release of the active agent: By suitable retardation oral pharmaceutical compositions containing propiverine or one or several pharmaceutically acceptable salts thereof in an amount of 4 mg to 60 mg propiverine and having a prolonged release of the active agent are produced. Preferably a blend of active agent and optionally one or more acidic substances... Agent: Vidas, Arrett & Steinkraus, P.A.

20080317851 - Immediate release dosage forms containing solid drug disbursions: High loading immediate release dosage forms containing at least 30 wt % of a solid drug dispersion, at least 5 wt % of a disintegrant and a porosigen are disclosed that exhibit excellent strength and aqueous solubility.... Agent: Pfizer Inc.

20080317853 - Mouth dissolving pharmaceutical composition and process for preparing the same: Disclosed herein is a orally disintegrating and/or dissolving oral pharmaceutical composition, comprising one or more active pharmaceutical ingredients, one or more fillers having particle size of 100 microns or above, a high and desirable amount of silicon dioxide, one or more disintegrating agents, optionally effervescent couple, wherein said composition has... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20080317852 - Pharmaceutical combination: A pharmaceutical formulation for the treatment of HIV is provided. The formulation is a combination of a nucleoside reverse transcriptase inhibitor and a nucleotide reverse transcriptase inhibitor in which the combination has an increased stability over prior art combination therapies. The invention also provides a pharmaceutical product containing the formulation.... Agent: Conley Rose, P.C.

20080317854 - Process for the production of an abuse-proofed solid dosage form: The present invention relates to a process for the production of an abuse-proofed solid dosage form containing at least one active ingredient with potential for abuse and a binder with a breaking strength of =500 N, by exposing a mixture comprising the active ingredient and the binder to ultrasound and... Agent: Norris, Mclaughlin & Marcus, P.A.

20080317855 - Particulate compositions comprising alginate and/or alginic acid: An ingestible particulate composition comprises: a. an alginate and/or alginic acid; b. a bicarbonate and/or carbonate; c. an organic acid; and d. an agglomerant, being a compound, such as a low molecular weight polyol, which allows the particulate composition to flow yet which substantially does not release fine particulates into... Agent: Fish & Richardson PC

20080317856 - Compositions containing a capillary -active system with application -relevant differentiability, and the use thereof: The invention also relates to the use of such compositions, in particular systemically or enterally, especially for the selective control, for example, of structural changes, functional disturbances of the target organs in question (hair, skin, cerebrum, skeleton, muscles, gastrointestinal tract, eyes) as supplements (food supplements, supplementary balanced diet, dietary components),... Agent: Collard & Roe, P.C.

20080317857 - V-atpase inhibitors of use in the treatment of septic shock: The use of vacuolar ATPase inhibitors in the prevention and/or treatment of septic shock is herein described. Vacuolar ATPase inhibitors are selected among products of natural, semi-synthetic or synthetic origin.... Agent: Squire, Sanders & Dempsey L.L.P.

20080317858 - Formulations of n-(2-acetyl-4,6-dimethylphenyl)-3--2-thiophenecarboxamide: Provided herein are intravenous and oral formulations of N-(2-acetyl-4,6-dimethylphenyl)-3-{[(3,4 dimethyl-5-isoxazolyl)amino]sulfonyl}-2-thiophenecarboxamide. Also provided are methods of making and using the formulations.... Agent: Jones Day

20080317859 - Stabilization of testosterone within transdermal devices: The present invention relates to the chemical stabilization of testosterone contained in self-adhesive transdermal devices by way of the association of a desiccant agent with said device within a sealing packaging. The use of a desiccant agent makes it possible to limit the chemical degradation of the testosterone to androstenedione... Agent: The Firm Of Hueschen And Sage

20080317860 - Use of a polysaccharide which is excreted by the vibrio diabolicus species for the engineering of non-mineralized connective tissue: The invention relates to the use of a polysaccharide which is excreted by the Vibrio diabolicus species for the engineering of non-mineralised connective tissues, in particular for skin and cartilage engineering.... Agent: Marshall, Gerstein & Borun LLP

20080317861 - Polymeric materials and methods: Chimeric polymer compositions and methods are provided in which a plurality of carbohydrate moieties and amino acids form the backbone of a polymer. Most preferably, the polymer includes alternating saccharide and peptide portions to form the chimeric polymer.... Agent: Fish & Associates, PC Robert D. Fish

20080317862 - Organic compounds comprising a glycopyrrolium salt: Medicaments comprising (A) an antimuscarinic agent and (B) a corticosteroid for the treatment of inflammatory or obstructive airways diseases.... Agent: Novartis Corporate Intellectual Property

20080317863 - Pharmaceutical compositions useful in the transmucosal administration of drugs: There is provided pharmaceutical compositions in the form of homogeneous interactive mixtures, which compositions comprise a pharmacologically-effective amount of an active ingredient in the form of microparticles of a size between about 0.5 μm and about 10 μm, which particles are attached to the surfaces of larger carrier particles with... Agent: Morgan Lewis & Bockius LLP

20080317864 - Chitosan and heparin nanoparticles: The invention is aimed at nanoparticulate systems for the controlled release of heparin. It is specifically aimed at nanoparticulate systems comprising chitosan, heparin and optionally a polyoxyethylenated derivative, and which are ionically cross-linked, as well as being aimed at processes for obtaining them.... Agent: Moore & Van Allen PLLC

20080317866 - Collagen-based microspheres and methods of preparation and uses thereof: A method of manufacture of ECM microparticles incorporating bioactive molecules for drug delivery has been developed, using a modified emulsification method or a water-in-oil-phase-separation method. The microspheres are photochemically crosslinked to control the release of the bioactive molecules for better drug delivery usage without compromising the biocompatibility of the crosslinked... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080317865 - Quench liquids and washing systems for production of microparticles: The present invention provides coacervation methods forming compositions for the sustained release water soluble active agents, including biologically active polypeptides. The invention further relates to the discovery of improved non-aqueous quench liquids and washing systems, which enable a reduction in the amount and concentration of hardening agents such as heptane... Agent: Elmore Patent Law Group, PC

20080317867 - Cosmetic system, and method for disguising skin defects: The present invention provides a cosmetic system for disguising dermatological blemishes. The cosmetic system includes a viscous silicone material and a catalyst. The silicone material is pigmented with a cosmetic pigment according to a selected skin tone. In one aspect, the cosmetic system also includes a flocking agent. The flocking... Agent: Baker, Donelson, Bearman, Caldwell & Berkowitz, PC

20080317868 - Composition for improving membrane composition and functioning cells: the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin... Agent: Banner & Witcoff, Ltd.

20080317869 - Method and compositions for treatment of add/adhd, depression, memory problems and other conditions: Disclosed herein are compositions and methods for treating a variety of mood and behavioral disorders, including attention deficit hyperactivity disorder (ADHD), anxiety, depression, memory loss, as well as other conditions. Also disclosed herein are methods for diagnosing certain conditions, such as ADHD, using these compositions.... Agent: Fennemore Craig

20080317870 - Compositions and mehtods for treating and preventing cancer using analogs of vitamin d: Disclosed are compositions and methods used to treat and/or prevent cancer and metabolic diseases, such as psoriasis. In one aspect, the present invention pertains to the use of cross-linking analogs of vitamin D and its metabolites employed for the treatment of prostate cancer.... Agent: Burns & Levinson, LLP

20080317871 - Use of hydrochloric acid for the manufacture of a medicament for the treatment of hypertension: A method of treating hypertension by administering to a patient an aqueous solution of HCl having a pH from 3 to 6.9 for a period of from 0.5 to 6 years and a method of treating a calculus disease by administering an aqueous solution of HCl having a pH from... Agent: Heslin Rothenberg Farley & Mesiti PC

20080317872 - Final finish aftershave: m

20080317873 - Pain relief compositions: A pain relieving composition for topical application is provided that includes magnesium sulfate (Epsom salts). The composition provides magnesium sulfate in an amount effective for providing pain relief. The composition has a viscosity effective for allowing topical application of the composition to an afflicted area where the magnesium sulfate is... Agent: Fitch Even Tabin And Flannery

20080317874 - Conversion of nitrogen dioxide (no2) to nitric oxide (no): A nitric oxide delivery system, which includes a gas bottle having nitrogen dioxide in air, converts nitrogen dioxide to nitric oxide and employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid. A nitric oxide delivery system may be used to... Agent: Steptoe & Johnson LLP

20080317875 - Inhibitor of pi3 kinase-dependent inflammatory cytokine synthesis and method for inhibiting the same: The present invention provides a novel inhibitor for inhibiting synthesis of a PI3 kinase-dependent inflammatory cytokine in vivo in a vertebrate and a method for inhibiting the same. More particularly, the present invention provides a suppressor for suppressing a cell-mediated immune response and a method for suppressing the same, as... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080317876 - Use of a magnesium isotope for treating hypoxia and a medicament comprising the same: wherein the residues A1, A2, A3, and A4 independently are a group containing 1 to 40 carbon atoms and at least one carboxylic group, the residues R, R′ and R″ independently are hydrogen or a group containing 1 to 80 carbon atoms, M is 2 H or an element capable... Agent: Kenyon & Kenyon LLP

20080317877 - Biofilm remover: A composition for the removal of biofilms from substrate surfaces formed by reacting: (a) one or more quaternary halide surfactants with (b) a source of reactive bromine ions in the ratio of 1 halide ion forming part of the quaternary surfactant to 0.05 to 8 moles of bromine ions in... Agent: Levisohn, Berger , LLP

20080317879 - Herb composition for asthma maintenance therapy and manufacturing method thereof: The present invention relates to a herb composition for asthma maintenance therapy based on Chungsangboha-tang, which is known to be effective in asthma, capable of reducing the long-term suffering of asthma patients and improving their quality of lives and a manufacturing method thereof. The herbal composition of the present invention... Agent: Ipla P.A.

20080317878 - Herbal therapy for the treatment of food allergy: The present invention provides herbal formulas, and compositions thereof, that can treat or reduce the severity, intensity, or duration of food allergy and food allergyrelated symptoms. The compositions may optionally include one or more adjuvants, cytokines, encapsulating materials, or pharmaceutically acceptable carriers or excipients, and may be administered prior to,... Agent: Choate, Hall & Stewart LLP

20080317881 - Method for sustainable transgene transcription: The present invention relates to constructs and methods for improving expression of transgenes in plants, animals and humans.... Agent: Wolf Greenfield & Sacks, P.C.

20080317880 - Plant isoflavone and isoflavanone o-methyltransferase genes: The invention provides enzymes that encode O-methyltransferases (OMTs) from Medicago truncatula that allow modification to plant (iso)flavonoid biosynthetic pathways. In certain aspects of the invention, the genes encoding these enzymes are provided. The invention therefore allows the modification of plants for isoflavonoid content. Transgenic plants comprising such enzymes are also... Agent: Sonnenschein Nath & Rosenthal LLP

20080317882 - Composistion comprising fremented tea extract as the main component and having effect of elevation adiponectin level: A composition capable of elevating blood adiponectin level and enlarging LDL particle size and thus lowering the concentration of small dense LDL in blood to thereby prevent diabetes and a heart disease such as a coronary artery disease or ameliorate the symptoms of these diseases, which originates in a natural... Agent: Drinker Biddle & Reath (dc)

20080317883 - Methods for treating depression: c

20080317884 - Enhancing disease resistance in an animal: A method to enhance disease resistance in an animal comprising feeding the animal a diet enriched in antioxidants and providing behavioral enrichment. In one embodiment, the behavioral enrichment comprises exercising the animal regularly effective to cause behavioral enrichment, wherein the feeding and exercising combination is effective to increase neutrophil phagocytosis... Agent: Colgate-palmolive Company

20080317885 - Compositions and methods for treating and preventing inflammatory and/or degenerative processes in humans and other animals: Disclosed are compositions useful for treating Alzheimer's disease, atherosclerosis, arteriosclerosis, osteoarthritis and other degenerative joint diseases, Huntington's chorea, Parkinson's disease, optic atrophy, retinitis pigmentosa, macular degeneration, muscular dystrophy, aging-associated degenerative processes, asthma, dermatitis, laminitis, pemphigoid, pemphigus, reactive airway disease (e.g., COPD, IAD), inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis),... Agent: Peter Rogalskyj Rogalskyj & Weyand

20080317886 - Compositions for preventing and reducing delayed onset muscle soreness: The present invention relates to the compositions that enhance post-exercise recovery processes to increase both strength and muscle mass, replace glycogen stores, and prevent inflammation, resulting in the prevention and/or reduction of delayed onset muscle soreness. Additionally, it provides a feeling of muscle relaxation as well as a feeling of... Agent: T. Ling Chwang Jackson Walker L.L.P.

20080317887 - Compositions and methods for treating and preventing migrainous headaches and associated symptoms: Compositions and methods of treating migrainous headaches and their associated symptoms are provided. Methods of treating migrainous headaches and their associated symptoms include administering a lipid-based composition containing feverfew extract and ginger extract sublingually to a patient in need thereof. Treatments are effective using low total administered amounts of feverfew... Agent: Akerman Senterfitt

20080317888 - Process for obtaining lignans: Process for obtaining lignan from plant material by extraction with an extraction solvent and separation of the liquid fraction from the plant material. The separated liquid fraction containing the lignan product is subjected to further processing to remove cyanogenic sugars and other impurities. The resulting lignan containing product may be... Agent: K&l Gates LLP Henry W. Oliver Building

20080317889 - Liquid compositions containing solubilized benzoyl peroxide, devices for application of same and methods of treatment using same: Liquid medicaments incorporate about 1.0-3.0% active benzoyl peroxide (BP) by weight in substantially fully solubilized form, while being substantially free of acetone and other harsh, dermatologically undesirable solvents. The novel compositions are produced by (a) creating an emulsion or slurry of BP in an emollient, topically acceptable ester, and (b)... Agent: Kirschstein, Ottinger, Israel & Schiffmiller, P.C.

20080317890 - Method for treating visual impairment through the prophylactic administration of a morinda citrifolia-based naturaceutical: Implementation of the present invention takes place in association with the utilization of one or more processed products produced from the Indian Mulberry plant, scientifically known as Morinda citrifolia L., to treat one or more eye disorders that affect vision, such as glaucoma, diabetic retinopathy, retinitis pigmentosa, cataracts, age-related macular... Agent: Michael F. Krieger Kirton & Mcconkie

20080317891 - Edible products having a high cocoa polyphenol content and improved flavor and the milled cocoa extracts used therein: Milling dry extracts containing cocoa polyphenols (CPs) to reduce the particle size improves the flavor of edible products (e.g., foods, medical foods, nutritional supplements, and pharmaceuticals) or additives containing the milled cocoa extracts. The products, e.g., chocolates, are less astringent and less bitter. The mean particle size after milling is... Agent: Gibbons P.C.

20080311034 - Anti-tissue factor antibodies and compositions with enhanced effector function: Variants of antibodies to human tissue factor are optimized for the capability to elicit effector functions produced by immune effector cells while maintaining the ability to neutralize the biological functions of tissue factor, such as the prevention of blood clotting via the extrinsic pathway, and are produced by mutations of... Agent: Philip S. Johnson Johnson & Johnson

20080311035 - Diagnostic agents for positron emission imaging using radiolabeled halogenated xanthenes: New diagnostic agents for positron emission tomography (PET) and methods for use of such agents for imaging of human or animal tissue are described, wherein a primary active component of such agents is a radiolabeled halogenated xanthene or halogenated xanthene derivative. Preferably, the radiolabeled halogenated xanthene is radiolabeled Rose Bengal... Agent: Cook Alex Ltd

20080311036 - Imaging of neural and organ injury or damage: In vivo determination of regional damage with neural and organ injury specific imaging agents. Rapid, and non-invasive imaging compositions and methods for assessment of the extent of neurotoxic cell loss or nervous system damage resulting from nervous system injury due to ischemia, stroke, trauma, chemical or electrical insult, acute drug... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080311037 - Compounds which bind psma and uses thereof: The compounds are useful as PSMA agents and in pharmaceutical compositions, methods for treating and detecting diseases such as cancer in a subject, methods for identifying cancer cells in a sample, methods for inhibiting tumor neovascularization, methods for identifying drugs that can treat cancer, and the like.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080311038 - Radicicol derivatives useful for position emission tomography: e

20080311042 - Loop-variant pdz domains as biotherapeutics, diagnostics and research reagents: The present invention provides polypeptides that contain one or more PDZ loop-variants and are useful in the detection of pathogens and disease-associated molecules. The polypeptides of the invention are also useful in the diagnosis, treatment, and prevention of diseases. Also provided are methods of preparing polypeptides of the invention.... Agent: Fish & Richardson PC

20080311040 - Methods and compositions for improved therapeutic effects with sirna: The present invention relates to chemically modified, linked double-stranded (ds)RNA compositions comprising two or more double-stranded (ds) oligoribonucleotides linked by at least one linking moiety and methods of formulating and delivering such compositions to modulate gene expression through target-specific RNA co-interference (RNAco-i). The compositions of the invention may optionally comprise... Agent: Noel E. Day Miller, Canfield, Paddock & Stone

20080311039 - Therapeutic and prognostic factor yy1 in human cancer: The present invention provides for the first time YY1, a transcription factor gene over-expressed and/or functionally overactive in human cancer. The present invention provides methods of diagnosing and providing a prognosis for cancer such as prostate cancer, as well as methods of drug discovery. YY1 is also a therapeutic target... Agent: Townsend And Townsend And Crew, LLP

20080311041 - Water-soluble, fluorescent compounds for detection of potassium ions: The invention provides chromoionophore compounds comprising a triazacryptand (TAC) K+ ionophore conjugated to at least a first chromophoric moiety (e.g., xanthylium dyes and derivatives thereof). In related embodiments, the chromoionophore compounds further comprise a second chromophoric moiety which is insensitive to potassium binding by the TAC ionophore, thus providing for... Agent: Bozicevic, Field & Francis LLP

20080311044 - Methods of determining hair follicle inductive properties: The present invention provides a method for determining hair inductive properties of a composition comprising injecting a composition comprising dissociated dermal cells and epidermal cells into skin of a mammal and determining whether at least one hair follicle forms.... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080311043 - Uses and compositions for treatment of psoriatic arthritis: The invention provides methods, uses and compositions for the treatment of psoriatic arthritis. The invention describes methods and uses for treating psoriatic arthritis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to psoriatic arthritis in a subject. Also described are methods for... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080311045 - Polymersomes for use in acoustically mediated intracellular drug delivery in vivo: Targeted therapeutic delivery systems comprising specially designed nanocarriers for intracellular therapeutic delivery, mediated by acoustic energy, for use either in vivo or in vitro, are described. Nanocarriers comprised of substantially polymersomes, and mixtures thereof, are used to treat a variety of diseases in humans and other species, such as cancer,... Agent: Biovaluation & Analysis, Inc.

20080311048 - Imaging agent: The invention provides a conjugate comprising an iron containing colloidal particle, the particle being conjugated to one or more sugar targeting moieties. The conjugate is useful as a contrast agent in medical imaging, particularly in magnetic resonance imaging (MRI). The agents of the present invention may cross the blood brain... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20080311046 - Ultrasound contrast agent: An ultrasound contrast agent composed of at least one kind of low-boiling water-insoluble substance (with a boiling point lower than 37° C.) and at least one kind of high-boiling water-insoluble substance (with a boiling point higher than 37° C.). The former vaporizes to absorb ultrasonic energy upon application of ultrasound,... Agent: Reed Smith LLP

20080311047 - Multimetric biosensors and methods of using same: Multimeric tryptophan biosensors are disclosed, which comprise tryptophan-binding domains conjugated to donor and fluorescent moieties that permit detection and measurement of Fluorescence Resonance Energy Transfer upon tryptophan binding. Such biosensors are useful for real time monitoring of tryptophan metabolism in living cells.... Agent: Morgan Lewis & Bockius LLP

20080311049 - Abuse-proof dosage form: The invention relates to a dosage form that is thermoformed without discoloration and is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse. The invention... Agent: Norris, Mclaughlin & Marcus, P.A.

20080311051 - Caspase-2 inhibitors and their biological applications: The invention relates to selective new caspase-2 inhibitors that recognize caspase-2 and prevent and block its activity based on the following backbone: 2-Quinolinylcarbonyl-L-Valinyl-L-Aspartyl (methyl ester)-L-Vanilyl-L-Alaninyl-L-Aspartyl (methyl ester) 2,6-difluorophenyl ester (SEQ1) and derivatives thereof, SEQ 1 corresponding to formulae (Ia) or (Ib). Application of said inhibitors for preventing and treating diseases... Agent: Nixon & Vanderhye, PC

20080311052 - Isis pharmaceuticals, inc.: Disclosed herein are compounds, compositions and methods for modulating the expression of STAT 6 in a cell, tissue, or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of STAT 6, airway hyperresponsiveness, and/or... Agent: Knobbe, Martens, Olson & Bear, LLP

20080311050 - Method for producing shape memory effects in hair in connection with hydrophobic active ingredients: A method for achieving a retrievable hair restyling is described. Here a composition is applied to the hair, said composition containing at least one first active ingredient or active ingredient complex which can provide a shape memory effect by itself or in combination with other substances after being applied to... Agent: Seed Intellectual Property Law Group PLLC

20080311053 - Fluorinated phosphate ester surfactant and fluorinated alcohol compositions: Foaming compositions having high solvent content and compositions for foaming high solvent content formulations are disclosed having a fluorinated phosphate ester surfactant (“FPES”) of the formula (Ra—O)x—P(O)—(ORb)y in combination with a fluorinated alcohol (“FA”) of the formula RcOH, where x is 1 to 3, y is (3−x), Ra is a... Agent: Irving M. Fishman

20080311054 - Compositions and methods to counteract oral malodour: The invention relates to hedonistically pleasing oral malodour counteracting compositions including flavour compositions and oral care products, methods to form such compositions and methods to counteract oral malodour. The compositions comprises 2 or more of oral malodour counteracting actives of formula I in a total concentration of at least 10%... Agent: Norris, Mclaughlin & Marcus

20080311055 - Mono-, di- and polyol alkoxylate phosphate esters in oral care formulations and methods for using same: This invention relates to a composition useful as an oral care composition comprising an organophosphate material, additional oral care composition ingredients, for example, a surfactant agent, and optionally an abrasive agent.... Agent: Novak Druce + Quigg, LLP

20080311056 - Bactericide against streptococcus mutans and streptococcus sobrinus: The present invention provides an enzyme with lytic activity against cariogenic bacteria and a means for treating and preventing tooth decay using the enzyme. The enzyme provided by the present invention is a lytic enzyme produced by Streptococcus mutans and has a substrate specificity for lysing selectively Streptococcus mutans and... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20080311057 - Bleaching toothpastes and methods for making and using them: In toothpaste, the addition of the Iodide ion by way of iodide salts, such as sodium iodide and potassium iodide, to a peroxide such as hydrogen peroxide in a basic medium yields free radical oxygen and water; generating large amounts of heat and depleting the Hydrogen Peroxide in a matter... Agent: Geoffrey E. Dobbin, Patent Attorney

20080311059 - Composition for skin care and method for the same: A skin whitening composition and a method for the same are provided. The skin whitening composition comprises a far-infrared ray releasing substance having a primary component of an oxide mineral, wherein the skin whitening composition achieves a whitening effect via an irradiation of the far-infrared ray releasing substance. In another... Agent: Volpe And Koenig, P.C.

20080311060 - Organopolysiloxane, a method of preparing the same and a cosmetic comprising the same: An organopolysiloxane having a main chain composed of the following repeating units (I), 2 to 199 side chain units (II) and 1 to 50 crosslinkage units (III) per 100 SiO units in the main chain, provided that the organopolysiloxane has at least 2, on average, crosslinkage units (III):... Agent: Birch Stewart Kolasch & Birch

20080311058 - Stable high internal phase emulsions and compositions comprising the same: High internal phase emulsions and end use compositions made therefrom are described. The high internal phase emulsions have superior stability and sensory characteristics and can be prepared with less than 20% by weight elastomer, an emulsifier and a steric stabilizer characterized as a polyether and/or polyglycerine cross-linked elastomer.... Agent: Unilever Patent Group

20080311061 - Cosmetic skin color determination and color mixing apparatus: A cosmetic color apparatus includes a color measurement device for measuring a skin color of an individual. A computer processing device is provided in communication the color measurement device for performing a comparison of the measured skin color with a desired color so as to provide color information. A color... Agent: Darby & Darby P.C.

20080311062 - Water-in-oil emulsions for hair treatment: The present invention provides a water-in-oil emulsion for hair treatment comprising: (a) an oil phase comprising: (i) a first oily component which is one or more glyceride fatty esters, and (ii) a second oily component which is one or more hydrocarbon oils of average carbon chain length less than 20... Agent: Unilever Patent Group

20080311065 - Anti-oxidant macromonomers and polymers and methods of making and using the same: The present invention relates to macromonomer compounds possessing antioxidant properties, antioxidant polymers comprising the antioxidant macromonomers as a recurring unit, and methods of inhibiting oxidation in a substance comprising contacting the substance with the antioxidant polymers. In one embodiment, substantially all of the recurring macromonomeric units of the antioxidant polymers... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080311064 - Higher performance capsule particles: It is an object of our invention to provide capsule particles and a method of creating larger and robust capsule particles that will have excellent storage stability and enhanced perfumer performance in a range of consumer products.... Agent: International Flavors & Fragrances Inc.

20080311068 - Hair conditioning composition comprising amine-type cationic surfactant and direct dye: Disclosed is a hair conditioning composition comprising by weight: (a) from about 0.2% to about 10% of a cationic surfactant which is a salt of: (i) primary, secondary, and tertiary amines wherein the amines have one long alkyl or alkenyl group of from about 20 to about 24 carbon atoms;... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080311066 - Cosmetics compositions comprising at least one surfactant and at least one novel ethylene copolymer with polyethylene glycol grafts: s

20080311067 - Hair conditioning compositions:

20080311063 - Method for imparting curl to lashes: There is a method for imparting curl to eyelashes. The method has the step of applying to the eyelashes an anhydrous liquid composition having the following: a) an organic solvent and b) an alkyl cycloalkylacrylate copolymer soluble or dispersible in the solvent. The organic solvent is present in an amount... Agent: Avon Products, Inc.

20080311069 - Malodor counteracting compositions and method for their use: The present invention relates to the field of perfumery and more particularly to the field of malodor counteractancy. In particular, it relates to a malodor counteracting (MOC) compositions capable of neutralizing in an efficient manner, through chemical reactions, malodors of a large variety of origins and which can be encountered... Agent: Winston & Strawn LLP Patent Department

20080311070 - Ophthalmic composition with hyaluronic acid: An ophthalmic composition comprising a polymeric biguanide composition having less than 18 mol % of terminal amine groups and 55 mol % or greater of terminal guanidine groups as measured by 13C NMR, and 0.005 w/v % to 0.04 w/v % hyaluronic acid. Alternatively, the ophthalmic composition comprises a polymeric... Agent: Bausch & Lomb Incorporated

20080311071 - Film forming compositon: The present application relates to a film forming composition for application to mammalian skin, which composition comprises at least one polyurethane based polymer together with at least one acrylate based polymer. The film forming composition provides effective skin coating with good adhesion to the skin, and may be used as... Agent: Barlow, Josephs & Holmes, Ltd.

20080311072 - Preparation of soluble and colloidal molecularly imprinted polymers by living polymerization: The present invention describes a method for synthesis of relatively low molecular weight imprinted polymers using living polymerization, and their application in analytical chemistry, pharmacology, medicine and the food industry. Specifically the low-molecular weight polymers are synthesized by the polymerization of functional monomers in the presence of a template, such... Agent: Stites & Harbison PLLC

20080311075 - Hepatitis c virus inhibitors: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080311073 - Ilt3 polypeptides and uses thereof: This invention provides a first polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water-soluble and does not comprise the Fc portion of an immunoglobulin. This invention also provides a second polypeptide comprising (i) all or a portion of the extracellular domain of... Agent: Ropes & Gray LLP

20080311074 - Inhibitors against activation of nf-kappab: A method of inhibiting NF-κB activation in a mammal including a human, which comprises the step of administering an effective dose of a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and... Agent: Greenblum & Bernstein, P.L.C

20080311077 - Antiviral compounds: The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Gilead Sciences Inc

20080311076 - Morpholinylanilinoquinazoline derivatives for use as antiviral agents: Compounds of formula (Ia) are found to be active in inhibiting replication of flaviviridae viruses, wherein R1, R2, R3 and R4 are as defined in the claims.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080311078 - Self-buffering protein formulations: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the... Agent: Larry S. Millstein Holland & Knight LLP

20080311079 - Inhibitors of serine proteases, particularly hcv ns3-ns4a protease: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these... Agent: Ropes & Gray LLP

20080311080 - Bifidobacterium in the treatment of inflammatory disease: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may... Agent: Wolf Greenfield & Sacks, P.C.

20080311096 - Combinations of cry1ab and cry1fa as an insect resistance management tool: Compositions for controlling lepidopteran insects use Cry1Fa and Cry1Ab core toxin containing proteins in combination to delay or prevent development of resistance.... Agent: Dow Agrosciences LLC

20080311091 - Engineered dopamine neurons and uses thereof: The invention relates to dopamine neuron determinants, the use of these determinants in differentiating cells to dopamine neurons, cells produced by the over-expression of these determinants, and uses of these cells.... Agent: Wolf Greenfield & Sacks, P.C.

20080311094 - Isolated liver stem cells: Isolated liver progenitor stem cells and cell populations of isolated liver progenitor stem cells are disclosed. The progenitor stem cells originate from adult liver, especially human adult liver. The isolated progenitor stem cells have uses in medicine, hepatology, inborn errors of liver metabolism transplantation, infectious diseases and liver failure. Methods... Agent: Knobbe Martens Olson & Bear LLP

20080311095 - Methods and compositions for increased transgene expression: Described herein are methods of expressing nucleic acids in T cells pre-exposed to a co-stimulatory signal and then transduced with adenoviral vectors. In some embodiments, the co-stimulation is provided by anti-CD3 and anti-CD28 antibodies and the adenoviral vector is pseudotyped for T-cell entry. The invention also relates to compositions for... Agent: Robins & Pasternak

20080311090 - Methods for inhibition of proliferative disease, including hepatocellular carcinoma: The present invention is related to a method for modulating expression of protein kinase C-alpha associated with proliferative diseases. The invention further relates to a screening method utilizing the association between transcription factors (MZF-1 and Elk-1) and their DNA binding element (PKC-.alpha. promoter) to identify novel anticancer agents.... Agent: Wpat, PC Intellectual Property Attorneys

20080311092 - Murine stem cells and applications thereof: The invention relates to animal solid tumour models which comprise a transgenic non-human mammal containing in its genome a DNA construct that comprises a gene created and/or activated by a genetic anomaly associated with human cancer operatively bound to a promoter that directs the expression of the gene in Sca1+... Agent: Morrison & Foerster LLP

20080311093 - Stem cell secretions and related methods: Stem cell secretions are derived from epithelial cells conditioned media. The stem cell secretions are then applied topically, orally, or rectally, etc., to derive health benefits from the growth factors and other molecules comprising the stem cell secretion. The stem cell secretion may optionally be modified by covalently bonding fatty... Agent: Greenberg Traurig LLP (la)

20080311081 - Bacteria mediated gene silencing: Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium or BTP. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating viral diseases and disorders. The... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080311097 - Treatment of ibd and ibs using both probiotic bacteria and fermented cereal as treatment effectors: The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors. Phospholipids may also be... Agent: Darby & Darby P.C.

20080311082 - Process for treating animal waste: The present invention is directed to a process for reducing a population of one, or more than one target pathogen present in animal waste, including livestock manure , comprising administering one, or more than one protected bacteriophage strain to livestock. The one, or more than one bateriophage strain is capable... Agent: Brinks, Hofer, Gilson & Lione

20080311089 - Augmentation and repair of vocal cord tissue defects: e

20080311087 - Human umbilical tissue-derived cell compositions for the treatment of incontinence: Compositions for the treatment of incontinence are disclosed. More particularly, compositions of human umbilical tissue-derived cells and a carrier are disclosed. The compositions are useful in the treatment urinary and fecal incontinence.... Agent: Philip S. Johnson Johnson & Johnson

20080311084 - Mapc engraftment in the hematopoietic system: The present invention relates to MAPCs and progeny derived therefrom to provide lymphohematopoietic cells in a tissue of the lymphohematopoietic system of a subject.... Agent: Thompson Hine L.L.P. Intellectual Property Group

20080311085 - Method for treating an animal having damaged tissue structure: A method for treating an animal having damaged tissue structure includes harvesting a tissue sample from a subject harvesting a tissue sample from the animal, growing tendon-like cells from the tissue sample, and transplanting the tendon-like cells into the damaged tissue structure. Growing the tendon-like cells from the tissue sample... Agent: Patrick R. Scanlon Preti Flaherty Beliveau & Pachios LLP

20080311088 - Method of treating lung diseases using cells separated or proliferated from umbilical cord blood: There is provided a method of treating lung diseases including administering cells separated or proliferated from umbilical cord blood to a patient suffering from such diseases.... Agent: Sughrue Mion, PLLC

20080311083 - Methods of modulating beta cell function: Methods of modulating pancreatic function by modulating MCH signaling in a β cell.... Agent: Fish & Richardson PC

20080311086 - Use of keratinocyte composition for the treatment of restenosis: Methods for treating and/or preventing restenosis in a subject by local administration to the subject of a composition that includes keratinocytes is disclosed. Administration is preferably by way of a catheter having an inflatable balloon, such as a double or dumbbell-shaped balloon.... Agent: Knobbe Martens Olson & Bear LLP

20080311098 - Compounds and methods for modulating the immune response against antigens: Chimeric nucleic acids and polypeptides comprising an antigen or an epitope thereof are described, as well as compositions and methods to increase the presentation of an antigen or epitope by MHC class II molecules and to modulate the immune response.... Agent: Goudreau Gage Dubuc

20080311099 - Pyridoxal-5-phosphate and related compounds in combination with therapeutic cardiovascular compounds for treating angina: Methods for treating angina are described. A method for treating angina includes concurrently administering a compound with a therapeutic cardiovascular compound. A combination therapy employs suitable therapeutic cardiovascular compounds, such as a calcium channel blocker, a β-adrenergic blocker, nitrates, partial fatty acid oxidation inhibitors, potassium channel activators, or a mixture... Agent: Merchant & Gould PC

20080311100 - Treatment of keratinous dryness with glycerides: The present invention provides the use of medium chain glyceride(s) as an active ingredient for the preparation of a composition for oral and/or parenteral absorption and intended to prevent and/or treat dry and/or delicate keratinous substances.... Agent: Oliff & Berridge, PLC

20080311101 - Method to reduce oxalate concentration by administration of oxalate oxidase crystals: The invention relates to methods to prevent, treat, or slow the progression of a disorder associated with elevated oxalate concentration, the method comprising administering oxalate oxidase crystals, cross-linked crystals, or compositions containing those crystals to an individual. Oxalate oxidase crystals and compositions for administration to an individual are also provided,... Agent: Lowrie, Lando & Anastasi, LLP

20080311102 - Acylglycerol acyltransferase-like protein mgat-x1 and uses thereof: The present invention is directed to a polynucleotide sequence of a novel acylglycerol acyltransferase-like protein MGAT-X1. The invention also provides the human MGAT-X1 associated with the dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases. The invention also provides... Agent: Banner & Witcoff, Ltd.

20080311103 - Anti-inflammatory peptides and methods of use thereof: Anti-inflammatory peptides derived from naturally occurring digests of proteins including apolipoprotein A-I, apolipoprotein A-II, fibrinogen γ chain, fibrinogen Aa, low-density lipoprotein receptor, ADAM 8, cadherin 4, and calcitonin receptor are provided, along with pharmaceutical compositions comprising same and methods of treating inflammatory diseases using same.... Agent: Heslin Rothenberg Farley & Mesiti PC

20080311105 - Reversibly inactivated acidified plasmin: The present invention provides a fibrinolytic composition useful as a therapeutic for administration to a patient having a thrombotic occlusion. In one aspect of the present invention, the fibrinolytic composition comprises a reversibly inactivated acidified serine protease substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally,... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080311104 - Stabilized thrombin compositions: Stabilized thrombin compositions, processes for preparing them, and kits comprising them are disclosed. The compositions comprise thrombin, a bacteriostatically effective amount of benzyl alcohol or chlorobutanol, and 0.10%-5.0% (w/v) sucrose in aqueous solution. The compositions are stable when stored at 2° C.-8° C. for four weeks or more.... Agent: Zymogenetics, Inc. Intellectual Property Department

20080311110 - Chimeric vaccine for haemophilus influenzae-induced disease: The invention described herein relates to a chimeric protein comprising the NTHi twitching pilus major subunit protein (PilA) presenting a portion of the NTHi OMP P5 protein. The invention provides for vaccine compositions comprising the recombinant chimeric protein and methods of eliciting an immune response using the recombinant chimeric proteins... Agent: Marshall, Gerstein & Borun LLP

20080311111 - Competitive domain antibody formats that bind interleukin 1 receptor type 1: The invention relates to dAb monomers that bind IL-1R1 and inhibit binding of IL-1 (e.g., IL-1α and/or IL-1β) and IL-1ra to IL-1R1, and to ligands comprising such dAb monomers. The invention relates to protease resist and dAb monomers, and to ligands comprising protease resistant dAb monomers. The invention also relates... Agent: Mcdermott Will & Emery LLP

20080311109 - Compositions and methods for the therapy and diagnosis of breast cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group PLLC

20080311113 - Method for treating adamts-5-associated disease: The present invention relates to methods of treating ADAMTS-5-associated diseases and particularly osteoarthritis comprising administering an agent capable of modulating ADMATS-5 activity to a subject afflicted with the disease. The agent is preferably a biaryl sulfonamide compound. The invention is based, in part, on the discovery that transgenic animals that... Agent: Fitzpatrick Cella (wyeth)

20080311107 - Novel gene disruptions, compositions and methods relating thereto: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO188, PRO235, PRO266, PRO337, PRO361, PRO539, PRO698, PRO717, PRO846, PRO874, PRO98346, PRO1082, PRO1097, PRO1192, PRO1268, PRO1278, PRO1303, PRO1308, PRO1338, PRO1378,... Agent: Genentech, Inc.

20080311108 - Polypeptides: The invention relates to antigenic polypeptides expressed by pathogenic microbes, vaccines comprising said polypeptides; therapeutic antibodies directed to said polypeptides and methods to manufacture said polypeptides, vaccines and antibodies.... Agent: Speckman Law Group PLLC

20080311106 - Product comprising a c4bp core protein and a monomeric antigen, and its use: The invention provides a product which comprises a C4bp core protein and a monomeric antigen, desirably in the form of a fusion protein. Monomeric antigens include malarial and influenza antigens. The C4bp core protein provides for assembly of multimeric complexes of the monomeric antigen, or mixtures thereof. The complexes are... Agent: Nixon & Vanderhye, PC

20080311114 - Use of morphogenic proteins to treat human disc disease: Bone morphogenetic proteins (BMPs) are introduced into an affected intervertebral disc without the inclusion of disc cells. The inventions applies to all known and yet-to-be developed or discovered BMPs, including BMP-1, -2, -3, -4, -5, -6, -7, -8, -9, -10, . . . BMPn. The BMP(s) may be obtained from... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20080311112 - Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders: The present invention relates to the use of a TLR9 agonist and/or a TLR4 antagonist and/or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis and necrotizing enterocolitis.... Agent: Baker Botts L.L.P.

20080311115 - Anti-il-20 antibody and its use in treating il-20 associated inflammatory diseases: This invention features an antibody specifically binding to human IL-20 (e.g., mAb 7E and a equivalent thereof) and its use in treating an IL-20 associated inflammatory disease, such as atherosclerosis, RA, psoriasis, psoriatic arthritis, bacteria-induced gastric ulcer, and acute renal failure.... Agent: Occhiuti Rohlicek & Tsao, LLP

20080311117 - Antibodies against pd-1 and uses therefor: This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders,... Agent: Wolf Greenfield & Sacks, P.C.

20080311119 - Antibody formulations: Formulations of VLA-4 binding antibody are described.... Agent: Lowrie, Lando & Anastasi, LLP B2047

20080311120 - Autocrine growth factor receptor antibodies and methods: Disclosed herein are antitumor compositions and methods of interfering with the biological activity of PC cell derived growth factor (PCDGF), anti-PCDGF receptor antibodies, fragments thereof, and methods of making anti-PCDGF receptor antibodies. The methods involve inhibiting the proliferation of tumor cells expressing the PCDGF receptor by contacting the surface of... Agent: Connolly Bove Lodge & Hutz LLP

20080311116 - Process for the determination of inflammatory process and pharmaceutical compositions for the treatment thereof: A method for analyzing extracellular body fluids as to the presence of the Y-box protein YB-1 and fragments thereof, which are secreted by the cell, in order to determine inflammatory processes and malignant diseases in mammals. Also, it relates to the use of YB-1 as a marker and a kit... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20080311118 - Vascular endothelial cell growth factor antagonists and uses thereof: The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided.... Agent: Jones Day

20080311122 - Antagonists of hmgb1 and/or rage and methods of use thereof: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present... Agent: Medimmune, LLC Jonathan Klein-evans

20080311121 - Antibody antagonists of ve-cadherin without adverse effects on vascular permeability: The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine cells indicated that E4B9 indeed cross-reacts with human VE-cadherin. (FIG. 6). This finding facilitates... Agent: Imclon Lerner, David, Littenberg, Krumholz & Mentlik, LLP

20080311123 - Compositions and methods for the therapy and diagnosis of breast cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group PLLC

20080311124 - Compositions and methods for the therapy and diagnosis of breast cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group PLLC

20080311125 - Scytovirin domain 1 related polypeptides: A scytovirin domain 1 (SD1) polypeptide, a nucleic acid encoding the polypeptide, and related fusion proteins, conjugates, isolated cells, vectors, and antibodies, as well as a method of inhibiting a viral infection using the same.... Agent: Leydig, Voit & Mayer, Ltd.

20080311126 - Antisense oligonucleotides directed to ribonucleotide reducatase r2 and uses thereof in combination therapies for the treatment of cancer: Combination products comprising an antisense oligonucleotide against the gene encoding a mammalian ribonucleotide reductase R2 protein and one or more immunotherapeutic agents, such as cytokines, non-cytokine adjuvants, monoclonal antibodies and cancer vaccines. The combinations can further comprise one or more chemotherapeutic agents. Methods of treating cancer in a mammal using... Agent: Clark & Elbing LLP

20080311127 - Combination therapy for treating disease: Disclosed are methods for treating cancer comprising administering a xenotypic antibody and a chemotherapeutic drug to a patient suffering from cancer. Also disclosed is a method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen present in the host serum, which antigen does... Agent: Ropes & Gray LLP

20080311128 - Method for treating pathological pulmonary conditions and bleomycin associated pulmonary fibrosis: Methods for treating pathological pulmonary conditions and bleomycin associated pulmonary fibrosis administer IL-16 antagonists, for example, anti-IL-16 antibodies, to subjects.... Agent: Philip S. Johnson Johnson & Johnson

20080311129 - Adherence inhibitor directed to and method of making and using: A method for the production of antibodies or microbial adherents administers is disclosed. The antibodies or microbial adherents inhibitors are administered to a patient suffering from strep throat to substantially prevent the adherents of colony-forming immunogens or haptens in the throat of the patient. Application of the antibodies should decrease... Agent: Westman Champlin & Kelly, P.A.

20080311130 - Integrin alpha l i domain mutants with increased binding affinity: The present invention provides an isolated polypeptide capable of binding to aCAM-1, comprising the integrin (XL I domain or biologically active portion thereof, wherein one or more residues is substituted, wherein the substituted polypeptide binds ICAM-I at a higher affinity than wild type integrin CCL protein. The invention provides a... Agent: David S. Resnick

20080311131 - Human mob-5 (il-24) receptors and uses thereof: The present invention provides the receptors for Mob-5 (IL-24). One of the Mob-5 receptors comprises IL-22R1 and IL-20R2. Another Mob-5 receptor comprises IL-20R1 and IL-22R2. The invention also provides methods of inhibiting the Mob-5 receptor as well as methods of detecting cancer by detecting the presence of the Mob-5 receptor.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080311134 - Cysteine engineered anti-muc16 antibodies and antibody drug conjugates: e

20080311132 - Human complement c3 derivates with cobra venom factor-like function: A modified human complement C3 protein (C3) is disclosed comprising a substitution of a portion of a human C3 protein, with a corresponding portion of a Cobra Venom Factor protein (CVF) which results in a human C3 protein with CVF functions, but with substantially reduced immunogenicity. Advantageously, the C3 protein... Agent: Morrison & Foerster LLP

20080311135 - Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations: The present invention generally concerns methods and compositions for improving the immune system of an individual that is an immune-compromised individual. In particular aspects, the immune-compromised individual is elderly or is immunosuppressed, such as from chemotherapy or immunosuppressants following organ or tissue transplantation. In specific embodiments, the invention relates to... Agent: Fulbright & Jaworski, LLP

20080311133 - Methods of using multivalent mhc class ii-peptide chimeras: The present invention provides a multimeric complex of at least two chimeric molecules, wherein the chimeric molecules comprise an immunoglobulin constant region element and two MHC elements wherein each MHC element is associated with a peptide, and wherein the chimeric molecules are covalently linked through a carbohydrate residue of the... Agent: Marshall, Gerstein & Borun LLP

20080311136 - Triazole-containing releasable linkers, conjugates thereof, and methods of preparation: This invention relates to compounds comprising one or more therapeutic and/or diagnostic moieties and one or more functional moieties linked together via one or more triazole-containing linkers and to their intermediates and methods of their preparation. The triazole-containing linker may optionally contain one or more conditionally-cleavable or conditionally-transformable moieties and... Agent: K&l Gates LLP

20080311138 - Adjuvant activity of gastrointestinal peptides: Gastrointestinal peptides (GPs) have been found to function as vaccine adjuvants, and in particular as mucosal adjuvants. The invention provides an immunogenic composition comprising: (a) a GP adjuvant; and (b) an antigen. The composition is preferably suitable for mucosal administration e.g. intranasal administration.... Agent: Banner & Witcoff, Ltd.

20080311140 - Antigen specific immunosuppression by dendritic cell therapy: The invention includes genetically modified dendritic cells expressing at least two immunosuppressive molecules. The genetically modified dendritic cells have the ability to induce tolerance. Enhanced tolerogenicity is useful for prolonging survival of a foreign transplant and for treatment of autoimmune diseases.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080311137 - Carcinoembryonic antigen fusions and uses thereof: Polynucleotides encoding carcinoembryonic antigen (CEA) fusion proteins are provided, the CEA fusion proteins comprising a CEA protein, or functional variant thereof, fused to a substantial portion of an immunoenhancing element. The polynucleotides of the present invention can elicit an immune response in a mammal, which, in preferred embodiments, is stronger... Agent: Merck And Co., Inc

20080311139 - Plant produced vaccine for amebiasis: Disclosed herein are methods of making a vaccine against Entamoeba histolytica and methods of immunizing a subject using such vaccine. Specifically exemplified are plants expressing a LecA polypeptide and plant material obtained from such plant being used as a basis for vaccination.... Agent: Timothy H. Van Dyke

20080311141 - Cancer vaccines and vaccination methods: Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.... Agent: Fish & Richardson PC

20080311142 - Cancer vaccines and vaccination methods: Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.... Agent: Fish & Richardson PC

20080311143 - Construction of chimera prrsv, compositions and vaccine preparations: Chimeric replicons of North American Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) containing the 5′ sequence of an avirulent strain of PRRSV and a 3′ sequence of a virulent strain of PRRSV are provided. Further provided is a method of producing attenuated PRRSV from the chimeric replicon. Also provided are... Agent: Michael Best & Friedrich LLP

20080311146 - Immunogenic composition: The present invention discloses an immunogenic composition comprising at least two different isolated staphylococcal polypeptides, each comprising an IgG binding domain. In a further embodiment, the invention discloses a polypeptide comprising: a protein A part including at least one IgG binding domain and an Sbi part including at least one... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080311144 - Mutant forms of cholera holotoxin as an adjuvant: Mutant cholera holotoxins having single or double amino acid substitutions or insertions have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in antigenic compositions to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus,... Agent: Howson And Howson

20080311145 - Protein cage immunotherapeutics: The present invention provides compositions of heat shock protein cages for use in therapeutic vaccines. The heat shock protein cages of the invention have attached antigen, located either on the interior or exterior of the protein cage, and optionally an adjuvant.... Agent: Townsend And Townsend And Crew, LLP

20080311148 - Dna-transfection system for the generation of infectious influenza virus: The present invention is based on the development of a dual promoter system (preferably a RNA pol I-pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080311149 - Dna-transfection system for the generation of infectious influenza virus: The present invention is based on the development of a dual promoter system (preferably a RNA pol I-pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080311150 - Novel sequences encoding hepatitis c virus glycoproteins: The present invention concerns a modified nucleic acid molecule comprising a nucleotide sequence coding for a full length hepatitis C virus (HCV) glycoprotein selected from the group consisting of E1 glycoprotein and E1/E2 glycoprotein heterodimer, this molecule having at least one nucleotide alteration, wherein, due to this alteration, at least... Agent: Cooper & Dunham, LLP

20080311147 - Rhabdoviral n-fusion proteins as carrier for foreign antigens: Rabies virus (RV) nucleoprotein (N) tightly encapsidates the genomic and antigenomic RNA thereby forming the ribonucleoprotein (RNP) complex. Antigens presented in a rigid and repetitive organization are sufficient to activate B cells to proliferate. In addition to the repetitive organization, it has been shown that RV N protein induces potent... Agent: Pepper Hamilton LLP

20080311151 - Vaccine for periodontal disease: The present invention relates to novel bacterial isolates identified by their 16S rRNA DNA, that cause periodontal disease in companion animals, polynucleotide sequences contained therein, polypeptides encoded by such polynucleotide sequences and vaccines comprising such bacteria, polynucleotides, or polypeptides. Also provided are methods for treating and preventing periodontal disease and... Agent: Scully Scott Murphy & Presser, PC

20080311152 - Modulation of developmental immune programming and protection against cardiovascular disease, diabetes, infectious diseases, and cancer: Maternal adaptive immunity conveys temporary humoral immune protection to neonates. The disclosure demonstrates the influence of the in utero environment on adult atherosclerosis and provides evidence for persistent effects of maternal immunization on adult immune responses. The disclosure provides methods and compositions useful for immunization and more particularly for actively... Agent: Gavrilovich Dodd & Lindsey LLP Joseph R. Baker, Apc

20080311153 - Attenuated influenza virus and a live vaccine comprising the same: The present invention relates to an isolated attenuated influenza virus strain and a live vaccine comprising the same. The isolated attenuated influenza virus strain is prepared by cold-adaptation of a mother strain which carries 6 internal genomes of A/PR/8/34(H1N1) and two surface antigens HA and NA of A/Aichi/2/68(H3N2). The attenuated... Agent: Lucas & Mercanti, LLP

20080311154 - Cold-adapted equine influenza viruses: The present invention provides experimentally-generated cold-adapted equine influenza viruses, and reassortant influenza A viruses comprising at least one genome segment of such an equine influenza virus, wherein the equine influenza virus genome segment confers at least one identifying phenotype of the cold-adapted equine influenza virus, such as cold-adaptation, temperature sensitivity,... Agent: Heska Corporation Legal Department

20080311155 - Strain-independent amplification of pathogens and vaccines thereto: This in invention relates to methods for the nucleic acid amplification of multiple variants (strains) of any pathogen present in a sample, and preferably in a sample from a pathogen infected individual. In preferred embodiments, the pathogen is a retrovirus, such as HIV. The amplified pathogen nucleic acid can be... Agent: Merix Bioscience, Inc.

20080311156 - Vaccines: The present invention relates to adjuvant compositions which are suitable to be used in vaccines. In particular, the adjuvant compositions of the present invention comprises a saponin and an immunostimulatory oligonucleotide, optionally with a carrier. Also provided by the present invention are vaccines comprising the adjuvants of the present invention... Agent: Glaxosmithkline Corporate Intellectual Property

20080311157 - Pharmaceutical compound capable of induce immune protective response against dengue virus having the capsid protein of the dengue virus: This invention describe the a pharmaceutical compound having the capsid protein of Dengue virus capable of induce in the receptor a protective immune response before the viral challenge without inducing the Ab-dependent enhancement phenomenon.... Agent: Hoffmann & Baron, LLP

20080311158 - Hepatitis c virus replication system: A cell including: (a) a hepatitis C virus genome, and/or nucleic acid encoding a hepatitis C virus genome; and (b) nucleic acid encoding one or both of hepatitis C virus proteins E1 and E2. The cells can be grown in culture in order to support HCV replication, and HCV virions... Agent: Novartis Vaccines And Diagnostics Inc.

20080311159 - Methods and means for diagnostics, prevention and treatment of mycobacterium infections and tuberculosis disease: The invention identifies a narrow subset of Mycobacterium latency associated antigens and or epitopes that are capable of eliciting an immune response in vivo and in vitro in a mammal. The invention provides methods and compositions for detection and immunization against latent Mycobacterium infections. These compositions comprise those Mycobacterial latency... Agent: Morgan Lewis & Bockius LLP

20080311160 - Clear pharmaceutical aqueous emulsion composition which comprises propofol and process for preparing this composition: The present invention concerns a clear pharmaceutical aqueous emulsion composition which comprises Propofol and a surfactant system and which is particularly usable for a safe administration through intravenous injection. A composition according to the invention is characterized in that the surfactant system comprises in combination at least one pharmaceutically acceptable... Agent: Alston & Bird LLP

20080311161 - Compositions and methods for enhanced gastrointestinal stability of oligopeptides and polypeptides: Methods and compositions are provided for stabilizing polypeptides for oral administration, particularly where enteric delivery is desirable. By administering the polypeptides with a bile sequestering agent, the stability of the polypeptide can be increased. Pharmaceutical formulations for this purpose are provided.... Agent: Bozicevic, Field & Francis LLP

20080311163 - Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor: A cosmetic treatment method, and a device therefor, are provided that allow for cosmetic treatment of cosmetic disorders, caused by chronological age, environmental factors, changes in physiological functions of skin, such as psoriasis, dermatitis, acne, cellulites, and viral and/or bacteriological attacks. The device comprises a nitric oxide (NO) eluting polymer... Agent: Inskeep Intellectual Property Group, Inc

20080311164 - Gelling agent: Gelling agents which contain a specific N-acylamino acid monoamide monoalkyl ester have a melting temperature of about 100° C., are capable of solidifying a wide variety of oily base materials including silicones, and do not cause “sweating” while retaining a practical level of gel strength. When applied to skin, the... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080311162 - Solid form: A solid form comprising at least one film enrobing a compacted fill material comprising a pressure sensitive multiparticulate and at least one cushioning agent, in which the multiparticulate and/or the cushioning agent comprises at least one active material, having low friability and wherein the compacted fill material has a density... Agent: Patent Administrator Fmc Corporation

20080311166 - Cooling towel: Absorbent cloths (cooling towels) impregnated with a formulation including purified water, denatured alcohol, Aloe vera, menthol, and at least one scented essential oil, have been developed for quickly and conveniently cooling the skin. A typical cooling towel as described herein is made from 100% cotton terry cloth, made of all-natural... Agent: Akerman Senterfitt

20080311165 - Copper containing materials for treating wounds, burns and other skin conditions: The invention provides a method for treating and healing sores, cold sores, cutaneous openings, ulcerations, lesions, abrasions, burns and skin conditions comprising applying to a body surface exhibiting the same, a material incorporating water-in-soluble copper compounds which release cu+ ions, cu++ ions or combinations thereof upon contact with a fluid... Agent: Townsend And Townsend And Crew, LLP

20080311167 - Topical composition for treating pain: Topical compositions having as the active ingredient a lipid, fatty acid ester, natural wax, sterol, or combinations thereof referred to herein as “lipophilic vehicle” or “LV” and methods of use, have been developed for the amelioration or prevention of pain or the sequelae of pain. The composition may be in... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080311168 - Process for combating acarids: The invention relates to a novel use of zinc sulfide as agent for combating acarids. The invention also relates to compositions with acarid-combating properties comprising zinc sulfide as additive, in particular polymer compositions, and to yarns, fibers, filaments and articles obtained from these compositions; it is also targeted at liquid... Agent: Buchanan, Ingersoll & Rooney PC

20080311169 - Composition comprising ginsenosides for treating or preventing angiostenosis and restenosis: The present invention relates to use of ginsenoside Rg3, Rg5 or Rk1, or extract of ginseng, red ginseng or processed ginseng comprising the ginsenosides; a composition for preventing or treating angiostenosis and restenosis comprising the ginsenosides or extracts; a method for preventing or treating angiostenosis and restenosis by administrating the... Agent: Fitzpatrick Cella Harper & Scinto

20080311170 - Implant device release agents and methods of using same: Medical implant devices are prepared from a polymeric material and a release agent, where the device is a molded, reservoir implant, and the release agent has a molecular weight (MW) of at least 1000. The release agent may be a non-ionic surfactant such as Brij 35, polyoxyetheylene(20)sorbitan trioleate, Tween 20,... Agent: Foley And Lardner LLP Suite 500

20080311171 - Implantable polymeric device for sustained release of dopamine agonist: The present invention provides compositions, methods, and kits for treatment of Parkinson's disease and other conditions for which treatment with a dopamine agonist is therapeutically beneficial. The invention provides a biocompatible nonerodible polymeric device which releases dopamine agonist continuously with generally linear release kinetics for extended periods of time. Dopamine... Agent: Morrison & Foerster LLP

20080311172 - Programmed-release, nanostructured biological construct: A biologically engineered construct comprising of a polymeric biomatrix, designed with a nanophase texture, and a therapeutic agent for the purpose of tissue regeneration and/or controlled delivery of regenerative factors and therapeutic substances after it is implanted into tissues, vessels, or luminal structures within the body. The therapeutic agent may... Agent: Cislo & Thomas LLP

20080311173 - Implantable or insertable medical devices for controlled delivery of a therapeutic agent: The present invention is directed to novel implantable or insertable medical devices that provide release of a therapeutic agent. According to a first aspect of the present invention, a therapeutic-agent-releasing medical device is provided, which comprises: (a) an implantable or insertable medical device; (b) a release layer disposed over at... Agent: Mayer & Williams PC

20080311174 - Food and process for producing food: The present invention retains the original shape, color, taste, flavor and texture, suppresses liquating out nutritional contents, can easily adjust the hardness of a food, can efficiently manufacture a processed food which uses a wide variety of food materials, can preserve by suppressing microbial deterioration due to its hygienic manufacture,... Agent: Knobbe Martens Olson & Bear LLP

20080311175 - Compositions and methods for promoting weight gain and feed conversion: The invention features compositions for administration of an oxidatively transformed carotenoid or a component thereof and methods of promoting weight gain and feed conversion efficiency therewith.... Agent: Clark & Elbing LLP

20080311176 - Drug condensation aerosols and kits: The present invention provides novel condensation aerosols for the treatment of disease and/or intermittent or acute conditions. These condensation aerosols have little or no pyrolysis degradation products and are characterized by having an MMAD of between 1-3 microns. These aerosols are made by rapidly heating a substrate coated with a... Agent: Swanson & Bratschun, L.l.c

20080311177 - Self assembled films for protein and drug delivery applications: Provided are systems for controlled release of proteins from decomposable thin films constructed by layer-by-layer deposition. Such films generally comprise alternating layers of polymers and proteins, and may further comprise additional layers of polyions. In some embodiments, decomposable thin films and methods of using such films allow proteins to be... Agent: Patent Department Attn: Sam Pasternack, Esq.

20080311178 - Gel composition and use thereof: The present invention provides a composition for a medical material or a hygiene material, which contains a large amount of an organic liquid component, has sufficient flexibility and can retain shape. The present invention provides a gel composition for a medical material or a hygiene material, which contains a liquid... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080311180 - Method of preventive on-demand hormonal contraception: The invention relates to a method of hormonal female controlled on-demand contraception in which a pharmaceutical preparation comprising at least one progestogen is administered transdermally on demand and on a single occasion prior to anticipated sexual intercourse.... Agent: Millen, White, Zelano & Branigan, P.C.

20080311179 - Sulfonylpyrazole and sulfonylpyrazoline carboxamidine derivatives as 5-ht6 antagonists: and derivatives thereof, which are antagonists of 5-HT6 receptors, wherein the symbols have the meanings given in the description. The invention also concerns methods for the preparation of these compounds, to novel intermediates useful for their synthesis, and to uses of such compounds and compositions, particularly their use in administering... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080311185 - Deregulated genes and/or processes in inflammatory arthritis: The invention provides means and methods for determining whether a sample is derived from an individual suffering from inflammatory arthritis or from an individual at risk of suffering there from, said method comprising measuring in said sample the level of expression of at least one gene product of a gene... Agent: Hoffmann & Baron, LLP

20080311184 - Method for developing, testing, and using associates of macromolecules and complex aggregates for improved payload and controllable de/association rates: This invention describes the principles and procedures suitable for developing, testing, manufacturing, and using combinations of various amphipatic, if necessary modified, macromolecules (such as polypeptides, proteins, etc.) or other chain molecules (such as suitable, e.g. partly hydrophobised, polynucleotides or polysaccharides) with the aggregates which comprise a mixture of polar and/or... Agent: Wilson Sonsini Goodrich & Rosati

20080311182 - Multistage delivery of active agents: Multistage delivery vehicles are disclosed which include a first stage particle and a second stage particle. The first stage particle is a micro or nanoparticle that contains the second stage particle. The second stage particle includes an active agent, such as a therapeutic agent or an imaging agent. The multistage... Agent: Conley Rose, P.C. David A. Rose

20080311183 - Novel inhibitors of pyruvate kinase as therapeutic agents for cancer: The present invention relates to compounds for the inhibition of pyruvate kinase and ATP production which are capable of inhibiting cancer cells proliferation.... Agent: Bereskin And Parr

20080311181 - Serum-stable amphoteric liposomes: The invention relates to amphoteric liposomal formulations which are provided with great serum stability and are suitable for the intracellular delivery of oligonucleotides.... Agent: Millen, White, Zelano & Branigan, P.C.

20080311186 - Composition having effect on treatment and prevention of dry eye syndrome: Provided is a composition comprising, as an active ingredient, at least one material selected from the group consisting of uridine and derivatives thereof which promote synthesis of hyaluronic acid in animal and human cell and body, and a pharmaceutical preparation containing the same. The composition and pharmaceutical preparation of the... Agent: Cantor Colburn, LLP

20080311187 - Crush resistan delayed-release dosage form: The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance... Agent: Norris, Mclaughlin & Marcus, P.A.

20080311188 - Solid pharmaceutical compositions comprising a sip receptor agonist and a sugar alcohol: e

20080311189 - Compositions comprising organometallic molybdenum compounds for treating cancer: The invention provides several molybdenum (II) complexes (see classes I and II, FIG. 1) as well as pharmaceutical compositions comprising these compounds, that are useful for treating cancer and describes synthetic methods and intermediates useful for preparing the compounds.... Agent: Sughrue Mion, PLLC

20080311190 - Thrombin-free biological adhesive and use thereof as a medicament: The invention relates to a thrombin-free, fibrinogen-based biological adhesive for therapeutic use, which comprises factor VIIa and a source of calcium ions. The invention also relates to the use of the biological adhesive as a medicament, in particular as a dressing for biological tissues, wounds or biomaterials.... Agent: Marsh, Fischmann & Breyfogle LLP

20080311191 - Multi-layer tablets and bioadhesive dosage forms: e

20080311192 - Enteric-coated glucosinolates and beta-thioglucosidases: The present invention relates to a particulate composition comprising enteric-coated glucosinolate and beta-thioglucosidase particles. The present invention further provides a method of converting glucosinolate to isothiocyanate in the small intestine comprising orally administering to a subject an enteric-coated chemoprotectant precursor composition comprising enteric-coated glucosinolate and beta-thioglucosinodase particles. In another aspect,... Agent: Fitch Even Tabin & Flannery

20080311196 - All day rhinitic condition treatment regimen: A therapeutic regimen is disclosed. The regimen includes a first pharmaceutical dosage form comprising a first therapeutically effective amount of a first antihistamine and an anticholinergic agent; and a second pharmaceutical dosage form comprising a therapeutically effective amount of a second antihistamine and an anticholinergic agent. The second antihistamine either... Agent: Intellectual Property / Technology Law

20080311195 - Basis particles, method for manufacturing the same, and orally-disintegrating tablet: A basis particle comprises a basic or acidic basis particle coated by a water-insoluble coating film, wherein the water-insoluble coating film contains a substance that is acidic with respect to the basic basis or basic with respect to the acidic basis. According to the basis particles (i.e., a main ingredient... Agent: Sughrue Mion, PLLC

20080311194 - Dispersible tablets comprising deferasirox: b

20080311197 - Process for the production of an abuse-proofed dosage form: The present invention relates to a process for the production of an abuse-proofed dosage form containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer (C) with a breaking strength of at least 500 N,... Agent: Norris, Mclaughlin & Marcus, P.A.

20080311193 - Sustained release formulation of alprazolam: The present invention is directed towards the preparation of extended release Alprazolam formulation. The formulation thus obtained provides an efficient mode of delivery of Alprazolam in a continuous manner.... Agent: Ladas & Parry LLP

20080311200 - Controlled slow release formulation of thiamine and use thereof in the treatment of pathologies connected to defective process of learning and memorization: The present invention relates to thiamine controlled-release pharmaceutical compositions and their use in medicine for resolving absorption defects or deficiencies of thiamine itself from the organism. Said compositions have revealed to be useful in the treatment of cerebral pathologies connected with learning and memorizing processes. In particular, said compositions have... Agent: Pearne & Gordon LLP

20080311198 - Tamper-resistant oral opioid agonist formulations: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tampering to the... Agent: Davidson, Davidson & Kappel, LLC

20080311199 - Tamper-resistant oral opioid agonist formulations: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tampering to the... Agent: Davidson, Davidson & Kappel, LLC

20080311201 - Modified release solid or semi-solid dosage forms: A solid or semi-solid pharmaceutical dosage form comprising non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, along with a second active ingredient having a shorter therapeutically effective plasma concentration duration, such as phenylephrine, and methods of administering the same are provided. This method provides improved therapeutic effect, in... Agent: Philip S. Johnson Johnson & Johnson

20080311203 - Oral formulation of anhydrous olanzapine form i: The invention relates to a solid formulation for the oral administration of olanzapine that comprises a core of anhydrous olanzapine Form I or a pharmaceutically acceptable salt thereof and, optionally, pharmaceutically acceptable excipients, said core being coated with a functional polymer that acts as filmogenic agent. The method for obtaining... Agent: Wolf, Block, Shorr And Solis-cohen LLP

20080311202 - Pharmaceutical composition containing donepezil hydrochloride, tablets produced therefrom and methods for producing the same: A pharmaceutical composition is provided according to the invention which is suited for the production of tablets by direct compression and which contains donepezil hydrochloride of polymorphic form I. The polymorphic form I of donepezil hydrochloride in the directly compressed tablet is also stable during long storage.... Agent: Smith Patent Consulting Consulting, LLC

20080311204 - Stable oral formulation containing benzimidazole derivative: p

20080311205 - Abuse resistant drug formulation: A pharmaceutical composition may include a coated particulate which may include at least one active pharmaceutical ingredient, particularly one susceptible to abuse by an individual. The coated particles may include a fat/wax and have improved controlled release and/or crush resistance. Method of making these coated particulate and dosage forms therewith... Agent: Cephalon, Inc.

20080311206 - Anti-chafing compositions comprising boron nitride: The invention in one aspect relates to an anti-chafing composition with improved efficacy, in one embodiment, comprising an effective amount of boron nitride suspended in a dermatologically acceptable carrier vehicle. Another embodiment relates to an anti-chafing composition in the form of a powder or a stick containing boron nitride. The... Agent: Momentive Performance Materials Inc.-quartz C/o Dilworth & Barrese, LLP

20080311212 - Crystalline isoxazole derivative and pharmaceutical preparation thereof: e

20080311211 - Easily dispersible lipidic phase: The present invention relates to the use of a lipidic phase comprising an oil and a lipophilic additive (LPA), which is suitable to make an oil-in-water emulsion by application of low energy or a manual operation. The lipidic phase contains a Lipophilic Additive (LPA) which forms self-assembly structures inside the... Agent: Bell, Boyd & Lloyd LLP

20080311207 - Micelles and nanoemulsions for preventive and reactive treatment of atherosclerosis: The subject invention is directed to microemulsion-based (ME) nanoparticles and methods of using same. The ME nanoparticles of the subject invention encompass self-assemblies of oil in water emulsions in the presence of at least two emulsifiers. One of the emulsifiers is a salt of a fatty acid, and the combined... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080311210 - Pharmaceutical composition for use as a laxative: The invention relates to a pharmaceutical composition which is suitable in particular for use as purgative (cathartic), where the composition comprises in combination and in each case in pharmaceutically effective amounts (A) senna fruit dry extract and (B) plantago seeds (plantaginis ovatae semen). The composition can advantageously be manufactured by... Agent: Alston & Bird LLP

20080311208 - Pharmaceutical formulations useful in the treatment of insomnia: There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable... Agent: Morgan Lewis & Bockius LLP

20080311209 - Topical compositions comprising nanoparticles of an isoflavone: The present invention is directed to topical compositions, comprising isoflavone nanoparticle compositions. The isoflavone nanoparticle compositions contain isoflavone in the form of nanoparticles and preferably a carrier. In the topical compositions recrystallization of the isoflavone to bigger particles is avoided.... Agent: Nixon & Vanderhye, PC

20080311213 - Topical formulations containing sporopollenin: Topical formulation containing an active substance which is chemically or physically bound to, or encapsulated within, an exine shell of a naturally occurring spore. The active substance can be released from the exine shell on application to a living or non-living surface. The invention may be used to provide gradual... Agent: Beyer Weaver LLP

20080311214 - Polymerized solid lipid nanoparticles for oral or mucosal delivery of therapeutic proteins and peptides: The present invention encompasses lipid nano/micro particles, which have been modified, preferably on their surface, to contain a molecule or ligand, which targets the nano/micro particles to a specific site. The invention also encompasses the use of the modified lipid nano/micro particles for the oral delivery of drugs and antigen... Agent: Foley And Lardner LLP Suite 500

20080311215 - All-natural composition and method for repelling and killing insects: An all-natural composition can be used to repel or kill insects. The composition is an aqueous solution or mixture of available non-toxic ingredients. These include a weak acid to lower the pH, and one or more aromatics. The ingredients include one or more herbal essential oils, such as rosemary oil,... Agent: Marjama Muldoon Blasiak & Sullivan LLP

20080311216 - Epidermal growth factor composition, a process therefor and its application: A composition for treating a wound, wherein the composition can comprise therapeutically effective amount of an epidermal growth factor and a physiologically acceptable agent, wherein the physiologically acceptable agent comprises at least one of a stabilizer, a preservative, a thickening agent, carrier/diluent, and optionally pH regulating agent and humectant.... Agent: Fenwick & West LLP

20080311218 - Topical composition for treating pain: Topical compositions having as the active ingredient a lipid, fatty acid ester, natural wax, sterol, or combinations thereof referred to herein as “lipophilic vehicle” or “LV” and methods of use, have been developed for the amelioration or prevention of pain or the sequelae of pain. The composition may be in... Agent: Morrison & Foerster LLP

20080311217 - Topicial composition for treating pain: Topical compositions having as the active ingredient a lipid, fatty acid ester, natural wax, sterol, or combinations thereof referred to herein as “lipophilic vehicle” or “LV” and methods of use, have been developed for the amelioration or prevention of pain or the sequelae of pain. The composition may be in... Agent: Morrison & Foerster LLP

20080311219 - Tissue fragment compositions for the treatment of incontinence: Compositions for the treatment of incontinence are disclosed. More particularly, compositions of viable muscle tissue fragments and a carrier are disclosed. The compositions are useful in the treatment urinary and fecal incontinence.... Agent: Philip S. Johnson Johnson & Johnson

20080311220 - Method for producing demineralized bone matrix easily releasing bone morphogenetic protein and method for extracting bone morphogenetic protein using demineralized bone matrix by irradiation: Disclosed is a method for producing demineralized bone matrix with improvement of releasing bone morphogenetic protein by irradiating the demineralized bone matrix, the demineralized bone matrix produced by the producing method, a method for extracting bone morphogenetic protein using the demineralized bone matrix, and the bone morphogenetic protein extracted by... Agent: The Nath Law Group

20080311221 - Lewis acid and oil-soluble hybrid pesticide concentrate that spontaneously forms a water-based microemulsion: A chemically and physically stable, transparent, hybrid pesticide concentrate is provided for preparation of a water-based microemulsion formulation. The pesticides preferably comprise an oil-soluble pesticide component, and a pesticide component having a Lewis acid pesticide portion and a pesticide complex portion. An inactive biphasic coupling agent for the pesticide ingredients... Agent: Hovey Williams LLP

20080311222 - System and method for applying medication to a hoof: A gel that includes a fungicide or an anti-bacterial is contained within a single dosage packet that includes a tapered nozzle end and a body. The fungicide or anti-bacterial gel is applied to the hoof of a horse by opening the packet at the tapered nozzle end and squeezing the... Agent: Dergosits & Noah LLP

20080311223 - Injectable polymer-lipid blend for localized drug delivery: An injectable polymer-lipid blend is provided as a localized drug delivery system for a pharmaceutically active agent. The blend may be prepared from a chitosan-based material, fatty acid and phospholipid. The chitosan-based material may be a water soluble chitosan derivative. The fatty acid may be a fatty acid or a... Agent: Stephen R. Burri

20080311224 - Long-lasting mildew stain remover and method for making same: The active life of a fungicidal metal hydrochlorite is greatly enhanced by adding only small amounts of active fungicidal compounds selected from the group consisting of lithium hydrochlorite and iodopropynyl butyl carbamate.... Agent: Epstein Drangel Bazerman & James, LLP

20080311225 - Process and kit for formation of active hydrogen water, gypsum feeder for the formation, active hydrogen forming materials and process for the production of the materials: An active hydrogen-dissolved water generator 10 contains a container 11 such as a PET bottle, a first case 12 filled with magnesium metal, and a second case 13 filled with gypsum. The first case 12 and the second case 13, and a drinking water are introduced into the container 11... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080311226 - Methods and compositions for improving stool quality: A method for improving stool quality by administering to an animal a composition comprising from about 1% to about 20% zeolite. Preferably, the zeolite is fed to ah animal as part of a food composition containing least one ingredient suitable for consumption by an animal.... Agent: Colgate-palmolive Company

20080311227 - Long-lasting mildew stain remover and method for making same: The fungi-preventative-over-time characteristic of a fungicidal metal hydrochlorite, as distinguished from the fungi-removal characteristic thereof, is greatly enhanced by adding thereto only small amounts of active fungicidal compounds selected from the group consisting of lithium hydrochlorite and iodopropynyl butyl carbamate.... Agent: Epstein Drangel Bazerman & James, LLP

20080311228 - Pharmaceutical composition for protecting neurons comprising extract of lithospermum erythrothizon sieb. et. zucc or acetylshikonin isolated therefrom as an effective ingredient: The present invention relates to a pharmaceutical composition for protecting neurons or for preventing and treating ischemic neuronal diseases comprising the extract of Lithospermum erythrorhizon Sieb. Et Zucc extracted with water, low-alcohols or their mixture or acetylshikonin separated therefrom as an effective ingredient. The extract of Lithospermum erythrorhizon Sieb. Et.... Agent: Lucas & Mercanti, LLP

20080311229 - Functional food composition for treating allergy, natural tea using the same and the manufacturing method thereof: A functional food composition for treating allergy, comprising Saururus chinensis, Plantago asiatica, Poncirus trifoliata and Schisandra chinensis extracts, as active ingredients, a tea composition comprising the same and a manufacturing method thereof. The functional food and tea compositions for treatment of allergy in accordance with the present invention are therapeutically... Agent: Iphorgan, Ltd.

20080311230 - preparation of artemisia to treat human cancer, autoimmune disease, iga-nephropathy, and to counteract weight loss in cancer patients: In human cancer, reduced appetite and weight loss are serious symptoms and are difficult to manage. These symptoms not only effect the quality of life, but also reduce the tolerance and response to anti-cancer drugs, thereby effecting the prognosis and survival to disease. These symptoms are caused, among others, by... Agent: Harun Omer

20080311231 - Broad spectrum non-traditional preservative system: Preservative compositions containing emollient solvents such as octanediol or Symdiol™ or octoxyglycerine monoesters in combination with organic acids such as alpha hydroxyl acids can be used for preventing microbial growth and spoilage in cosmetic and topical skin formulations with the added benefit of providing silky smooth texture to skin. The... Agent: Baker Botts L.L.P.

20080311232 - Cooling compounds: e

20080311233 - Naturally occurring phenolic substances useful as pesticides: Two phenolic compounds occurring in nature were useful in the control of some pests. Salicylaldehyde is a substance produced by some plants and some animals. A novel pest control agent is based on salicylaldehyde. It is active against caterpillars (larvae of butterflies and moths) as well as earthworms and molluscs.... Agent: Yoram Tsivion

20080311234 - Oil-in-water emulsified composition, and external preparation for skin and cosmetics using the composition: An oil-in-water emulsified composition suitable for external preparation for skin and cosmetic product, which comprised 0.1 to 5% by mass of (A) lipopeptide compound derived from a microorganism such as surfactin and its analogous compound, 0.05 to 1.5% by mass of (B) xanthan gum, 25 to 70% by mass of... Agent: Sughrue Mion, PLLC

20080305037 - Linkers for anchoring targeting ligands: An improved linker which lacks chiral centers between a hydrophobic anchor for coupling to lipid-based particles and a targeting agent has suitable hydrophobic/hydrophilic properties for use in vivo.... Agent: Morrison & Foerster LLP

20080305038 - Transport of nano-and macromolecular structures into cytoplasm and nucleus of cells: The present invention refers to novel conjugate molecules and their use or the transport of nano- and macromolecular structures into cells and/or the nucleus. More particularly, the present invention refers to conjugate molecules containing a carrier, preferably thiopyridyl moieties, and a cargo moiety. Thereby, the thiopyridyl moiety is bound to... Agent: Connolly Bove Lodge & Hutz LLP

20080305039 - Facilitated transport of bisphosphonates by vitamin c: Compounds of the formula: are described wherein: A1 is ascorbic acid, dehydroascorbic acid, ascorbyl-2-phosphate, an analog thereof, or a salt thereof; L is a linking group coupled to A1 at the C5 or C6 position thereof; and B1 is an active agent such as an imaging agent or therapeutic agent... Agent: Myers Bigel Sibley & Sajovec

20080305040 - In vivo or in vitro method for detecting amyloid deposits having at least one amyloidogenic protein: An amyloid deposit can be detected by administering to a subject or applying to a sample a compound of Formula (I) or Formula (II) or structures 1-45, as described, and then imaging to detect binding of the compound to an amyloid deposit, where the amyloido genie protein of the deposit... Agent: Foley And Lardner LLP Suite 500

20080305041 - Pf4 pharmacophores and their uses: The invention provides a novel PF4 pharmacophore that is useful, inter alia, for identifying peptidomimetics and other compounds capable of modulating PF4 activity (e.g., as inhibitors, agonists or antagonists). Mutant PF4 polypeptide sequences are also provided that modulate PF4 activity in cells.... Agent: Darby & Darby P.C.

20080305042 - Radiolabelling method using polymers: The present invention provides a method for the preparation of radioisotopically-labelled imaging agent compositions. The method uses precursors which are bound to soluble polymers, so that the radiolabelling reaction is carried out in solution. Also described are radiopharmaceutical compositions, automated versions of the radiolabelling method and disposable cassettes for use... Agent: Ge Healthcare, Inc.

20080305043 - Assay method: Described is a method of detecting non-viable cells in a sample of cells, the method comprising contacting a sample of the cells with a detectable reagent and detecting binding of said reagent to cells of said sample. The detectable reagent is milk, a milk product or component thereof. A component... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080305044 - Engineered antibodies and immunoconjugates: Antibody drug conjugates with predetermined sites and stoichiometries of drug attachment are provided. Also provided are methods of using antibody drug conjugates.... Agent: Townsend And Townsend And Crew LLP

20080305045 - Methods of synthesis of non-toxic multifunctional nanoparticles and applications: The present invention involves multifunctional nanoparticle dispersions and methods for making them using sol-gel chemistry, doping, and sonication. These methods avoid the high thermal budget processes of the reference art. The dispersions can accommodate greater concentrations of nanoparticles, dopants, and ions than has previously been possible since these components can... Agent: Katherine N. Addison Esq.

20080305046 - Molecular imaging methods for diagnosis and evaluation of ocular and systemic diseases: This invention relates generally to minimally-invasive, in vivo methods of detecting one or more ligands on an intraluminal surface of a blood vessel using microparticles coated with one or more ligand binding partners. More particularly, in certain embodiments, the invention relates to minimally-invasive, in vivo methods of detecting endothelial and... Agent: Goodwin Procter LLP Patent Administrator

20080305048 - Self-assembling nanoparticle conjugates: This invention relates to magnetic nanoparticle conjugates and related compositions and methods of use.... Agent: Fish & Richardson PC

20080305049 - Mri contrast agents for diagnosis and prognosis of tumors: The invention relates to bifunctional conjugates comprising a receptor ligand moiety and a metal binding moiety and complexes thereof with paramagnetic lanthanide or transition metals, and to the use of the metal complexes as contrast agents in magnetic resonance imaging (MRI) of tumors and other abnormalities.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080305047 - Chemosensors based on quantum dots and oxazine compounds: We identified a mechanism to detect chemical changes with a modified semiconductor nanoparticle (e.g., an oxazine-adsorbed CdSe—ZnS core-shell quantum dot). Our strategy is based on the chemical transformation of chromo-genie ligands adsorbed on the surface of a quantum dot. This activates an energy transfer pathway from the quantum dot to... Agent: Nixon & Vanderhye, PC

20080305050 - Analysis of p. aeruginosa infection in patients: The present invention relates to methods for detecting P aeruginosa infection and bacterial burden in the lungs of patients who are at risk for P. aeruginosa infections, especially including patients with Cystic Fibrosis (CF). The present method provides numerous tests (breath, blood, urine) which are readily administered to a patient... Agent: Coleman Sudol Sapone, P.C.

20080305051 - Menthane carboxamide derivatives having cooling properties: e

20080305052 - Use of hesperetin for enhancing the sweet taste: The use of hesperetin of formula (I) is described wherein the hesperetin of formula (I) is in the form of a (2S)-enantiomer, (2R)-enantiomer or any desired mixture of the two enantiomers, a salt of hesperetin of formula (I), —a mixture comprising or consisting of two or more salts of the... Agent: Connolly Bove Lodge & Hutz, LLP

20080305053 - Fluoride-releasing strips for tooth: The present invention discloses fluoride-releasing strips for tooth, wherein the fluoride-releasing strips comprises a fluoride-containing solution for releasing fluorine ion and a support substrate. A formula of fluoride-containing solution comprises a fluoride solution, at least one buffer, at least one moisturizer and a tackiness agent. The support substrate is waterproof... Agent: Wpat, PC

20080305055 - Anti-radical agents: Compounds of the formulae (1), (2) and selected hindered nitroxyl, hydroxylamine and hydroxylamine salt compounds such as the compound of formula (3), wherein Gi is hydrogen; C1-C22alkyl; C1-C22alkylthio; C2-C22alkylthioalkyl; C5-C7cycloalkyl; phenyl; C7-C9phenylalkyl; or SO3M; G2 is C1-C22alkyl; C5-C7cycloalkyl; phenyl; or C7-C9phenylalkyl; E is oxyl or hydroxyl; V is —O—; or... Agent: Joann Villamizar Ciba Corporation/patent Department

20080305056 - Stable, low viscosity cosmetic compositions: m

20080305054 - Use of glycosylated flavanones for the browning of skin or hair: The use of a compound having formula (I) is described as an agent for the browning of skin or hair, Formula (I) wherein: R1 and R2 are mutually independently H, OH, C1-C10-alkyl, C1-C10-O-alkyl or O-prenyl, R3 is H, OH, O-glucose or O-rhamnose and R4 is a monosaccharide radical or an... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20080305057 - New and improved skin treatment systems: A basic facial and body treatment cosmetic formulation is a combination of a cationic emulsifying agent, an oil soluble liquid polymer and a naturally occurring lactate buffer system. The basic formulation is a starter system that can be specialized to skin moisturizers, skin lighteners, skin pigmenting agents, sunscreens, antioxidants, line... Agent: Lerner Greenberg Stemer LLP

20080305058 - Photoprotective cosmetic compositions comprising photostabilized dibenzoylmethane compounds and merocyanine sulfone compounds: Photostable, topically applicable cosmetic/dermatological compositions contain at least one dibenzoylmethane compound UV-A sunscreen and at least one merocyanine sulfone compound.... Agent: Buchanan, Ingersoll & Rooney PC

20080305060 - Aqueous-alcoholic depigmenting gels: Stable, topically applicable cosmetic/pharmaceutical skin depigmenting compositions contain at least one phenolic compound, at least one retinoid and at least one corticoid, and are formulated as aqueous-alcoholic gels in topically applicable, physiologically acceptable media therefor.... Agent: Buchanan, Ingersoll & Rooney PC

20080305059 - Skin lightening compositions and methods: Skin lightening/even toning compositions are provided for reducing skin pigmentation of normal skin and for lightening hyper-pigmented skin said compositions comprising (i) highly purified hexylresorcinol which is substantially free or resorcinol, (ii) optionally, at least one other skin lightening agent, and (iii) a dermatologically acceptable carrier.... Agent: Edward K. Welch Ii Ip&l Solution

20080305061 - Comfortable transfer-resistant colored cosmetic compositions containing a silsesquioxane wax: The present invention is directed to a composition containing: (a) at least one propylsilsesquioxane wax substituted with alkyl units having at least 30 carbons; (b) a liquid fatty phase; (c) at least one emulsifier chosen from an emulsifying silicone elastomer; (d) at least one colorant; (e) water; and (f) optionally,... Agent: L'oreal Usa/ Patent Department

20080305062 - Cosmetic compositions containing a propylphenylsilsesquioxane resin and a cosmetically-acceptable aromatic solvent: The present invention is directed to a cosmetic composition containing: (a) at least one propylphenylsilsesquioxane resin; (b) at least one cosmetically-acceptable aromatic solvent; (c) at least one colorant, and (d) optionally, at least one co-solvent, and wherein the composition is substantially free of volatile solvents. Also disclosed is a method... Agent: L'oreal Usa/ Patent Department

20080305063 - 1-aza-3,7-dioxabicyclo[3.3.0]octane compounds and their use as pro-fragrances: 1-aza-3,7-dioxabicyclo[3.3.0]octane compounds, process for their preparation, their use as pro-fragrances, and washing and cleaning compositions, fabric softeners and cosmetics comprising them, and a process for prolonging the odor perception of such compositions.... Agent: Paul & Paul

20080305064 - Hair styling compositions containing a combination of a propylphenylsilsesquioxane resin and a phenylsilsesquioxane resin: A process of styling hair involving applying onto the hair a composition containing: (a) at least one propylphenylsilsesquioxane resin comprising from about 30 to about 50 mole % of propyl siloxy units, based on the total mole % of siloxy units of the resin, and from about 50 to about... Agent: L'oreal Usa/ Patent Department

20080305065 - Novel polysiloxanes having quaternary ammonium groups, a process for the preparation thereof and the use thereof in cleaning and care formulations: p

20080305066 - 2-c-substituted propane-1,3-dicarbonyl compounds and their use in neutralising malodour:

20080305067 - Comfortable, long wearing colored cosmetic compositions: The present invention is directed to a composition containing: (a) at least one tackifier component having a glass transition temperature (Tg) of greater than about 20° C.; (b) at least one film former chosen from a propylphenylsilsesquioxane resin having a molecular weight of from about 2,000 to about 30,000 and... Agent: L'oreal Usa/ Patent Department

20080305068 - Cosmetic compositions having improved transfer resistance: Cosmetic compositions and methods with improved transfer resistance and long wear properties are disclosed. The cosmetic compositions contain a synergistic combination of at least one silicone polyurethane polymer and at least one elastomer.... Agent: Joan M. Mcgillycuddy, Esq. Avon Products Inc.

20080305069 - Cosmetic use of tensing agents to improve the thickness of the skin and/or the radiance of the complexion: The invention relates in particular to the cosmetic use of a composition containing, in a physiologically acceptable medium, an effective amount of at least one mosaic-effect tensing agent for improving the thickness of the skin and/or promoting the radiance of the complexion. The invention also relates to the cosmetic use,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080305070 - Releasable polymeric conjugates based on aliphatic biodegradable linkers: e

20080305072 - Attractant for the anastrepha obliqua fruit fly: The invention relates to a specific attractant for male and female Anastrepha obliqua fruit flies. The inventive attractant comprises a mixture of identified, isolated synthetic compounds which have been formulated according to the proportions in which they were found in the Spondia mombin volatiles.... Agent: Hunton & Williams LLP Intellectual Property Department

20080305071 - Surface cleaning method and composition: The present disclosure provides a method for treating a contaminated surface. According to one embodiment of the present disclosure, the method preferably includes a first step of providing a cleaning composition which includes from about 0.002 to about 2 percent, by weight, of a cationic surfactant which is capable of... Agent: Luedeka, Neely & Graham, P.C.

20080305076 - Method of inducing memory b cell development and terminal differentiation: A method is disclosed herein for inducing differentiation of a B cell progenitor into a memory B cells and/or a plasma cell. The method includes contacting a population of cells including a mature B cell or a B cell progenitor with an effective amount of IL-21, and isolating memory B... Agent: Leydig, Voit & Mayer, Ltd.

20080305079 - Myeloid suppressor cells, methods for preparing them, and methods for using them for treating autoimmunity: The present invention relates to novel myeloid suppressor cells (MSCs) and to methods of isolating these MSCs are also included. The MSCs of the present invention can be used to treat or prevent autoimmune diseases or alloimmune responses. The MSCs of the present invention may also be used to reduce... Agent: Darby & Darby P.C.

20080305077 - Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system: Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to, inter alia, the CNS applied via intranasal administration while reducing non-target exposure are provided. In certain embodiments, at least one vasoconstrictor is provided intranasally prior to intranasal administration of at least one therapeutic compound. In other embodiments, the vasoconstrictor(s)... Agent: Altera Law Group, LLC

20080305078 - Soluble il-17rc variant and uses thereof: The present invention relates to a new soluble IL-17RC variant and its therapeutic uses thereof, in particular for treating or preventing inflammatory or autoimmune disorders or neurological diseases.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080305074 - Stem cell factor: Novel stem cell factors, oligonucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders involving blood cells are also disclosed.... Agent: Marshall, Gerstein & Borun LLP

20080305073 - Therapeutic agents for the treatment of hmgb1-related pathologies: The present invention relates to the use of synthetic double-stranded nucleic acid or nucleic acid analogue molecules with a bent shape structure for the prevention and treatment of pathologies induced directly or indirectly by the HMGB1 protein.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080305075 - Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs: The present invention relates to vinca alkaloid and analog N-oxides having activity for treating hyperproliferative disorders. Further, the invention relates to pharmaceutical compositions and methods of using vinca alkaloid and analog N-oxides, alone or in combination with one or more other active agents or treatments, to treat hyperproliferative disorders.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080305080 - Recombinant super-compound interferon: This invention provides a recombinant super-compound interferon or an equivalent thereof with changed spatial configuration. The super-compound interferon possesses anti-viral or anti-tumor activity and therefore is useful to prevent and treat viral diseases and cancers. This invention also provides an artificial gene which codes for the super-compound interferon or its... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20080305081 - Novel aminopyrimidine derivatives as plk1 inhibitors: or a pharmaceutically acceptable salt or ester thereof, wherein R1 and R2, which may be the same or different, are each a hydrogen atom, a lower alkyl group, a cycloalkyl group, or the like; R3 and R4, which may be the same or different, are each a hydrogen atom, a... Agent: Merck And Co., Inc

20080305082 - 1,4-bis-n-oxide-5,8- dihydroxyanthracenedione compounds and the use thereof: Disclosed are compounds having Formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, A, and B are as defined herein, for use in methods for treating, preventing or ameliorating hyperproliferative disorders, such as cancer and other diseases and conditions. The invention... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080305083 - Gfap-based gene therapy for treatment of retinal diseases: Compositions and methods for reducing neovascularization. Purified nucleic acid constructs and vectors encoding an anti-angiogenic protein operably linked to a GFAP promoter. Vectors can include at least one hypoxia regulated element, enhancer element and silencer element. Gene therapy methods for reducing, delaying or preventing neovascularization based on the nucleic acid... Agent: Margaret J. Mclaren, P.A. Mclaren Legal Services

20080305084 - Methods for delivering dna to muscle cells using recombinant adeno-associated virus virions: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle... Agent: Robins & Pasternak

20080305088 - Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy: A novel nucleic acid construct for down-regulating angiogenesis in a tissue of a subject is provided. The nucleic acid construct includes: (a) a first polynucleotide region encoding a chimeric polypeptide including a ligand binding domain fused to an effector domain of an apoptosis signaling molecule; and (b) a second polynucleotide... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20080305089 - Pharmaceutical composition for protection from allergies and inflammatory disorders: The present invention relates to a pharmaceutical composition which includes naturally occurring, non-transgenic isolated bacteria from the group of Lactococcus and Acinetobacter or fragments thereof or mixtures thereof, to such a bacterium as a medicament for the prevention and/or treatment of allergic or chronic inflammatory disorders and to a process... Agent: Knobbe Martens Olson & Bear LLP

20080305090 - Composition for promoting the proliferation of lactobacillus casei subsp. casei: A composition for promoting bacterial proliferation and selectively proliferating Lactobacillus casei subsp. casei is disclosed, which includes a dextran. A variety of biological activities originating from L. casei subsp. casei can be sustained in a living body by selectively growing-proliferating and colonizing L. casei subsp. casei in the intestine of... Agent: Knobbe Martens Olson & Bear LLP

20080305093 - Liquid formulations of carboxamide arthropodicides: c

20080305085 - Compositions and methods for stem cell expansion: The present invention features methods and compositions that are useful for promoting stem cell survival and expansion. In addition, the invention also provides compositions and methods for the treatment of neoplasia.... Agent: Ewards Angell Palmer & Dodge LLP

20080305087 - Device and method using integrated neuronal cells and an electronic device: The present invention provides a device of integrated neuronal cells interfaced with an electronic device and a method of producing the same.... Agent: Kathryn Doyle, Ph.d., J.d. Drinker Biddle & Reath LLP

20080305086 - Human late stage motor neuron progenitor cells and methods of making and using same: Motor neuron progenitor (MNP) cells and populations of MNP cells, are provided, in particular, populations of human late stage MNP cells having a purity of greater than about 65% late stage MNP cells and high-purity populations of MNP cells having greater than 95% viable cells, as well as method of... Agent: Pillsbury Winthrop Shaw Pittman LLP

20080305092 - Methods of treating autoimmune disease via ctla-4ig: The method of immunotherapy of the present invention involves the regulation of the T cell immune response through the activation or suppression/inactivation of the CD28 pathway. Induction of activated T cell lymphokine production occurs upon stimulatory binding of the CD28 surface receptor molecule, even in the presence of conventional immunosuppressants.... Agent: Casimir Jones, S.c.

20080305091 - Poly-epitope peptide derived from thymidylate synthase having immunological and anti-tumour activity: The present invention concerns a peptide having anti-tumour activity and its related pharmaceutical compositions. In particular, the invention concerns a peptide with anti-tumour preventive and therapeutic activity, also in combination with other known anti-tumour compounds such as, for example, 5-fluorouracil.... Agent: Juneau Partners

20080305094 - Nutritional composition for improving skin condition and preventing skin diseases: The present invention pertains to the use of an ingestable composition containing L-carnitine and at least one component having an anti-oxidative activity for stimulating the lipid metabolism in the skin of an individual, which results in an improvement of the general condition of the skin in particular dry, sensible or... Agent: Bell, Boyd & Lloyd LLP

20080305095 - Nutritional drink: A first composition of drink ingredients specifically designed to lower cholesterol that addresses multiple mechanisms including hepatic synthesis and release, intestinal absorption of cholesterol, while, at the same time, including ingredients that mitigate the side effects of the constituents and increase their efficacy by affecting emotional factors that influence compliance... Agent: Ruden, Mcclosky, Smith, Schuster & Russell, P.A.

20080305096 - Method and composition for providing controlled delivery of biologically active substances: A method of providing controlled release of a biologically active substance within a subject's digestive system. The biologically active substance is administered concurrently with one or more soluble fibers in an oral dosage unit. The soluble fibers interact with the biologically active substance within the subject's digestive system to moderate... Agent: Kirton And Mcconkie

20080305098 - Recombinant polypeptides and methods for detecting and/or quantifying autoantibodies against tsh receptor: The present invention relates to unglycosylated isolated and purified recombinant polypeptides comprising a fusion protein able to bind to autoantibodies produced in response to an autoimmune disease associated with an immune reaction to a TSH-receptor (TSHR). Also disclosed are methods of detecting and/or quantifying such autoantibodies using the isolated and... Agent: Volpe And Koenig, P.C.

20080305097 - Use of protease or a protease inhibitor for the manufacture of medicaments: The invention relates to the use of a cathepsin K inhibitor (CTKI) or CTK, a mutein, isoform, fused protein, functional derivative, active fraction, circularly permutated derivative, a salt or inducer thereof in the manufacture of a medicament for treating a disease in which SDF-1 activity and/or concentration is involved with... Agent: Marshall, Gerstein & Borun LLP

20080305099 - Pharmaceutical composition, composition for screening therapeutics preventing and treating beta amyloid accumulation in brain comprising gcp ii (glutamate carboxypeptidase ii) as an active ingredient and method for screening using the same: The present invention relates to a pharmaceutical composition for the prevention and treatment for β-amyloid(Aβ) accumulation in brain comprising GCP-II (Glutamate carboxypeptidase-II) as an active ingredient, a composition for screening method of the same. GCP-II of the present invention not only degrades Aβ monomer and oligomer but also degrades soluble... Agent: Klarquist Sparkman, LLP

20080305100 - Activated protein c inhibits undesirable effects of plasminogen activator in the brain: Activated protein C (APC), a prodrug, and/or a variant of APC may be used to inhibit undesirable effects of plasminogen activator: e.g., apoptosis or cell death of neurons and endothelial cells, brain hemorrhage or intracerebral bleeding, and/or tissue damage in a subject's brain. Inhibition appears to act through the extrinsic... Agent: Nixon & Vanderhye, PC

20080305103 - Intraocular pressure-regulated early genes and uses thereof: The present invention relates to methods to treat glaucoma and glaucoma-related conditions through the regulation of changes in gene expression that are mediated by high intraocular pressure or α2 macgroglobulin administration. Glaucoma, retinal ganglion cell (RGC) death and chronic ocular hypertension are treated using pharmaceutical compositions which comprise substances that... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080305101 - Methods and compositions related to clot binding compounds: Disclosed are compositions and methods related to clot binding compounds. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20080305102 - Therapeutic agent for cancer comprising substance capable of inhibiting expression or function of synoviolin as active ingredient and screening method for the therapeutic agent for cancer: Inhibition of synoviolin function was found to activate the cancer-suppressing protein p53. Substances inhibiting the function of synoviolin are useful as cancer therapeutic agents. The inhibition of synoviolin function was also found to lead to the inhibition of p53 ubiquitination, increased activity of p53 phosphorylation proteins, and the like. Based... Agent: Foley & Lardner LLP

20080305104 - Cytotoxicity mediation of cells evidencing surface expression of trop-2: This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a... Agent: Mchale & Slavin, P.A.

20080305105 - Bispecific antibodies: The present invention discloses bispecific antibodies comprising two antibody variable domains on a single polypeptide chain, wherein a first portion of the bispecific antibody is capable of recruiting the activity of a human immune effector cell by specifically binding to an effector antigen on the human immune effector cell, the... Agent: Fulbright & Jaworski L.L.P.

20080305106 - Novel gene disruptions, composition and methods relating thereto: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO256, PRO34421, PRO334, PRO770, PRO983, PRO1009, PRO1107, PRO1158, PRO1250, PRO1317, PRO4334, PRO4395, PRO49192, PRO9799, PRO21175, PRO19837, PRO21331, PRO23949, PRO697 or... Agent: Genentech, Inc.

20080305107 - Novel methods of cancer diagnosis and therapy targeted against a cancer stem line: Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment.... Agent: Jones Day

20080305111 - Anti-c35 antibodies for treating cancer: The present invention is directed to methods of killing cancer cells, the methods comprising administering at least one C35 antibody and a chemotherapeutic agent. In some preferred embodiments, two C35 antibodies are administered with a chemotherapeutic agent. The present invention is further directed to C35 antibodies useful in these methods.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080305112 - Immunisation against chlamydia trachomatis: The present invention provides antigenic proteins of Chlamydia trachomatis. The proteins of the present invention are useful for eliciting an immune response to Chlamydia in a patient. For example, an effective amount of protein of the present invention or fraction thereof may be administered to a patient for eliciting a... Agent: Novartis Vaccines And Diagnostics Inc.

20080305109 - Method of passive immunization: e

20080305110 - Novel ligand of g protein coupled receptor protein and use thereof: The present invention provides a method of screening an agonist or antagonist to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, which comprises using the receptor protein or... Agent: Edwards Angell Palmer & Dodge LLP

20080305108 - Peptides of il1 beta and tnf alpha and method treatment: The present invention relates to peptides derived from the proinflammatory cytokines, interleukin-1β, (IL1β) and tumor necrosis factor α, (TNFα), and their use in human or veterinary therapy, such as to generally treat diseases linked to the overproduction of IL1β or TNFα as well as acute or chronic inflammatory diseases, rheumatoid... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080305113 - Pharmaceutical composition for preventing or treating chronic graft-versus-disease comprising anti-cd137 monoclonal antibody: e

20080305114 - Human antibodies that bind human il-12 and methods for producing: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody... Agent: Lahive & Cockfield, LLP/abbott Floor 30, Suite 3000

20080305115 - Reduced-mass, long-acting dosage forms: Methods and compositions are disclosed whereby free antibody or nucleic acid co-administered with a long-acting formulation, such as a microparticle or implant, containing the antibody or nucleic acid to achieve a long duration of antibody or nucleic acid release. One result is that less of the long-acting formulation excipient or... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20080305116 - Anti-cd154 antibodies: The present invention provides peptides, and fragments thereof, and antibodies, or fragments thereof comprising the same, wherein the peptide comprises at least one amino acid substitution compared to wild type 5c8 antibody. The present invention also provides compositions and methods of treating CD154-related diseases or disorders in a subject.... Agent: Pepper Hamilton LLP

20080305117 - Kir-binding agents and methods of use thereof: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, 5 upon binding of KIR to its HLA class I... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080305118 - Treatment of type 1 diabetes with inhibitors of macrophage migration inhibitory factor: Methods of treating a mammal having type 1 diabetes or a risk for type 1 diabetes are provided. The methods comprise administering to the mammal a pharmaceutical composition comprising an agent that inhibits MIF in the mammal. Also provided are methods of evaluating whether a compound is useful for preventing... Agent: Amster, Rothstein & Ebenstein LLP

20080305119 - Modified bacteriophage vectors and uses thereof: Provided herein are modified phage surface polypeptides, phages with modified surface polypeptides, nucleic acids that encode the modified surface polypeptides, and related vectors and phages comprising the vectors. The provided phage surface polypeptides optionally comprise one or more modifications, including, for example, one or more modifications to enhance targeting to... Agent: Fish & Richardson P.C.

20080305121 - Agents for regulating the activity of interferon-producing cells: The present invention provides agents for regulating the activity of interferon-producing cells (IPCs), which comprise as active ingredients antibodies that bind to BST2 and/or to its homologues, and methods for regulating IPC activity that use these antibodies. According to the present invention, the ability of IPCs to produce interferons (IFNs)... Agent: Foley & Lardner LLP

20080305123 - Functional epitopes of streptococcus pneumoniae psaa antigen and uses thereof: Provided is a P4 peptide, which contains functional epitopes of the PsaA protein of Streptococcus pneumoniae, and related methods and compositions. A peptide that comprises the amino acid sequence defined in SEQ ID NO:1 (an example of the P4 peptide) is provided. Also provided is a peptide comprising the amino... Agent: Klarquist Sparkman, LLP

20080305122 - Ii-key/antigenic epitope hybrid peptide vaccines: Disclosed is a nucleic acid molecule comprising a first expressible sequence encoding a protein of interest or polypeptide of interest which contains an MHC Class II-presented epitope. In addition, the nucleic acid molecule comprises a second expressible nucleic acid sequence encoding an antigen presentation enhancing hybrid polypeptide. The antigen presentation... Agent: Kevin M. Farrell Pierce Atwood

20080305120 - Immunogenic compositions comprising hmgb 1 polypeptides: The present invention relates to novel immunogenic compositions (e.g., vaccines), the production of such immunogenic compositions and methods of using such compositions. More specially, this invention provides unique immunogenic molecules comprising an HMGB1 polypeptide (e.g., an HMGB1 B-box polypeptide) and an antigen. Even more specifically, this invention provides novel fusion... Agent: Medimmune, LLC Jonathan Klein-evans

20080305125 - Mutant forms of etxb and ctxb and their use as carriers: The present invention describes the use of a mutant form of EtxB or CtxB to deliver an agent to a target cell wherein the mutant has GM-1 binding activity; but wherein the mutant has a reduced immunogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB.... Agent: St. Onge Steward Johnston & Reens, LLC

20080305124 - Oral pertussis vaccine and method for producing pertussis vaccine: The present invention is related to an oral pertussis vaccine and a method for producing pertussis vaccine, wherein the oral pertussis vaccine comprises amino acid sequence of 1094 to 1279 (SEQ ID NO.1) of filamentous hemagglutinin. The method for producing pertussis vaccine comprises following steps: constructing a vector comprising amino... Agent: Wpat, PC Intellectual Property Attorneys

20080305126 - Separation of unconjugated and conjugated saccharide by solid phase extraction: The invention is based on the use of solid phase extraction for separating conjugated saccharide from unconjugated saccharide in sample, e.g. a vaccine. Solid phase extraction (SPE) provides faster and more reproducible separation of conjugated saccharides from unconjugated saccharides, thereby allowing quantitative separation of these saccharides. The separation of conjugated... Agent: Novartis Vaccines And Diagnostics Inc.

20080305127 - Conjugate vaccines: The invention provides vaccines against Neisseria meningitidis, pneumococcus and DTPa/w. In particular, it provides vaccines based on conjugated capsular saccharides from multiple meningococcal and/or pneumococcal serogroups. It further provides vaccine administration schemes for the immunisation of human patients with two or more of these vaccines.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080305128 - Treatment of prdc in pigs: The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment, including a reduction in the severity of, duration of, and manifestations of, porcine respiratory disease complex (PRDC) in animals, preferably in pigs.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080305129 - Highly attenuated pox virus strains, method for the production thereof and the use thereof as paramunity inducers or for producing vector vaccines: The present invention relates to highly attenuated animal smallpox viral strains and to the use thereof as paramunity inducers or for producing vector vaccines. As a result of the high attenuation process, the claimed animal smallpox strains lose their virulent and immunising properties. The invention also relates to a method... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080305130 - Marked bovine viral diarrhea virus vaccines: The present invention is directed to a bovine viral diarrhea virus comprising at least one helicase domain amino acid mutation wherein the mutation in the NS3 domain results in a loss of recognition by a monoclonal antibody raised against wild-type NS3 but wherein viral RNA replication and the generation of... Agent: Pharmacia & Upjohn

20080305131 - Cancer immunotherapy with semi-allogeneic cells: The present invention relates to improved semi-allogeneic immunogenic cells which act to stimulate and induce an immunological response when administered to an individual. In particular, it relates to cells which express both allogeneic and syngeneic MHC determinants and which also express at least one antigen recognized by T lymphocytes. The... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080305132 - Cosmetic patch for skin treatment: There is provided a treatment product (1) comprising a patch (3), said patch (3) comprising a polysiloxane as a treatment agent, and wherein the patch (3) is arranged such that it can be removeably adhered to a user's skin. Also provided are other treatment products, the use of polysiloxane for... Agent: Trego, Hines & Ladenheim, PLLC

20080305133 - Novel cosmetic or dermatological combinations comprising modified titanium dioxide particles: The present invention relates to novel cosmetic or dermatological compositions comprising multiply coated titanium dioxide particles with a water content of less than 1.5%. More particularly, the present invention relates to novel cosmetic or dermatological compositions comprising multiply coated titanium dioxide particles with a water content of less than 1.5%... Agent: Nixon & Vanderhye, PC

20080305134 - Treated bedding cover: A bedding cover treated with an anti-pest chemical. The cover repels or kills bedbugs, dust mites, ticks, fleas, and other pests for use in bedrooms, hotels, motels, pet beds, and the like. The cover is preferably waterproof and disposable.... Agent: Peacock Myers, P.C.

20080305135 - Wasp repellents: A method of repelling wasps, which method comprises using a preparation comprising (a) one or more of ethyl 3-(N-n-butyl-N-acetylamino)propionate, dihydronepetalactone, and extract of catmint, and (b) at least one compound selected from certain perfume ingredients. This abstract is neither intended to define the invention disclosed in this specification nor intended... Agent: Greenblum & Bernstein, P.L.C

20080305136 - Disinfective adhesive tape: A disinfective adhesive tape has a carrier layer, a silver nanoparticle layer and an adhesive layer. The carrier layer has a top surface and a bottom surface. The silver nanoparticle layer is formed on the top surface of the carrier layer and comprises multiple silver nanoparticles. The adhesive layer is... Agent: Hershkovitz & Associates, LLC

20080305137 - Coating material with biocide microcapsules: The invention relates to a coating material for protection against microorganism invasion on surfaces which are exposed to the effects of damp or water. The coating material has either a pH-value of at least 11.0 or is provide with a base material for the coating whereby the pH-value is at... Agent: Hedman & Costigan P.C.

20080305138 - Photostable wound dressing materials and methods of production thereof: The invention provides a method of preparing an antimicrobial sponge material for medicinal use, comprising the steps of: treating an anionic polysaccharide with a solution of a silver salt to produce a complex of the anionic polysaccharide with silver; dispersing said complex in aqueous ascorbic acid to form an acidified... Agent: Philip S. Johnson Johnson & Johnson

20080305139 - Pharmaceutical compositions comprising dextran with a molecular weight of 1.0-100 kda and processes for their preparation: A solid or semisolid implant obtainable by providing a liquid composition comprising an aqueous solution of dextran with molecular weight of 1.0-100 kDa and introducing the liquid composition into the body of a mammal, whereby the implant is formed in situ in the body of the mammal. A process for... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080305142 - Cell free biosynthesis of high-quality nucleic acid and uses thereof: The invention provides an improved cell free amplification method capable of producing large quantities of therapeutic-quality nucleic acids and methods of using the synthesized nucleic acid in research, therapeutic and other applications—The methods combine several different state-of-the-art procedures and coordinate their applications to affordably synthesize nucleic acids for therapeutic purposes.... Agent: Osha & Liang LLP / Cytogenix

20080305143 - Controlled radical polymerization-derived block copolymer compositions for medical device coatings: Controlled radical polymerization-derived biocompatible block copolymer coatings for medical devices are disclosed. Specifically, block copolymer coatings designed to control the release of bioactive agents from medical devices in vivo are disclosed. The present application also discloses providing vascular stents with drug-eluting controlled release block copolymer coatings and related methods for... Agent: Medtronic Vascular, Inc.IPLegal Department

20080305147 - Drug delivery system for the prevention of cerebral vasospasm: The present invention relates to the treatment and prevention of vasospasm. The present invention provides a system for treating a cerebral vasospasm in a human utilizing a pharmaceutical composition and administrating a therapeutically effective amount of the pharmaceutical composition to a predetermined location in close proximity to a cerebral artery... Agent: Wolf, Block, Shorr And Solis-cohen LLP

20080305141 - Freeze-thaw method for modifying stent coating: Methods are disclosed for controlling the morphology and the release-rate of active agent from a coating layer for medical devices comprising a polymer matrix and one or more active agents. The methods comprise exposing a wet or dry coating to a freeze-thaw cycle. The coating layer can be used for... Agent: Squire, Sanders & Dempsey LLP

20080305144 - High strength devices and composites: An oriented implantable, biodegradable device is disclosed. The oriented implantable, biodegradable device is formed from a homogeneous polymer blend comprising a polylactic acid in admixture, in an amount of not more than 10% by weight of the polymer blend, with an additive which both plasticises polymer draw and is a... Agent: Chief Patent Counsel Smith & Nephew, Inc.

20080305140 - Long-term delivery formulations and methods of use thereof: The present invention provides a method, a kit and compositions for long-term release of a drug at a constant therapeutically effective level for nervous system disorders where adherence to therapeutic regimen is problematic. In particular, to the therapy of psychotic disorders.... Agent: Pearl Cohen Zedek Latzer, LLP

20080305145 - Process for demineralization of bone matrix with preservation of natural growth factors: A demineralized bone matrix is produced by a process in which a bone body is placed in a first processing solution comprising an acid to demineralize the bone body. The bone body is periodically removed from the first solution at specific time intervals to perform at least one test, such... Agent: Kinney & Lange, P.A.

20080305146 - Selective cell therapy for the treatment of renal failure: Provided herein are isolated populations of kidney cells harvested from differentiated cells of the kidney, wherein cells have been expanded in vitro. The kidney cells may include peritubular interstitial cells of the kidney, and preferably produce erythropoietin (EPO). The kidney cells may also be selected based upon EPO production. Methods... Agent: Myers Bigel Sibley & Sajovec

20080305148 - Treatment of spinal injuries using human umbilical mesenchymal stem cells: Transplantation of human umbilical mesenchymal stem cells (HUMSCs) to an area of a spinal injury is therapeutically effective in treating the spinal injury. Methods for treating spinal injuries based on such transplantation are described.... Agent: Panitch Schwarze Belisario & Nadel LLP

20080305149 - Mucoadhesive vesicles for drug delivery: Vesicles for delivery of active macromolecules which are formed from amphiphilic segmented copolymers having one or more mucoadhesive groups or regions and which can be used for delivery of an active agent to an area of the body having a mucous membrane, such as but not limited to the gastrointestinal... Agent: Law Office Of Collen A. Beard, LLC

20080305151 - Dipeptide-comprising composition for oral administration: (wherein X represents alanyl, glycyl, arginyl, seryl, α-aspartyl or α-glutamyl, and Y represents valine, leucine or isoleucine), with an object of providing a composition for oral administration which is excellent in nutrition, pharmacological effect and gustation and comprises at least one kind selected from valine, leucine and isoleucine, or providing... Agent: Fitzpatrick Cella Harper & Scinto

20080305150 - Polymer composition and dosage forms comprising the same: A composition comprising a high molecular weight, water soluble polymer having a cloud point from about 20 to about 90° C. and a gelling polymer is provided. The composition may be used as a component of a pharmaceutical dosage form, such as the shell of a dosage form, or as... Agent: Philip S. Johnson Johnson & Johnson

20080305153 - Antibacterial sol-gel coating solution, method for preparing antibacterial sol-gel coating solution, antibacterial articles, and method and equipments for preparing antibacterial articles: The invention relates to an antibacterial sol-gel coating solution, a process for preparing the antibacterial sol-gel coating solution, an antibacterial article, and a process and an apparatus for producing the antibacterial article. Said antibacterial sol-gel coating solution comprises a. at least one substance selected from the group consisting of Ti... Agent: Knobbe Martens Olson & Bear LLP

20080305152 - Methods of inducing melanogenesis in a subject: Described herein are methods and compositions for inducing melanogenesis in a human subject. The method comprises administering to a subject an alpha-MSH analogue, in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of subject without inducing homologous desensitization of the melanocortin-1 receptors.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20080305154 - Transdermal medicament patch and active electrode for same: A transdermal medicament patch includes a biocompatible substrate having a therapeutic face on one side configured for disposition against the skin of a patient, a biocompatible adhesive on the therapeutic face, a planar medicament matrix covering a portion of the therapeutic face, and a release liner covering the portion of... Agent: Kent S. Burningham, P.C.

20080305155 - Transdermal systems containing multilayer adhesive matrices to modify drug delivery: t

20080305156 - Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi: We disclose a composition comprising an echogenic liposome (ELIP) having an exterior surface, an interior surface, and at least one bilayer comprising at least one lipid selected from the group consisting of saturated phospholipids, unsaturated phospholipids, mixed phospholipids, and cholesterol, and a thrombolytic compound trapped by the ELIP. We also... Agent: Williams, Morgan & Amerson

20080305157 - Encapsulation and separation of charged organic solutes inside catanionic vesicles: Catanionic vesicles including solute ion, methods for forming these, and methods of using these.... Agent: Venable LLP

20080305158 - Methods for the preparation of stable pharmaceutical solid dosage forms of atorvastatin and amlodipine: The present invention relates to pharmaceutical compositions comprising amlodipine and pharmaceutically acceptable salts thereof, and atorvastatin and pharmaceutically acceptable salts thereof, and processes for their preparation.... Agent: Ranbaxy Inc.

20080305159 - Ibuprofen-hydrocodone-antihistamine composition: A pharmaceutical composition for use in relieving cold and cough symptoms in a mammal includes ibuprofen, hydrocodone bitartrate and an antihistamine (or a decongestant). The ibuprofen is in a therapeutically effective amount sufficient to act as an analgesic and an anti-inflammatory. The hydrocodone bitartrate is in a therapeutically effective amount... Agent: Bryan W. Bockhop, Esq. Bockhop & Associates, LLC

20080305163 - Butylphthalide soft gel capsule and its preparation procedure: The present invention discloses a novel dosage form of butylphthalide soft capsule and its preparation procedure. Butylphthalide soft capsule is composed of a coating material and a drug-containing oil. The drug-containing oil is basically composed of butylphthalide and diluent—vegetable oil, wherein the weight ratio of butylphthalide to oil ranges from... Agent: Knobbe Martens Olson & Bear LLP

20080305164 - Crystalline composition containing escitalopram: Crystalline particles of escitalopram oxalate with a particle size of at least 40 μm is disclosed. Method for the manufacture of said crystalline particles and pharmaceutical compositions comprising said crystalline particles are also disclosed.... Agent: Darby & Darby P.C.

20080305162 - Incontinence treatment methods: The invention relates to the fields of pharmaceutical chemistry and pharmacological treatments. More specifically, the invention relates to compositions and methods for the treatment of incontinence, voiding disorders associated with lower urinary tract dysfunctions and/or the urethro-vesical and anal sphincteral disorders. The invention can be used, for example, for the... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080305161 - Injectable depot formulations and methods for providing sustained release of nanoparticle compositions: Pharmaceutical formulations comprising: a compound selected from the group consisting of ziprasidone, having a maximum average particle size; a carrier; and preferably at least two surface stabilizers are disclosed. The present invention also comprises methods of treating psychosis with such a formulation and processes for making such a formulation.... Agent: Pfizer Inc Steve T. Zelson

20080305160 - Oral medicament for the modified release of at least one active principle, in multimicrocapsule form: The field of the invention is that of oral medicaments or pharmaceutical compositions, in particular of the type including one or more active principles. The aim of the invention is to provide an improved oral medicament to be administered in one or several daily doses and enabling the modified release... Agent: Patton Boggs LLP

20080305165 - Sustained release oral formulation and process for the preparation thereof: Disclosed is a multiple unit type sustained release oral formulation comprising sustained release pellets formed from granules containing an active ingredient and a water-insoluble polymer, the granules being coated with a sustained release base material; and rapid release granules containing the active ingredient, and a method for preparing the same.... Agent: Knobbe Martens Olson & Bear LLP

20080305166 - Robust rapid disintegration tablet formulation: A rapidly disintegrating, orally administered tablet or compressed dosage form, comprising ethylcellulose (EC) as a directly compressible binder which enhances tablet robustness as manifested by improved strength, lower friability, lower hygroscopicity and yet, hydrophobic nature notwithstanding, does not retard disintegration, but shortens disintegration time or is disintegration time neutral when... Agent: Hercules Incorporated Hercules Plaza

20080305168 - In-situ melting and gelling tablet composition for oral care: Disclosed herein is an oral care composition that provides pleasant cooling sensation and easy delivery of an oral care active ingredient. The tablet-type oral care composition of the present invention is prepared by compressing porous plastic granules at a pressure of 500 kg/cm2 or less and undergoes in situ melting... Agent: Birch Stewart Kolasch & Birch

20080305167 - Tamper-resistant oral opioid agonist formulations: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tampering to the... Agent: Davidson, Davidson & Kappel, LLC

20080305169 - Pharmaceutical compositions comprising nitrogen-containing fused ring coumpounds: s

20080305172 - Ophthalmic depot formulations for periocular or suconjunctival administration: The present invention relates to ophthalmic depot formulations comprising an active agent, e.g. embedded in a pharmacologically acceptable biocompatible polymer or a lipid encapsulating agent, e.g. for periocular or subconjunctival administration.... Agent: Novartis Corporate Intellectual Property

20080305171 - Pyrrolopyrazine, formulations, methods of manufacture, and methods of use there: Disclosed herein is a pyrrolopyrazine COMPOUND I having defined amounts of R isomer, particle size, and stability. Also disclosed are pyrrolopyrazine oral dosage forms comprising the described COMPOUND I material as well as methods of treating disorders amenable to therapy using COMPOUND I.... Agent: Cantor Colburn, LLP

20080305170 - Method for producing calcium component powder containing oil-soluble substance: The present invention provides a method for producing a powder containing an oil-soluble substance, from which substantially no oil-soluble substances are eluted upon application of pressure, heat, or water. The present invention relates to a method for producing a powder containing an oil-soluble substance, which comprises, dispersing an oil-soluble substance... Agent: Greenblum & Bernstein, P.L.C

20080305173 - Amorphous drug beads: The present inventive subject matter relates to amorphous drug beads comprising an amorphous active drug and an organic surfactant having improved solubility, absorption and wettability characteristics. The present inventive subject matter further relates to methods of preparing the amorphous drug beads, wherein molten drug beads are subject to a cooling... Agent: Richard R. Muccino

20080305174 - Polymeric nanocapsules for use in drug delivery: The present invention relates to drug delivery formulations that utilize nanocapsules, such as nanovesicles, micelles, lamellae particles, polymersomes, dendrimers, and other nano-size particles of various other fabrications, including those that are known in the art. The invention employs diblock copolymers or single block polymers that hold, adhere to, absorb or... Agent: Ostrolenk Faber Gerb & Soffen

20080305175 - Micro-container: There is disclosed a method of making a micro-container. The method comprises the step of evaporating a swelling agent solution absorbed in a polymer micro-particle to form an inner void therein. The evaporating step is undertaken under conditions to form a conduit extending through the shell wall of said micro-particle... Agent: Marshall, Gerstein & Borun LLP

20080305176 - Process for loading polymer particles with drug: The present invention relates to processes for loading microsphere polymer particles with crystallisable drug, in the presence of a crystallisation inhibitor whereby crystallisation of the drug is inhibited. The invention is of particular value for loading polymer beads with paclitaxel, ibuprofen and/or dexamethasone. The polymer is suitably an anionic polyvinyl... Agent: Sughrue Mion, PLLC

20080305177 - Method of administering testosterone: A method of administering testosterone by the oral ingestion of a delivery system with sustained release properties where the micronized testosterone is present as a solid or liquid lipid suspension and, optionally, at least part of the testosterone is microencapsulated.... Agent: Greensfelder Hemker & Gale PC

20080305178 - Use of a high molecular weight extracellular haemoglobin as a blood substitute: A blood substitute, of an extracellular haemoglobin having a molecular weight of approximately 3 to approximately 4 million daltons, comp sing chains of polymerised globins, containing free cysteines capable of binding to NO and/or SNO groups, and having a P50 of approximately 6 to approximately 7 mm Hg, and methods... Agent: Young & Thompson

20080305179 - Composition comprising natural substances having healing, repellent and biocidal properties for the treatment and the cure of external wounds: Compositions of natural substances for human and veterinary use are provided and include neem oil mixed with the oil extract of Hypericum. The compositions have healing, anti-bacterial, anti-inflammatory, and pain relieving properties combined with a repellent effect against myiasigenic diptera and non-myiasigenic diptera. The compositions can be used for the... Agent: The Nath Law Group

20080305180 - Method of administration of a pulmonary surfactant: m

20080305181 - Compositions and methods for treatment of vascular grafts: The present invention contemplates compositions and methods for the treatment of vascular grafts both ex vivo and in vivo. Ex vivo treatment comprises completely removing a vessel (i.e., vein or artery) from the body and treating with the compositions of the present invention. In vivo treatment comprises treating the vessel... Agent: Peter G. Carroll Medlen & Carroll

20080305182 - Hydrogen peroxide disinfectant containing a cyclic carboxylic acid and/or aromatic alcohol: An aqueous disinfecting solution, a concentrated version of the solution, and a dry powdered composition which may be dissolved in water to provide the solution. The solution has a pH of from 0.6 to 7 and comprises (a) hydrogen peroxide in a concentration of from 0.01 to 6% w/w; and... Agent: Clark & Brody

20080305183 - Process for eliminating bacterial spores on surfaces and sporicide for use in the process: A process for eliminating bacterial spores on surfaces by contacting the surfaces with an aqueous composition comprising 3 to 30 wt. % of hydrogen peroxide and having a pH value of 6 to 8 for a period of 1 to 60 minutes at a temperature of 0 to 35° C.,... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20080305184 - Pigment mixture: The invention relates to a pigment mixture consisting of at least two constituents, constituent A being uncoated, monocoated or multicoated glass lamellae, and constituent B being nacreous pigments based on phyllosilicates, SiO2 lamellae, Fe2O3 lamellae or Al2O3 lamellae. The invention also relates to the use of said pigment mixture, inter... Agent: Millen, White, Zelano & Branigan, P.C.

20080305185 - Composition and method for preventing or treating urolithiasis: A method for preventing or treating urolithiasis in an animal by feeding the animal a food composition comprising potassium in an amount equivalent to more than about 1% by weight potassium chloride and a food composition suitable for preventing or treating urolithiasis in an animal comprising potassium in an amount... Agent: Colgate-palmolive Company

20080305186 - Method and composition for the treatment of cardiac hypertrophy: The present invention includes compositions and methods treat a patient suffering from one or more symptoms of cardiac hypertrophy, hypertension and/or ischemia by administering a pharmaceutically effective amount of a pharmaceutical composition having an anti-epileptic drug and an antibiotic to the patient, for example, the anti-epileptic drug may be carbamazepine... Agent: Chalker Flores, LLP

20080305187 - Use of parathyroid hormone for treating periodontal disease and for other dental applications: Method for treating or preventing periodontal disease associated with mild to severe alveolar bone loss, and for improving the prognosis of dental implant procedures by administering human parathyroid hormone to a patient in need thereof.... Agent: Eli Lilly & Company

20080305188 - Composition and method for supporting cancer treatments: The present invention relates to a novel composition comprising geranium oil and extracts from the roots of the plants of the genus Sophora, preferably Sophora tonkinesis. Said composition can be administered to mammalian animals undergoing cancer treatments, such as chemotherapy and radiation therapy, that would induce the side effect of... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080305189 - Treatment of aspirin resistance with radix salviae miltiorrhizae, its extract and composition: The present invention relates to the treatment of aspirin resistant cardio-cerebrovascular diseases using RSM (RSM), its extract and composition comprising any or both of them, especially the formulation Dan Shen Drop Pills (Drop Pills of RSM).... Agent: Harness, Dickey & Pierce, P.L.C

20080305190 - Salvia hispanica i (chia) in the management and treatment of cardiovascular disease, diabetes and associated risk factors: Described is use of Salvia hispanica L. (Chia) for controlling, in one embodiment reducing, blood glucose levels, preferably post-prandial blood glucose levels. This is useful in both non-diabetic and diabetic individuals, but especially in diabetic individuals. Also described is the use of chia in reducing postprandial blood glucose, insulin sensitivity,... Agent: Bereskin And Parr

20080305191 - Drinking water for a diabetic and manufacturing process thereof: A drinking water for a diabetic including water of 93˜97 wt %; budded Oryza sativa of 2.5˜5 wt %; Zingiber officinale of 0.04˜0.07 wt %; and Glycyrrhiza uralensis of 0.01-0.05 wt %.... Agent: Greer, Burns & Crain

20080305192 - Marrubiin and composition for reducing snoring, package and method: The invention comprises a composition for the reduction of snoring, a packaging therefor and a method for the manufacture hereof. The composition can be applied in the pharynx in different variants, in particular as spray, as gel or as foam formulation. Application of the composition at least temporarily reduces the... Agent: Demont & Breyer, LLC

20080305193 - Cosmetic compositions: A cosmetic composition suitable for topical application to human or animal skin comprising an effective amount of active ingredient dispersed in an acceptable cosmetic base or carrier, wherein the active ingredient comprises a mixture of an amino acid, a low glycemic glycoside and a Vitamin, wherein the amino acid is... Agent: S. Michael Bender

20080305194 - Extracts of passion fruit and uses thereof: An extract of passion fruit is prepared. The extract has the effect of lowering blood pressure and serum nitric oxide levels in mammals. The extract also provides a hepatoprotective effect, as well as antioxidant and anti-inflammatory effects in mammals. A novel compound was identified in the extract and given the... Agent: Davis, Brown, Koehn, Shors & Roberts, P.C. The Davis Brown Tower

20080299038 - Luminescent metal complexes for monitoring renal function: Some embodiments of the present invention may be said to be directed to metal complexes of Formula I, wherein at least one of X1, X2, X3, R1, R2, R3, R4 and R5 is what may be characterized as an antenna capable of providing (e.g., absorbing and/or emitting) an appropriate electromagnetic... Agent: Mallinckrodt Inc.

20080299039 - Aprotinin polypeptides for transporting a compound across the blood-brain barrier: The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides derived from aprotinin and from aprotinin analogs as well as conjugates and pharmaceutical compositions comprising these polypeptides or conjugates. The present invention also relates to the use of these polypeptide for transporting... Agent: Clark & Elbing LLP

20080299040 - Somatostatin receptor 2 antagonists: The invention is directed to somatostatin analogs which are receptor antagonists of the somatostatin receptor, including receptor-selective antagonists, especially sst2-selective antagonists. Related compounds and compositions are included, including antagonists complexed with or conjugated to radioactive nuclides. The antagonists of the invention are useful in diagnosing and treating neoplastic and non-neoplastic... Agent: Foley And Lardner LLP Suite 500

20080299041 - Heterocyclic indene derivatives and their radioisotope labeled compounds for imaging beta-amyloid deposition: The invention is directed to heterocyclic indene derivatives useful for β-amyloid plaque imaging, their radiolabeled compounds and their preparation methods. The compounds of the invention are easily labeled with radioisotopes and have high affinities to β-amyloid depositions, thus they facilitate diagnosis of Alzheimer's disease by imaging the distribution of β-amyloid... Agent: Heslin Rothenberg Farley & Mesiti PC

20080299043 - Higher fatty acid triester compound having diethylenetriamine-type metal chelate structure: wherein R1, R2 and R3 independently represent an alkyl group or an alkenyl group having 8 to 25 carbon atoms; X represents —O—, or —N(Z)- (Z represents hydrogen atom, or an alkyl group having 1 to 3 carbon atoms); and L represents a divalent bridging group constituted by atoms selected... Agent: Sughrue Mion, PLLC

20080299042 - Membrane associated molecules: The present invention is directed to novel methods of treating, identifying or diagnosing a hyperproliferative disorder in a patient in need thereof. The methods of the invention include administering to a patient a composition comprising a binding molecule which binds to a cell surface expressed glycoprotein expressed predominantly in tumor... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20080299047 - Method for preparation of water-soluble and dispersed iron oxide nanoparticles and application thereof: The present invention relates to a process for preparing water-soluble and dispersed iron oxide (Fe3O4) nanoparticles and application thereof, characterized in which two-stage additions of protective agent and chemical co-precipitation are employed in the process. In the first stage, Fe3O4 nanoparticles are obtained using absorbent-reactant coexistence technology. In the second... Agent: Bacon & Thomas, PLLC

20080299046 - Methods for controlling surface functionality of metal oxide nanoparticles, metal oxide nanoparticles having controlled functionality, and uses thereof: Methods for controlling surface functionality of metal oxide nanoparticles, nanoparticles having controlled surface functionality, and uses thereof are described herein. Methods for controlling the surface functionality of a metal oxide nanoparticle are can include attaching a ligand to a metal oxide nanoparticle, where the ligand can include a functional portion... Agent: Wilmerhale/columbia University

20080299044 - Saccharide fluorescent substrates, preparation method and uses thereof: The invention concerns saccharide type fluorescent enzymatic substrates comprising on the same saccharide unit a fluorophor F1 and an inhibitor of the fluorescence of F1, and their use for preparing a diagnostic reagent for in vivo functional imaging, as well as a diagnostic reagent containing at least such an enzymatic... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080299045 - Composition for prevention, treatment, and diagnosis of chronic obstructive pulmonary disease (copd): The present invention provides a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease (COPD) comprising cytokeratin 18 protein as an active ingredient. The present invention also provides a diagnostic composition and a diagnostic kit for diagnosing COPD comprising cytokeratin 18 protein. The present invention further provides a composition... Agent: Porter Wright Morris & Arthur, LLP Intellectual Property Group

20080299049 - Inhalation nebulizer: The aerosol generator of an inhalation therapy device according to a preferred embodiment of the invention continuously produces an aerosol at a generation rate of about 0.2 ml/min to about 1.5 ml/min, preferably 0.4 ml/min to about 1.2 ml/min and the mixing chamber has a volume of about 60 ml... Agent: Wolf Greenfield & Sacks, P.C.

20080299048 - Mixed drug aerosol compositions: The present invention pertains to aerosols which comprise a first compound which is physiologically active and a second compound which is different from the first compound. Such aerosols may be produced “on demand” and can be used to control drug release, to improve vaporizability, or to reduce, modify or eliminate... Agent: Swanson & Bratschun, L.l.c

20080299050 - Topical therapies for oral mucositis and other conditions: A method for treating oral mucositis in a subject comprises topically administering to an oral mucosal surface of the subject phenyloin or a pharmaceutically acceptable salt thereof in an amount effective to inhibit mucosal degeneration or promote mucosal regeneration, and optionally an analgesic agent in an amount effective, in combination... Agent: Kv Pharmaceutical Company

20080299052 - Formulation to prevent plaque formation: A composition for preventing plaque formation comprises; 98.267 kg deionised water; 0.2 kg delmopinol; 0.01 kg sodium saccharide; 0.02 kg herb flavour COD 76634-34; 1.5 kg 99.5% ethanol; and 0.003 kg sodium hydroxide.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080299051 - Pharmaceutical composition for the oral hygiene, the treatment of the periodontal illnesses and the halitosis: The invention is a pharmaceutical composition for the oral hygiene for the treatment of the periodontal illnesses and the Halitosis. It consists of a mixture 0.01 a 5 g of Hydrogen Peroxide; 0.001 a 0.5 g de Eugenol: 0.001 a 0.5 g de Permonochlorophenol; 0.001 a 0.3 g of Camphor;... Agent: Furr Law Firm

20080299053 - Enhanced delivery of certain fragrance components from personal care compositions: A personal care composition is provided having a fragrance which incorporates limonene, gamma terpinene, ethylene brassylate or combinations thereof in conjunction with a quaternary ammonium salt. The salt has a structure AB, wherein A is a cationic charge component, B is an anionic charge component, and A has one quaternized... Agent: Unilever Patent Group

20080299054 - Personal care compositions with enhanced fragrance delivery: A personal care product is provided which includes a fragrance, a substituted urea and a quaternary ammonium salt. The substituted urea and quaternary ammonium salt operate together as a scent boosting system to enhance volatilization of fragrance components upon the personal care composition being first applied to human skin or... Agent: Unilever Patent Group

20080299057 - Method and compositions for dispersing particulate solids in oil: This invention relates to a method for preparing dispersions of solid particles, especially pigments, metal oxides and mineral fillers in organic media, to dispersing compositions used in this method and to dispersions containing these dispersion compositions. The dispersing compositions include an oil soluble surfactant selected from the group consisting of... Agent: Michael P. Aronson Mp&g Aronson Inc.

20080299055 - Monomer 5, 6-diphenyl-1.2.4-traizinic derivatives and the use thereof: The invention relates to the use of 5,6-diphenyl-1,2,4-triazinic compounds of general formula (I), wherein cycle penetrating bonds display an ortho, meta or para indifferent substitution position, identical or different R1 and R2 represent a hydrogen, fluoride, chloride or bromine atom, C1 to C12 linear or branched alkyl, C1 A C18... Agent: Birch Stewart Kolasch & Birch

20080299058 - Multi-formulation cosmetic compositions: The present invention relates to a cosmetic composition a) from about 10% to about 90% of water-in-oil emulsion as a first formulation which comprises i) from about 0.1% to about 15% of an emulsifying crosslinked siloxane elastomer; ii) from about 1% to about 40% of a solvent for the emulsifying... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080299056 - Passivated nano-titanium dioxide particles and methods of making the same: The invention is directed to a method for reducing the chemical activity and photo activity of titanium dioxide nanoparticles comprising adding a densifying agent, such as citric acid, to an aqueous slurry of the titanium dioxide nanoparticles; treating the aqueous slurry with a source of silica, such as a solution... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20080299059 - Cosmetic compositions containing functionalized metal-oxide layered pigments and methods of use: The disclosure relates to cosmetic compositions containing functionalized metal-oxides layered pigments. The disclosure also relates to the use of the functionalized metal-oxide layered pigments in cosmetics such as hair, eyes, lips, skin and nail compositions. The metal-oxide layered pigments are functionalized with ligands which provide improved properties to the pigments... Agent: Connolly Bove Lodge & Hutz LLP

20080299060 - Pharmaceutical composition for the treatment of nail diseases: A method for topically and systemically delivering a pharmaceutical composition to a human nail is disclosed, said method comprising the application of a pharmaceutical composition to the nail, covering the nail and the pharmaceutical composition with a protective layer, and a dissolvent to remove the protective layer and the pharmaceutical... Agent: Dickstein Shapiro LLP

20080299061 - Skin whitening cosmetic composition, pack containing the same, and preparation method thereof: A skin whitening cosmetic composition having excellent whitening effects without causing any side effects, which includes a carbonized pine cone, as well as a pack containing the same. The skin whitening cosmetic composition includes natural substances, unlike prior commercially available products, and has excellent whitening effects without causing any side... Agent: Iphorgan, Ltd.

20080299062 - Use of oxocarboxylic acids-containing combinations for deodorization: Described is the use of a combination of an oxocarboxylic acid with metal ions, organic bases or polymers substantive for keratin material for combating, suppressing or eliminating odors of the hair of skin. Preferred oxocarboxylic acids are those of general formula R—C(═O)—A—CO2H wherein R stands for hydrogen or a monovalent... Agent: Michael J. Striker

20080299064 - Compositions and method for management of head lice: A composition for the management of head lice includes a hair treatment base which is at least partially hair conditioner and a coloring agent in a concentration sufficient to colorize lice nits covered with the composition. The composition does not include a pediculicide selected from the group consisting of organochlorines,... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20080299063 - Hair cosmetic composition: in the formula (1), R1 represents an aliphatic C11-23 hydrocarbon group, R2 represents H or a C1-4 alkyl group, and m stands for a number from 2 to 4; in the formula (2), R3 represents a C6-24 alkyl or alkenyl group, and R4 and R5 each represents a C1-6 alkyl... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080299065 - Composition containing sulfonic acid and/or sulfuric acid compound: Composition containing an aqueous phase and an emulsifying system comprising a sulfonic acid compound or a salt of the compound, or a sulfuric acid compound or a salt thereof, and mixtures thereof.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080299066 - Energy-activated compositions for controlled sustained release of a gas: A composition for energy-controlled generation and release of at least one gas, which includes an energy-activated catalyst capable of being activated by electromagnetic energy, and a solid or a liquid containing anions capable of being oxidized by the activated catalyst or reacted with species generated during activation of the catalyst... Agent: Senniger Powers LLP

20080299067 - Functionalised siloxanes for scar tissue treatment: A novel composition for use in treating a wound, burn or other skin condition comprises one or more compounds of formula (I), wherein: m = 0-6, n = 6-100, Q, R and R′ may be independently selected from, C1-5 alkyl, OU, UOCH2CH3, CH2CH3, UOCH3, OH, O(CH2)y(OU)yCH3, (OCH2CH2)yOU, (OCH2CH2)yOH, UOH, UOU′,... Agent: Leydig Voit & Mayer, Ltd

20080299068 - Skin preparation for external use: The present invention provides an external composition for skin that has excellent effects in improving elasticity and alleviating wrinkles while moisturizing the skin, has good spreadability on the skin, and has no stickiness. The external composition for skin of the present invention is characterized by comprising: (A) an acrylic polymer... Agent: Rankin, Hill & Clark LLP

20080299070 - Antiviral compounds: The present invention relates to novel antiviral compounds which are covalently attached to solid, macro surfaces. In another embodiment, the invention relates to novel antiviral compositions including a polymeric material and, embedded therein, an antiviral compound. In other embodiments, the invention relates to making a surface antiviral and making a... Agent: Hoffmann & Baron, LLP

20080299069 - Polymer derivatives comprising an acetal or ketal branching point: The invention provides a polymer comprising (i) a first water-soluble polymer segment that is covalently attached, either directly or through one or more atoms, to a first oxygen atom that is covalently attached to a linking carbon atom; (ii) a second water-soluble polymer segment is covalently attached, either directly or... Agent: Mark A. Wilson Nektar Therapeutics

20080299072 - Chemokine antagonists: New CC-chemokine antagonists are provided. Compounds prepared in accordance with the present invention can be used as anti-inflammatory and immunomodulatory compounds and in the treatment or prevention of CC-chemokine-related diseases.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080299071 - Stable aqueous solutions of granulocyte macrophage colony-stimulating factor: The invention provides formulations of GM-CSF to which a chelating agent has been provided to stabilize the GM-CSF against N-terminal degradation.... Agent: Seed Intellectual Property Law Group PLLC

20080299074 - A-beta immunogenic peptide carrier conjugates and methods of producing same: The present invention is directed to methods of producing conjugates of Aβ peptide immunogens with protein/polypeptide carrier molecules, which are useful as immunogens, wherein peptide immunogens are conjugated to protein carriers via activated functional groups on amino acid residues of the carrier or of the optionally attached linker molecule, and... Agent: Townsend And Townsend And Crew, LLP

20080299076 - Compunds and compositions that cause non-apoptotic cell death and uses thereof: The present invention relates to erastin analogs, particularly compounds of formulae I and II, including compounds 1-20, 22-24, 34, and 40. The invention also relates to pharmaceutical compositions containing such analogs and to methods of treating conditions in a mammal with such analogs and pharmaceutical compositions.... Agent: Kevin C. Hooper, Esq. Bryan Cave LLP

20080299075 - Hepatitis c virus inhibitors: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080299077 - Isolation and growth of stem cells from hemangiomas: The present invention describes stem cells and progenitor cells derived from hemangiomas, including testing of angiogenic inhibitors using these cells. The invention as described is useful in providing a process to culture and propagate hemangioma stem cells and generate xenograft models to develop treatments for infantile hemangiomas and other types... Agent: Dla Piper LLP (us)

20080299073 - Method for treatment or prophylaxis of an infection using either an antibody which binds to il-9 or an agent which stimulates production of autoantibodies to interleukin-9: The invention relates to methods for the treatment and/or prophylaxis of infections that produce an imbalance of Th1 and Th2 CD4 cells such as Leishmaniasis, via the administration of an antibody to IL-9 or an agent that stimulates production of anti-IL-9 antibodies sufficient to neutralize native IL-9 in a subject.... Agent: Fulbright & Jaworski, LLP

20080299078 - Tumor associated amino acids and uses therefor: The invention describes SAGE (sdph3.10) and sdp3.5 tumor associated nucleic acids, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such nucleic acid molecules, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of... Agent: Wolf Greenfield & Sacks, P.C.

20080299079 - Absorption enhancers for drug administration: A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper US LLP

20080299081 - Polynucleotides and polypeptides of the ifnalpha-21 gene: Polynucleotides and polypeptides derived from the nucleotide sequence of the IFNα-21 gene comprising SNPs, and their therapeutic uses.... Agent: Hunton & Williams LLP Intellectual Property Department

20080299080 - Thiophene analogues for the treatment or prevention of flavivirus infections: l

20080299083 - Adenoviral vectors having a protein ix deletion: Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used... Agent: Townsend And Townsend And Crew, LLP

20080299084 - Bacterially derived intact minicells that encompass plasma free functional nucleic acid for in vivo delivery to mammalian cells: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.... Agent: Foley And Lardner LLP Suite 500

20080299082 - Novel recombinant t4 phage particle containing hiv, h. pylori or cancer antigens and uses thereof: The invention is directed to a novel recombinant T4 phage particle expressing a HOC and/or SOC Helicobacter pylori and/or SCLC fusion peptide as well as methods for their preparation and methods of use in compositions and kits.... Agent: Cheryl H Agris Phd

20080299097 - Isolated population of rapidly proliferating marrow stromal cells for enhanced in vivo engraftment: Multipotent stromal cells “MSCs” have been described as consisting of at least two populations of cells, rapidly self-renewing stem cells (RS-MSCs), and larger, slowly replicating cells (mMSCs). The present invention provides methods for enhancing engraftment of MSCs in vivo by administering an enriched fraction of RS-MSCs that express certain cell... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080299094 - Methods and kits for predicting liver fibrosis progression rate in chronic hepatitis c patients: Methods and kits for determining predisposition of an individual to develop fast progression rate of liver fibrosis are provided. Also provided are agents and pharmaceutical compositions useful in preventing fast progression of liver fibrosis and a method of identifying drug molecules which accelerate or induce liver fibrosis.... Agent: Martin D. Moynihan Prtsi

20080299096 - Modified nucleotide sequence encoding glucagon-like peptide-1 (glp-1), nucleic acid construct comprising same for production of glucagon-like peptide-1 (glp-1), human cells comprising said construct and insulin-producing constructs, and methods of use the: An isolated chimeric GLP-1 nucleic acid sequence encoding a human pro-insulin leader, a glucagon-like peptide-1 (GLP-1), and a furin cleavable site between the human pro-insulin leader sequence and the GLP-1 is provided. Also provided is an isolated modified chimeric GLP-1 nucleic acid sequence encoding a human pro-insulin leader, a glucagon-like... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080299095 - Nup98-hox fusions for expansion of hemopoietic stem cells: Nucleic acid constructs encoding homeobox-nucleoporin fusions are disclosed, compositions comprising same, and methods which provide enhanced expansion of stem cells. In particular, an isolated nucleic acid construct encoding a NUP98-HOX fusion is provided, which when introduced into hemopoietic stem cells provides enhanced expansion of these cells. Methods of expanding stem... Agent: Merchant & Gould PC

20080299098 - Broad-spectrum antibacterial and antifungal activity of lactobacillus johnsonii d115: The present invention demonstrated the potential use of Lactobacillus johnsonii D115 as a probiotic, as a prophylactic agent or as a surface treatment of materials against human and animal pathogens such as Brachyspira pilosicoli, Brachyspira hyodysenteriae, Shigella sonnei, Vibrio cholera, Vibrio parahaemolyticus, Campylobacter jejuni, Streptococcus pneumoniae, Enterococcus faecalis, Enterococcus faecium,... Agent: Davis, Brown, Koehn, Shors & Roberts, P.C. The Davis Brown Tower

20080299099 - Strain composition of the lactobacillus genus and the application of strain composition of the lactobacillus genus: A subject of the invention is a composition containing strains Lactobacillus fermentum 57A, Lactobacillus plantarum 57B and Lactobacillus gasseri 57C of special characteristics such as a feature of strong diversified affinity for the digestive tract and vaginal epithelia enabling the colonization of the vagina and anus after the crossover through... Agent: Horst M. Kasper

20080299085 - High-throughput assay for virus entry and drug screening: The present invention provides a rapid virus entry/binding detection assay. An enzyme such as luciferase was incorporated at the C-terminal end of viral envelope proteins of the HIV Nef protein that would specifically associate with cell membranes to deliver the enzyme into viral particles upon viral assembly. Virus entry/binding can... Agent: Benjamin Aaron Adler, Ph.d., J.d. Adler & Associates

20080299087 - Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition: Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from... Agent: Wilson Sonsini Goodrich & Rosati

20080299092 - Cosmetic preparation and method for preparing the same: The present invention relates to the use of dedifferentiated plant cells in cosmetic preparations for protecting of stem cells against intrinsic and extrinsic stress factors, in particular for promoting proliferation of stem cells and for protecting them against apoptosis. In particular, the invention relates to the use of dedifferentiated plant... Agent: Maginot, Moore & Beck, LLP Chase Tower

20080299086 - Cultured muscle cells with high metabolic activity and method for production of the cultured muscle cells: The object of the present invention is to provide a method of preparing excellent cultured muscle cells having high metabolic capacity and insulin responsiveness, and further provide a method for the measurement of sensitive metabolic capacity using the cells. Moreover, its purpose is to provide a culture system/culture apparatus that... Agent: Birch Stewart Kolasch & Birch

20080299089 - Endogeneous repair factor production promoters: It relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (PG) 12 agonist, EP2 agonist and EP4 agonist. Since prostaglandin (PG) 12 agonist, EP2 agonist or EP4 agonist has various endogenous repair factor production accelerating action, angiogenesis acceleration action and stem... Agent: Sughrue-265550

20080299091 - Patient-specific stem cell lines derived from human parthenogenetic blastocysts: Methods are disclosed for generating HLA homozygous parthenogenetic human stem cell (hpSC-Hhom) lines from both HLA homozygous and HLA heterozygous donors. These hpSC-Hhom lines demonstrate typical human embryonic stem cell morphology, expressing appropriate stem cell markers and possessing high levels of alkaline phosphatase and telomerase activity. Additionally, injection of these... Agent: Dla Piper LLP (us)

20080299093 - Premixed biological hydraulic cement paste composition and using the same: A premixed cement paste for use in medical or dental applications. The premixed cement paste remains fluid when stored in a hermetically sealed condition, but hydrates and hardens to set when placed in a physiological environment. The cement paste includes at least one calcium silicate compound and at least one... Agent: Todd N. Hathaway

20080299090 - Use of umbilical cord matrix cells: The invention relates to the isolation and use of stem cells from amniote species (potentially any animal with an umbilical cord, including humans). More particularly the invention relates to obtaining stem cells that are at least multipotent and may be totipotent or nearly totipotent and are envisaged to have a... Agent: Casimir Jones, S.c.

20080299088 - Uses of notch receptors, notch ligands, and notch modulators in methods related to metabolic diseases: Disclosed are methods for identifying and isolating a precursor cell. Also, disclosed are methods of increasing insulin synthesis from a pancreatic β-cell. Further, disclosed are methods of improving pancreatic β-cell function. Still further, disclosed are methods of preventing or delaying the onset of a metabolic disease, methods of treating or... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20080299101 - Cancer treatment resistance and agents modulating such resistance: The present invention concerns a method for detecting in vitro resistance of cancer cells to a treatment by detecting in the cancer cells supernumerary nucleolar organizer regions (NOR), whereby identification of the presence of supernumerary NOR in the cancer cells is indicative of treatment resistance. The present invention also concerns... Agent: Foley And Lardner LLP Suite 500

20080299100 - Topical co-enzyme q10 formulations and methods of use: Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20080299102 - Novel bace proteins, nucleic acid molecules therefor, novel crystal structure of novel bace proteins, and methods for making and using: Disclosed and claimed are novel BACE proteins, crystal structures thereof, nucleic acid molecules therefor, and methods for making and using and uses of the same, especially for ascertaining inhibitors of BACE; and thus, disclosed and claimed too are inhibitors of BACE and methods of making and using the same.... Agent: Foley & Lardner LLP

20080299103 - Well preserved aqueous organic compositions: Well-preserved aqueous topical compositions that satisfy one or more widely recognized organic certification standards. The compositions comprise a preservative system comprising an in situ hypoiodite generator; and a plant extract blend; optionally, an essential oil blend. Such compositions do not require synthetic preservatives, especially parabens. Suitable aqueous compositions may contain... Agent: Peter Giancana

20080299104 - Methods for detecting agents involved in neuronal apoptosis and compositions thereof: The invention provides methods of detecting and identifying agents which moduclate the expression or activity of synGAP, a brain-specific Ras/Rap GTPase activating protein. In vivo studies using knock-out and conditional knock-out transgenic animals show that the level of apoptosis in neurons correlates inversely with the level of synGAP protein, indicating... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper US LLP

20080299106 - Combinations of human proteins to enhance in vivo viability of stem cells and progenitor cells: Embodiments of the present invention include the use of placental alkaline phosphatase and other members of the alkaline phosphatase family alone or in combination with human transferrin and, optionally, human α1-antitrypsin to enhance the proliferation and survival of adult or embryonic stem cells and stem cell-derived progenitor cells in vivo.... Agent: Faegre & Benson LLP Patent Docketing

20080299107 - Combinations of human proteins to enhance viability of transplanted stem cells and progenitor cells: Embodiments of the present invention include the use of placental alkaline phosphatase alone or in combination with human transferrin and, optionally, human α1-antitrypsin to enhance the proliferation and survival of transplanted stem cells and stem cell-derived progenitor cells.... Agent: Faegre & Benson LLP Patent Docketing

20080299105 - Inhibition of feline calicivirus: We conducted feline calicivirus (FCV) inhibition experiment with two anti-viral aminohydrolases, asparaginase and glutaminase. We found that in the presence of 8 units and 4 units/ml of asparaginase, about 90% of FCV replication was inhibited. In contrast, glutaminase showed no significant inhibition effect on the virus replication. We have also... Agent: Ade & Company Inc.

20080299108 - Peptides for diagnostic and therapeutic methods for celiac sprue: Detection of toxic gluten oligopeptides refractory to digestion and antibodies and T cells responsive thereto can be used to diagnose Celiac Sprue. Analogs of such oligopeptides are useful in the inhibition of immune responses.... Agent: Bozicevic, Field & Francis LLP

20080299109 - Mechanism of astricyte-neuron signaling: The present invention relates to a novel communication mechanism between astrocytes and neurons at a synapse. More specifically, the present invention relates to a signaling mechanism between astrocytes and neurons, by activating astrocytic G-protein coupled receptors, thereby activating glutamate receptors on a membrane of neighboring postsynaptic neurons, resulting in increasing... Agent: LexyoumeIPGroup, LLC

20080299110 - Methods and kits for diagnosing and treating acute joint injury: The present invention provides methods, reagents and kits for diagnosing and/or for the prognosis of non-autoimmune acute joint inflammation by detecting cytokine biomarkers in a sample obtained from an individual thought to be suffering from joint injury. The cytokine biomarkers used with the methods and kits of the present invention... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080299111 - Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation: The invention provides compositions and methods for prevention and treatment of diseases associated with β-amyloid formation and/or aggregation. Such methods encompass the induction of an immune response against N-terminal truncated and/or post-translationally modified Aβ peptides. These peptides are further used in compositions and methods for the diagnosis of diseases associated... Agent: Howrey LLP-hn

20080299112 - Human polyclonal antibodies from genetically engineered animals: Substantially human antisera are provided by genetically modifying a domestic animal generally weighing at least about 1 kg. The domestic animal is genetically modified by generating inactive heavy and light chain immunoglobulin loci and integrating at least functional portions of the human heavy and light chain immunoglobulin loci, whereby the... Agent: Goodwin Procter LLP Attn: Patent Administrator

20080299115 - Antibody variants with faster antigen association rates: Antibody variants with faster antigen association rates are disclosed. The antibody variants have one or more amino acid alteration(s) in or adjacent to at least one hypervariable region thereof which increase charge complementarity between the antibody variant and an antigen to which it binds.... Agent: Genentech, Inc.

20080299113 - Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents: t

20080299118 - Fxr agonists for the treatment of malignancies: Provided are certain methods of treating maligancies with farnesoid X receptor agonists. Also provided are certain methods of inducing RECK gene expression with farnesoid X receptor agonists and methods of reducing at least one feature of a cell with farnesoid X receptor agonists... Agent: Wyeth/finnegan Henderson, LLP

20080299114 - Humaneered anti-factor b antibody: This invention relates to humaneered anti-factor B antibodies and antigen-binding fragments thereof with reduced immunogenicity. The humaneered anti-factor B antibodies and antigen-binding fragments thereof are derived from murine monoclonal antibody 1379, which binds factor B in the third short consensus repeat (“SCR”) domain and selectively inhibits activation of the alternative... Agent: Morrison & Foerster LLP

20080299119 - Polypeptides homologous to vegf and bmp1: The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be... Agent: Genentech, Inc.

20080299117 - Treatment method: The invention provides methods of treating autoimmune diseases using lower doses of anti-CD20 antibodies of 100 mg to 200 mg effective to deplete B cells in the patient.... Agent: Genentech, Inc.

20080299116 - Vascular endothelial cell growth factor antagonists and uses thereof: The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided.... Agent: Genentech, Inc.

20080299120 - Multivalent antibodies and uses therefor: The present application describes engineered antibodies, with three or more functional antigen binding sites, and uses, such as therapeutic applications, for such engineered antibodies.... Agent: Ginger Dreger Goodwin Procter LLP

20080299121 - Multivalent recombinant antibodies for treating hrv infections: The present invention relates to high affinity multivalent recombinant antibodies and multivalent peptides against ICAM-1 and/or LDL receptor and pharmaceutical compositions containing such multivalent antibodies or multivalent peptides. The present invention also relates to methods of using such multivalent antibodies or multivalent peptides to prevent and treat human rhinovirus infection... Agent: Foley & Lardner LLP

20080299122 - Modulating immune responses: The invention provides methods for modulating the immune system using anti-CD83 antibodies that can influence CD83 function.... Agent: Davis Wright Tremaine, LLP/seattle

20080299123 - Treatment of chemotherapy- or radiotherapy-resistant tumors: The present invention relates to the use of L1 interfering molecules, especially anti-L1 antibodies, in tumor treatment. Especially, the present invention relates to the use of said L1 interfering molecules in sensitizing tumor cells for the treatment with chemotherapeutic drugs of with radiotherapy and to the combined administration of L1... Agent: Foley And Lardner LLP Suite 500

20080299124 - Novel method for the stabilization of chimeric immunoglobulin or immunoglobulin fragments and, and stabilized anti-egp-2 scfv fragment: The present invention relates to a method for stabilizing chimeric immunoglobulins or immunoglobulin fragments. Furthermore, the invention also provides a stabilized anti-EGP-2 scFv fragment.... Agent: Dann, Dorfman, Herrell & Skillman

20080299126 - Anti-myostatin antibodies: A neutralizing epitope is identified within amino acids 40-64 of the mature form of human myostatin. Antibodies that bind this epitope with high affinity preferentially bind GDF-8 over GDF-11 and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the... Agent: Eli Lilly & Company

20080299125 - Genetic basis of treatment response in depression patients: The invention provides a collection of polymorphic sites associated with response to treatment by an SSRI or placebo in depression patients. The polymorphic sites and others in linkage disequilibrium with them are useful in determining whether to treat a patient with an SSRI or include a patient in a clinical... Agent: Townsend And Townsend And Crew, LLP

20080299127 - Protective staphylococcus aureus vaccine based on cell wall-associated proteins: The present invention relates to a pharmaceutical composition or a medicament, notably a protective Staphylococcus aureus vaccine, comprising at least one cell wall-associated Staphylococcus aureus protein or a fragment or derivative thereof causing an immune response that induces opsonophagocytic activity of human neutrophils for S. aureus. The invention further provides... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20080299128 - Effect of bst2 on inflammation: The application disclose a method of preventing immune cells from binding to other cells, which includes contacting the immune cells and the other cells with a composition comprising Bst2 antagonist.... Agent: Joseph Hyosuk Kim Jhk Law

20080299129 - Antagonists to il-17a, il-17f, and il-23p19 and methods of use: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody... Agent: Zymogenetics, Inc. Intellectual Property Department

20080299130 - Methods and compositions for the treatment of ocular neovascularization: The invention relates to compositions and methods for the treatment or prevention of ocular neovascularization by reducing macrophage infiltration into the eye. The compositions of the invention include an antagonist of MCP-1 and/or CCR2 that blocks MCP-1 binding to or activation of CCR2y.... Agent: Mcdermott Will & Emery LLP

20080299131 - anti-viral compositions: The invention provides a composition comprising for simultaneous, sequential or separate administration a) a polyanion; and b) an antibody reactive against an antigen on the surface of an intracellular form of a virus, which virus has an extracellular form that is surrounded by one lipid membrane more than the intracellular... Agent: Leon R Yankwich Yankwich & Associates

20080299133 - Anti-il-12 antibody based vectors, host cells, and methods of production and uses: Antibody expression vectors and plasmids can incorporate various antibody gene portions for transcription of the antibody DNA and expression of the antibody in an appropriate host cell. The expression vectors and plasmids have restriction enzyme sites that facilitate ligation of antibody-encoding DNA into the vectors. The vectors incorporate enhancer and... Agent: Philip S. Johnson Johnson & Johnson

20080299135 - Methods and compositions for nerve regeneration: Methods and compositions for modulating growth of a neuron with a Wnt, a Wnt-like substance, and/or a chemical compound affecting a Wnt signaling pathway are disclosed. Also disclosed are methods for identifying a substance that modulates growth of a neuron by obtaining a candidate substance and contacting the candidate substance... Agent: Michael Best & Friedrich LLP

20080299134 - Recombinant anti-interleukin-9 antibodies: The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified... Agent: Medimmune, LLC Jonathan Klein-evans

20080299132 - Synergistic compositions for treating hiv-1: Synergistic pharmaceutical compositions for treating or preventing HIV-1 infections comprising anti-CCR5 monoclonal antibodies and CCR5 antagonists, viral fusion inhibitors or viral attachment inhibitors are disclosed. The compositions exhibit significant greater activity than is anticipated from the activity of either component alone. Also provided are methods for treating or preventing HIV-1... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20080299137 - Fusion proteins that bind effector lymphocytes and target cells: Novel fusion proteins that comprise a first portion that corresponds to an antibody-like protein that is specific for an activating receptor on an effector lymphocyte or a variant thereof and a second portion that corresponds to a portion of a cell membrane protein and that binds to a cell-associated target... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080299139 - Mammalian cytokines; related reagents and methods: Nucleic acids encoding mammalian, e.g., primate, IL-1ζ, purified IL-1ζ polypeptides and fragments thereof. Binding proteins, e.g., antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.... Agent: Dnax Research Inc. Legal Department

20080299138 - Toll-like receptor 3 modulators and uses thereof: Modulators of TLR3 activity and their use are disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20080299136 - Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders: The present invention provides for chimeric Wnt antagonists comprising a Frz domain component derived from a Frizzled protein, a secreted Frizzled related protein or Ror protein and an Fc immunoglobulin component, and their use in the treatment and diagnostic detection of cellular Wnt signaling and Wnt-mediated disorders, including cancer.... Agent: Genentech, Inc.

20080299140 - Immunogenic composition and peptide sequences for prevention and treatment of an hsv condition: Immunogenic composition comprising at least one Herpes Simplex Virus type 1 (HSV-1) and/or type 2 (HSV-2) peptide sequence hearing at least one epitope from glycoprotein D (gD) and/or glycoprotein B (gB), a pharmaceutical carrier and/or a human compatible adjuvant, peptide sequences and uses thereof for prevention or treatment of an... Agent: Stout, Uxa, Buyan & Mullins LLP

20080299141 - Raccoon poxvirus expressing genes of porcine virus: The present invention relates to a new recombinant raccoon poxvirus vector vaccine in which the vector expresses one or more antigenic proteins encoded by multiple open reading frames, preferably the ORF5, ORF6 and/or ORF3/ORF4/ORF7, of one or more porcine reproductive and respiratory syndrome virus strains alone or in combination with... Agent: Wyeth Patent Law Group

20080299142 - Compounds and methods for treatment and diagnosis of chlamydial infection: Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with... Agent: Seed Intellectual Property Law Group PLLC

20080299143 - Cryptosporidium parvum antigens, antibodies thereof and diagnostic and therapeutic compositions thereof: Cloning and expression of genes encoding C. parvum antigenic polypeptides are described as are antibodies that recognize epitopes on these polypeptides. The antigenic polypeptides and antibodies thereto can be used in therapeutic compositions for the prevention and treatment of C. parvum infections, as well as in diagnostic methods for determining... Agent: Robins & Pasternak

20080299145 - Formula for improving physical performance and related methods: The present invention generally relates to the use of a formula that improves human and animal endurance, stamina, performance and other physical parameters. In one composition aspect, the formula or composition of the present invention includes a Flammulina velutipes extract and citrus peel.... Agent: 212 Consulting, Inc.

20080299144 - Grass based avian deterrent: The invention relates to uses and methods relating to grass and endophyte combinations to repel avian species from the grass and endophyte combination. In particular, methods are described to select grass and endophyte combinations in order to enhance or maximise the repellent effect. Preferred endophyte and grass combinations are described... Agent: Knobbe Martens Olson & Bear LLP

20080299146 - Satiating dietetic product: The invention concerns a dietetic product belonging to the family of food products, complements or supplements for slimming or anti-obesity and appetite-suppressing or satiating food products, complements or supplements containing an efficient dose of food proteins, 70% of which at least are hydrolysed yeast proteins. The invention also concerns the... Agent: Sughrue Mion, PLLC

20080299147 - Microalgae-derived compositions for improving the health and appearance of skin: Provided herein are microalgal skin care compositions and methods of improving the health and appearance of skin. Also provided are methods of using polysaccharides for applications such as topical personal care products, cosmetics, and wrinkle reduction compositions. The invention also provides novel decolorized microalgal compositions useful for improving the health... Agent: Townsend And Townsend And Crew, LLP

20080299148 - Novel antitoxin and vaccine platform based on nodavirus vlps: Antitoxin and vaccine compositions based on nodavirus VLPs are provided. Anthrax antitoxin and vaccine compositions are provided. Methods of treating toxins with VLP-based antitoxins are provided. Methods of raising an immune response with immunogen decorated VLPs are provided.... Agent: Quine Intellectual Property Law Group, P.C.

20080299149 - Raccoon poxvirus expressing genes of feline antigens: The present invention relates to new recombinant raccoon poxvirus vectors comprising two or more exogenous nucleic acid molecules, each encoding at least one feline protein, wherein at least two of the nucleic acid molecules are inserted into the hemagglutinin (ha) locus or the thymidine kinase (tk) locus, or at least... Agent: Wyeth Patent Law Group

20080299151 - Influenza vaccines: Described herein are vaccines and the use of naked DNA and/or RNA encoding hemagglutinin (HA) from pandemic influenza, e.g., the 1918 H1N1 and/or the 1957 H2N2 and/or the 1968 H3N2 influenza A virus, as a vaccine component against present day and coming H1, H2, H3, H5, N1, N2 containing influenza... Agent: Howson And Howson

20080299150 - Method and system for processing immuno-competent cells in view of an antiviral therapy, and related therapeutic process: s

20080299152 - Norovirus vaccine formulations: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080299153 - B. anthracis prevention and treatment: mutant b. anthracis lacking luxs activity and furanone inhibition of growth, ai-2 quorum sensing, and toxin production: The present invention pertains to the discovery that B. anthracis possesses a luxS gene that encodes a functional LuxS polypeptide, and that B. anthracis synthesizes a functional AI-2 quorum-sensing molecule. The invention provides mutant B. anthracis bacteria lacking the function of the luxS gene, which do not produce a functional... Agent: Darby & Darby P.C.

20080299159 - Anti-acne skin agent for external use: It is an object of the present invention to provide an anti-acne skin agent for external use which comprises highly safe protein nanoparticles having high transparency due to the small particle size, moisturizing properties, and high permeability into skin. The present invention provides an anti-acne skin agent for external use,... Agent: Sughrue Mion, PLLC

20080299155 - Color cosmetic compositions for topical anti-aging skin treatment: This invention discloses color cosmetic compositions and methods for anti-aging treatments that utilize plant-based copper antioxidant complexes.... Agent: Theodore Jay

20080299154 - Cosmetic hair compositions containing metal-oxide layered pigments and methods of use: The disclosure relates to cosmetic hair compositions containing metal-oxide layered pigments. The disclosure also relates to the use of the metal-oxide layered pigments in cosmetic hair compositions. The disclosure also relates to compositions containing film-formers and stabilizers in combination with the metal-oxide layered pigments.... Agent: Connolly Bove Lodge & Hutz LLP

20080299158 - Fully extended color bulk powder, bulk dispersion and method of use: The invention provides, among other things, fully and partially extended color bulk powders and partially and fully extended color bulk dispersions. Invention fully and partially extended color powders and fully and partially extended color dispersions can be used in cosmetic and makeup products, personal care products, and pharmaceutical products.... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20080299156 - Skin care compositions containing a high internal phase emulsion: The present invention is directed to a skin care composition comprising (a) at least one high internal phase emollient-in-water emulsion; (b) at least one fatty compound, capable of forming a liquid crystal; (c) at least one thickening agent; (d) at least one active agent; and (e) water. Also disclosed is... Agent: L'oreal Usa/ Patent Department

20080299157 - Skin care compositions having unique texture properties: The present invention is directed to a skin care composition comprising (a) at least one high internal phase emollient-in-water emulsion; (b) at least one thickening agent; (c) at least one primary emulsifier chosen from a water-in-silicone emulsifier; (d) at least one non-emulsifying silicone elastomer; (e) at least one active agent;... Agent: L'oreal Usa/ Patent Department

20080299160 - Method of manufacture of polymer composites: A simple and cost effective method of producing a polymer composite comprising a polymer matrix having metal nanoparticles incorporated therein comprises the steps of (i) mixing metal nanoparticles with a polymer dope; and (ii) solidifying the polymer composite from the dope. Antimicrobial fibres are produced by extruding a dope solution... Agent: Nixon & Vanderhye, PC

20080299161 - Solid biocide composition and sealed biocide article: A solid composition for forming chlorine dioxide on demand and a sealed biocide article.... Agent: Manelli Denison & Selter

20080299162 - Rodenticide agent: The present invention relates to a rodenticide agent used to exterminate rodents and, more specifically, to an agent embodied as a thermoplastic block having a hardness that will not give to rodent's continuous gnawing. The instant abstract is neither intended to define the invention disclosed in this specification nor intended... Agent: Patent, Copyright & Trademark Law Group

20080299163 - Anti-fomitic device incorporating anti-microbial metals: An anti-fomitic device in the form of a bag or envelope forms a cover for an object for preventing cross-infection by bacteria and other pathogens that may reside on the object. The anti-fomitic device is a flat, flexible bag or envelope with a closure mechanism at one or both ends... Agent: Roberts, Mardula & Wertheim, LLC

20080299165 - Compositions for treatment of diseases of the nail unit: A flowable composition suitable for use as a controlled release implant, the composition comprising a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid; a biocompatible polar aprotic solvent selected from the group consisting of an amide, an ester, a carbonate, a ketone, an... Agent: Schwegman, Lundberg & Woessner, P.A.

20080299166 - Novel biomaterials, their preparation and use: wherein said components are present in amounts effective to form said precipitate, and preferably to corresponding precipitates additionally comprising said cyclodextrin component. Both types of precipitates may optionally comprise one or more further components. The precipitates are particularly useful as controlled-release depot formulations suitable for long-lasting delivery of said further... Agent: Novartis Corporate Intellectual Property

20080299164 - Substituted polycaprolactone for coating: A coating formed of a substituted polycaprolactone and method of making and using the same are disclosed.... Agent: Squire, Sanders & Dempsey LLP

20080299171 - Growth factor modified extracellular matrix material and methods for preparation and use thereof: Described are tissue graft constructs that include submucosa and other extracellular matrix materials that incorporate a number of exogenous proteins. Further described are methods for making tissue graft constructs that include stripping endogenous heparin binding proteins from a porcine graft material and thereafter binding one or more human growth factors... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20080299170 - Medical devices and coatings therefor: A coating for a medical device, the device generally being of the type which is to be used internally in a subject, includes a transglutaminase (TGase) inhibitor. The Tgase inhibitor effectively prevents the activity of any Tgase involved in clot formation or clot stability. Preferably, the transglutaminase inhibitor is a... Agent: Andrus, Sceales, Starke & Sawall, LLP

20080299168 - Stabilized polymeric delivery system: The invention relates to a delivery system for the sustained and controlled delivery of a group of bioactive agents. More particularly, the invention relates to a delivery system and a method for delivery of a bioactive agent containing a nucleophilic functional group by means of a biodegradable, sustained-release implant. The... Agent: Schwegman, Lundberg & Woessner, P.A.

20080299172 - Tissue repair implant: An implant is formed from a sheet material and a plurality of microparticles. The sheet may be coated with a mixture of collagen and PMMA beads. The implant may be used to treat many types of defects, including hernias, skin defects, tendon defects, and ulcers. A biocompatible alloplastic mesh implant... Agent: Knobbe Martens Olson & Bear LLP

20080299169 - Topographical templating of polymeric materials using cellular morphology: Substrates for influencing the organization, spreading or adhesion of a selected cell to induce or stimulate growth, differentiation or regeneration of the cell or of tissue constituting the cells are provided as well as methods of making such substrates and methods of using such substrates.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080299167 - Vascular endothelial growth factors and methods of their use: Vascular endothelial growth factor alternative splice variants and methods of their use are provided.... Agent: Calfee Halter & Griswold, LLP

20080299173 - Chondrocyte container and method of use: Devices and methods for delivering a therapeutic agent produced via a genetically-altered chondrocyte are provided. More specifically, the device includes a housing which defines a cell chamber configured to retain a large volume of chondrocytes while selectively releasing therapeutic agents produced via these entrapped cells. In an exemplary embodiment, the... Agent: Nutter Mcclennen & Fish LLP

20080299174 - Bis-(alpha-amino)-diol-diester-containing poly (ester amide) and poly (ester urethane) compositions and methods of use: The present invention provides biodegradable, biocompatible bis-(α-amino acyl)-diol-diester-containing poly(ester amide) (PEA) and poly(ester urethane) (PEUR) co-polymer compositions with mechanical properties that can be readily tailored by selection of various combinations and proportions of the building blocks of the co-polymers. The compositions are suitable for use in production of drug-releasing biodegradable... Agent: Dla Piper US LLP

20080299175 - Preparation of bone material: The invention provides a bone material having a specific surface area of at least 80 m2/g and a protein content of less than 1800 ppm.... Agent: Brooks Kushman P.C.

20080299176 - Drug delivery device comprising crosslinked polyurethane-siloxane-containing copolymers: A drug delivery device for placement in the eye includes a drug core comprising a hydrophobic pharmaceutically active agent, and a holder that holds the drug core. The holder is made of a material impermeable to passage of the active agent and includes an opening for passage of the pharmaceutically... Agent: Bausch & Lomb Incorporated

20080299177 - Supramolecular complexes for use in acoustically mediated intracellular drug delivery in vivo: Targeted therapeutic delivery systems comprising specially designed nanocarriers for intracellular therapeutic delivery, mediated by acoustic energy, for use either in vivo or in vitro, are described. Nanocarriers comprised of substantially supramolecular complexes, and mixtures thereof, are used to treat a variety of diseases in humans and other species, such as... Agent: Biovaluation & Analysis, Inc.

20080299178 - Sustained release intraocular implants and methods for preventing retinal dysfunction: Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable... Agent: Allergan, Inc.

20080299179 - Solutions for ophthalmic lenses containing at least one silicone containing component: The present invention relates to a method for reducing the occurrence of superficial punctate staining comprising the step of packaging, storing or contacting an uncoated ophthalmic lens comprising at least one polymeric wetting agent and polymer units derived from at least one silicone containing component in a solution comprising an... Agent: Philip S. Johnson Johnson & Johnson

20080299181 - Odourless garlic supplement comprising an enteric coating and a deodorising layer: A garlic supplement comprises one or more cores comprising garlic and an enteric coating encasing the core(s) which is insoluble at pH less than about 5 but soluble at a pH greater than about 5. In one example, the enteric coating comprises a deodorizer. In another example, an external coating... Agent: Hahn Loeser & Parks, LLP

20080299180 - Peptides based on the sequence of human lactoferrin and their use: The invention relates to new peptides formed of at least seven subsequent amino acids of the amino acids in position 12-40, counted from the N-terminal end, in the sequence constituting human lactoferrin, and preferably modifications thereof. The invention also relates to medicinal products comprising such peptides, especially intended for treatment... Agent: Buchanan, Ingersoll & Rooney PC

20080299182 - Methods and formulations for topical gene therapy: Formulations of viral vectors for topical application are disclosed as well as methods for making the same. Also disclosed are methods of treating a subject or diagnosing disease in a subject using the formulations of the present invention.... Agent: Fulbright & Jaworski L.L.P.

20080299183 - Patch and patch preparation: r

20080299184 - Anticancer agent: It is an object of the present invention to provide a cancer-suppressing agent comprising a novel cancer-suppressing gene based on the discovery of such cancer-suppressing gene. The present invention provides A cancer-suppressing agent which comprises PCDH20 gene or a homologous gene thereof.... Agent: Birch Stewart Kolasch & Birch

20080299186 - Coatings for applying substances onto substrate carrier: Compositions of matter containing an active agent, and methods of manufacturing thereof, wherein the method comprises the step of coating a substrate with a coating composition comprising the active agent formulated for immediate release, wherein the coating composition does not contain an appreciable amount of cellulosic materials and preferably comprises... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080299185 - Stable digestive enzyme compositions: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080299187 - Substances for reducing occurence of major cardiac events in humans: A medicament comprising a dispersion of Red Yeast Rice extract in Omega-3 Oils. The medicament is supplied in capsules such that a daily dose is dispensed in an integral number of capsules. A dispersant is used, preferably Lysine and bamboo. The ratio of Red Yeast Rice Extract to EPA+DHA is... Agent: Foothill Law Group

20080299189 - Controlled release dopamine agonist compositions: The present invention relates to a multiphase release oral pharmaceutical formulation having a dopamine agonist as an active ingredient. The multiphase composition comprises at least two different release components. The invention relates to controlled release pharmaceutical compositions of pramipexole or a pharmaceutically acceptable salt thereof for once-daily administration.... Agent: Kv Pharmaceutical Company

20080299188 - Controlled release dosage forms combining immediate release and sustainted release of low-solubility drug: A controlled release dosage form comprises an immediate release portion and an enteric coated sustained release core.... Agent: Pfizer Inc Steve T. Zelson

20080299190 - Direct compression formulation and process: This invention relates to tablets especially tablets formed by direct compression of a dipeptidylpeptidase IV (DPP-IV) inhibitor compound, a process for the preparation thereof; to new pharmaceutical formulations, and new tableting powders comprising DPP-IV inhibitor formulations capable of being directly compressed into tablets. The invention relates further to a process... Agent: Novartis Corporate Intellectual Property

20080299191 - Fine-particle crosslinked polyvinylpyrrolidone as tablet disintegrant: Use of crosslinked polyvinylpyrrolidone with an average particle size of 5-60 μm and a hydration capacity of greater than 7 g/g as tablet disintegrant... Agent: Connolly Bove Lodge & Hutz, LLP

20080299192 - Intraorally rapidly disintergrating tablets and their production: The object of the present invention is to provide, as a solid preparation for making it easy to take, thus improving patient's compliance etc., an intraorally rapidly disintegrating tablet which can be produced easily without any particular problem by a usual method of producing tablets with a usual tabletting machine,... Agent: Dreier LLP Susan Formicola

20080299193 - Pharmaceutical composition comprising eszoplicone: The present invention relates to a stable pharmaceutical composition of eszopiclone with a defined particle size.... Agent: Sandoz Inc

20080299194 - Pharmaceutical formulation for producing rapidly disintegrating tablets: e

20080299196 - Controlled release pharmaceutical compositions comprising a fumaric acid ester: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designed to release the fumaric acid ester in a controlled manner so that... Agent: Darby & Darby P.C.

20080299195 - Use of ranolazine for elevated brain-type natriuretic peptide: This invention is directed to the use of ranolazine to reduce the risk of adverse coronary events in a mammalian patient. Typically, the natriuretic peptide is associated with coronary disease, acute coronary syndrome, and/or diastolic dysfunction. Ranolazine may be administered to the patient as an intravenous solution or in an... Agent: Cv Therapeutics, Inc.

20080299197 - Triple combination release multi-layered tablet: This invention pertains to a multi-layered tablet for a triple combination release of active agents to an environment of use. More particularly, the invention pertains to a multi-layered tablet (1) comprising two external drug-containing layers (2 and 3) in stacked arrangement with respect to and on opposite sides of an... Agent: Innovar, LLC

20080299198 - Polystyrene sulfonate polymer tablets, their preparation and use: The present invention provides tablets containing at least about 70% of polystyrene sulfonate polymer, binder and moisture. The invention further relates to methods of treating medical conditions including antibiotic-associated diarrhea such as that caused by Chlostridium difficile, comprising administration of the tablets to a subject in need thereof. Furthermore, pharmaceutical... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080299201 - Devices, methods, and systems for accessing native neurons through artificial neural mediators (anms): The present invention relates to devices, methods, and systems for accessing native neurons in the nervous system of an animal. Specifically, one or more artificial neural mediators (ANMs) each comprising a neural cell are first formed, and neural connection is then established between the ANMs and one or more native... Agent: Scully, Scott, Murphy & Presser, P.C.

20080299200 - Oil-in-water emulsion for creating new product consistencies: The invention concerns an oil-in-water emulsion wherein the oil droplets of a diameter in the range of 5 nm to hundreds of micrometers exhibit a nano-sized self-assembled structure with hydrophilic domains having a diameter size in the range of 0.5 to 200 nm, due to the presence of a lipophilic... Agent: Bell, Boyd & Lloyd LLP

20080299199 - Swellable dosage form comprising gellan gum: A novel dosage form. The dosage form is presented in particulate form and before oral ingestion the particulate material is subjected to an aqueous medium, whereby it is converted to a semi-solid form by swelling or gelling of one or more of the components, especially of a gellan gum, of... Agent: Foley And Lardner LLP Suite 500

20080299202 - Controlled-delivery system of pharmacologically active substances, preparation process and medical use thereof: The invention concerns a system for biocompatible drug release comprising: (i) a polymer matrix; (ii) an inorganic component located inside said matrix and characterized by a lamellar structure with a net positive or negative charge able to intercalate (iii) a pharmacologically active principle into said lamellar structure, by establishing an... Agent: Knobbe Martens Olson & Bear LLP

20080299203 - Solid pharmaceutical dosage formulation: The present invention provides a pharmaceutical dosage formulation, and more particularly, a pharmaceutical dosage formulation comprising an HIV protease inhibitor.... Agent: Robert Deberardine D-377/ap6a-1

20080299204 - Dosage forms for movement disorder treatment: The invention relates to the improvement in the treatment of certain neural disorders/diseases, such as Parkinson's disease and other motor disorders. One aspect of the invention relates to drug compositions and dosage forms comprising said drug composition. Another aspect of the invention relates to methods of manufacturing the drug compositions... Agent: Ropes & Gray LLP

20080299207 - Methods and compositions for administration of oxybutynin: Administration of Oxybutynin in nebulized dry powder form directly to a patient's lungs for treating urinary incontinence or respiratory disease.... Agent: Hayes Soloway P.C.

20080299206 - Ophthalmic preparations: The present invention provides ophthalmic formulations containing cyclosporine, methods for preparing the formulation, and methods for using the formulation.... Agent: Michele M. Simkin Foley & Lardner LLP

20080299205 - Particulate constructs for release of active agents: Particulate constructs stabilized by amphiphilic copolymers and comprising at least one active coupled to a hydrophobic moiety provide sustained release of the active in both in vitro and in vivo environments.... Agent: Morrison & Foerster LLP

20080299208 - Anisometric particles in the form of nanofibers/mesofibers,nanopipes, nanocables/mesocables, nanobands/mesobands, and the curved or branched variations thereof: The invention relates to novel anisometric mesoparticles and nanoparticles in the form of anisometric mesofibers/nanofibers, mesopipes/nanopipes, mesobands/nanobands, mesocables/nanocables, and the curved and branched or superimposed variations thereof as well as a novel method for the production thereof. The invention particularly relates to anisometric mesoparticles and nanoparticles which have an aerodynamic... Agent: Clark & Brody

20080299209 - Novel formulations of fat-soluble active ingredients with high biovailability: The present invention relates to formulations of a pharmacological effective fat-soluble active ingredient with a high bioavailability of said fat-soluble active ingredient as well as to their manufacture and use as dietary supplement, food, feed, personal care product and/or pharmaceutical. Such formulations are those which when dissolved, dispersed or diluted... Agent: Nixon & Vanderhye, PC

20080299211 - Fexofenadine suspension formulation: The present invention is directed to an aqueous pharmaceutical suspension of fexofenadine zwitterionic dihydrate Form I.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080299210 - Stable nanosized amorphous drug: Disclosed is a population of nanoparticles, together with methods of making a population of nanoparticles, wherein one or more of the nanoparticles includes: an amorphous drug core having an effective diameter less than or equal to about 2.0 microns, wherein the amorphous drug core is substantially free of dopant, and... Agent: Philip S. Johnson Johnson & Johnson

20080299212 - Pharmaceutical composition for treating avellino cornea dystrophy comprising blood plasma or serum: The present invention relates to a pharmaceutical agent for treating Avellino corneal dystrophy, and more particularly, to a pharmaceutical composition for treating Avellino corneal dystrophy comprising pharmaceutically effective amount of blood plasma or serum as an active ingredient. The pharmaceutical composition of the present invention has an effect of improving... Agent: Intellectual Property / Technology Law

20080299213 - Augmentation and repair of spincter defects with cells including adipocytic cells: An embodiment of the invention includes methods for the long-term augmentation and/or repair of skin defects (scars, skin laxness, skin thinning, and skin augmentation), cellulite, breast tissue, wounds and burns, urological and gastroesophageal sphincter structures, hernias, periodontal disease and disorders, tendon and ligament tears and baldness, by the injection or... Agent: Dardi & Associates, PLLC

20080299214 - Intervertebral disc repair, methods and devices therefor: The present application discloses compositions, methods and devices for treatment of a degenerative intervertebral disc. A composition can comprise chondrocytes expressing type II collagen. These chondrocytes can be obtained from human cadavers up to about two weeks following death, and can be grown in vitro. The compositions can further comprise... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20080299216 - Deuterium-enriched aripiprazole: The present application describes deuterium-enriched aripiprazole, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20080299217 - Deuterium-enriched bifeprunox: The present application describes deuterium-enriched bifeprunox, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20080299215 - Deuterium-enriched lestaurtinib: The present application describes deuterium-enriched lestaurtinib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20080299219 - Deuterium-enriched oxybutynin: The present application describes deuterium-enriched oxybutynin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20080299218 - Deuterium-enriched valsartan: The present application describes deuterium-enriched valsartan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20080299220 - Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses: A waterless composition suitable for delivery of an active agent to a body surface or cavity includes a vehicle having about 70% to about 99% by weight of a hydrophilic polar solvent, said hydrophilic solvent selected from the group consisting of (i) a mixture of two or more different polyethylene... Agent: Wilmerhale/boston

20080299221 - Method for decreasing postprandial glucose excursion: The invention relates to the method for decreasing postprandial glucose excursion in a mammal in need thereof comprising a step of administering to said mammal an effective amount of water comprising from 99.76 to 99.99 molecular % of isotopologue 1H20 at 0 to 240 min from the start of ingestion... Agent: Notaro And Michalos

20080299222 - Bioactive agrichemical compositions and use thereof: Bioactive agrichemical concentrates and compositions having improved bioactivity comprising combinations of acid solutions and conventional bioactive agrichemical actives or formulations.... Agent: Edward K. Welch Ii Ip&l Solution

20080299223 - Formulations and use of chlorate to reduce pathogens in food and livestock: Processes and formulations using chlorate for the control of pathogenic bacteria in food and livestock. At least one formulation includes sodium chlorate in a concentration effective against E. coli and Salmonella, and is used as a rinsing/washing agent to wash fruits and vegetables, poultry products and livestock facilities.... Agent: Reed Smith LLP

20080299224 - Resuscitation fluid: The present invention relates to a resuscitation fluid which includes an ionic salt at a concentration above about 0.9%, at least one soluble protein, at least one intermediate energy substrate, and optionally an agent to mitigate intracellular acidosis. Methods of making and using the fluid are also described.... Agent: Nelson Mullins Riley & Scarborough, LLP

20080299225 - Stable microbicidal composition: A microbicidal composition contains isothiazolone compounds, which contain 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-isothiazolin-3-one, a nitrate in a content of 3% by weight to 25% by weight with respect to a total weight of the composition, a haloacetamide in a content of 5 ppm to 500 ppm, and water. A nitrate in a... Agent: Lucas & Mercanti, LLP

20080299226 - Hemostatic agent composition and method of delivery: A hemostatic agent composition that includes a clay hemostatic agent which is inert and non-reactive relative to blood clotting proteins and platelets, yet is capable of accelerating the formation of a stable clot when applied to an actively bleeding wound.... Agent: Lerner Greenberg Stemer LLP

20080299227 - Method for removal of hiv from the gastrointestinal tract and bile of hiv-infected subjects and for the prevention of drug failure and prevention of development of aids in hiv-infected subjects: The present invention discloses a novel use of magnesium oxide and magnesium hydroxide formulation in adequate proportions and sufficient amounts to induce bowel movement to induce the excretion of HIV, along with HIV-infected pathogens present in the intestinal tract of HIV-infected persons, and to induce the excretion of HIV-loaded bile... Agent: George M Santamarina

20080299228 - Topical compositions comprising a macromolecule and methods of using same: Compositions, including those in which the active ingredient or agent is stable and capable of penetrating the sites of topical application are provided. The compositions can include a macromolecule, for example, a parathyroid hormone (PTH), a PTH-like hypercalcemic factor (CFF) or biologically active variant of a PTH or CFF in... Agent: Fish & Richardson PC

20080299231 - Herbal composition for treatment of neurodegeneration and neuronal dysfunction: This invention provides methods of using various herbal compositions to treat neurodegenerative diseases and neuronal dysfunctions, said compositions comprise a combination of Radix angelica sinensis (DangGui), Ligusticum chuanxiong (ChuanXiong), Hirudo (ShuiZhi), Polygonatum sibiricum (HuangJing), Carthamus tinctorius (Hong Hua), Astragalus membranaceus (HuangQi), and Glycyrrhiza uralensis (Gancao).... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20080299229 - Methods of reducing beta-amyloid polypeptides: The invention features methods of reducing the level of a β-amyloid (Aβ) polypeptide using an Cimicifuga extract. The invention also features methods of producing an active fraction from an extract of Cimicifuga. The invention further features a composition containing an active fraction of a Cimicifuga extract and an article of... Agent: Choate, Hall & Stewart LLP

20080299230 - Oil formulations and methods of use: The invention generally relates to various oil formulations for protecting plants from nematodes and other pathogens. The invention provides specific formulations which do not require the use of chemical additives. These formulations have low phytotoxicity and low volatility. Also, methods of applying the formulations for agricultural use are disclosed.... Agent: Wood, Phillips, Katz, Clark & Mortimer

20080299232 - Cinnamon oil formulations and methods of use: The invention generally relates to various cinnamon oil formulations for protecting plants from nematodes and other pathogens. The invention provides specific formulations which do not require the use of chemical additives. These formulations have low phytotoxicity and low volatility. Also, methods of applying the formulations for agricultural use are disclosed.... Agent: Wood, Phillips, Katz, Clark & Mortimer

20080299233 - Method and composition for treating ear inflammation caused by dry ear: A method of treating diseases and conditions associated with dry ear comprising topically applying to the ear canal of a subject that is suffering therefrom a liquid composition comprising an anti-irritant agent, a wound healing agent; and an anti-inflammatory agent dissolved in a polyhydroxy liquid solvent.... Agent: Walter A. Hackler, Ph.d. Patent Law Office

20080299234 - Medication comprising plant extracts as a lipase inhibitor: A medication having plant extracts is administered to a person as a lipase inhibitor. The medication includes one or more of the following plant extracts: cardamom, marjoram, thyme, chili (Capsicum frutescens), evening primrose, oregano leaves (Oreganum vulgare), camomile leaves (Chamomilla recutica), nutmeg (Myristica fragrans), apple marc (pomace), corn germ, almond,... Agent: Edwin D. Schindler

20080299235 - Methods of lowering blood cholesterol via oral fenugreek seed extract compositions: A method of lowering blood cholesterol in a non-diabetic human patient by at least 30% is described. The method involves orally administering for 30 consecutive days a fenugreek seed extract composition. Various methods of preparation and various formulations are described. Agents such as pharmaceutically acceptable excipients, lubricants, binders, glidants, fillers,... Agent: Dr. Raj Bawa Bawa Biotechnology Consulting LLC

20080299236 - Natural herb composition for the treatment of diabetes and manufacturing method thereof: The present invention refers to a new composition comprising natural herbs for the treatment of diabetes, and to a method for preparing said composition.... Agent: Defillo & Associates, Inc.

20080299237 - Personal care composition with cocoa butter and dihydroxypropyl ammonium salts: A personal care composition is provided that when the composition is applied to the skin provides improved translucency to reveal a healthy skin color. The composition is based upon a mixture of dihydroxypropyl quaternary ammonium salt and cocoa butter.... Agent: Unilever Patent Group

20080299238 - Novel abietane diterpenoid compound, and composition comprising extract of torreya nucifera, or abietane diterpenoid compounds or terpenoid compounds isolated from them for prevention and treatment of cardiovascular disease: p

20080299239 - Inhibitor of glucose absorption and method for producing the same: This invention provides an inhibitor of glucose absorption and a method for producing the same. Such inhibitor of glucose absorption comprises, as an active ingredient, an acerola-derived substance capable of inhibiting glucose absorption.... Agent: Sughrue Mion, PLLC